

NOVEL AMINOGLYCOSIDE ANTIBIOTICS EFFECTIVE AGAINST
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA's)

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 [0001] This patent application claims priority to the prior Japanese Patent Application No. 13642/2004 filed January 21, 2004, and the description of the specification of the prior patent application is incorporated herein by reference.

10 BACKGROUND OF THE INVENTION

[0002] Field of the Invention

The present invention relates to novel aminoglycoside antibiotics effective against bacteria causative of clinically severe infections, particularly against methicillin resistant Staphylococcus aureus (MRSA's).

15 [0003] Background Art

MRSA's have recently become regarded as problematic bacteria because they rapidly propagate through in-hospital infection and cause clinically severe infections, and, thus, studies have been made on therapeutic agents for the infections.

20 [0004] For example, the Journal of Antibiotics, vol. 24, 1971, p. 485 discloses that various derivatives of kanamycin, which is an amino glycoside antibiotic substance, have been synthesized, and 3',4'-deoxykanamycin B (dibekacin) has been found from the kanamycin derivatives. Dibekacin has been widely used as a chemotherapeutic agent effective against resistant bacteria since 1975.

[0005] The Journal of Antibiotics, vol. 26, 1973, p. 412 discloses (S)-1-N-(4-amino-2-hydroxybutyryl)dibekacin (arbekacin) in which the amino group at the 1-position of dibekacin has been acylated with aminohydroxybutyryl acid (HABA), and arbekacin has been used as a specific medicine for MRSA infections since the end of 1990.

30 [0006] Journal of the JAPANESE SOCIETY OF CHEMOTHERAPY, vol. 50, 2002, p. 494 discloses that, despite the elapse of 10 years or more since arbekacin become used as a therapeutic agent for MRSA infections, bacteria highly resistant to arbekacin hardly appears clinically yet although the presence of low-

resistant MRSAs has been found.

[0007] Japanese Patent No. 3215759 discloses that 5-substituted 2"-deoxy-2"-amino derivatives as a 5-substituted derivative of arbekacin are effective against resistant bacteria.

5 [0008] U.S Patent No. 4000261 and U.S Patent No. 4000262 disclose 5-epi derivatives in which the steric configuration of hydroxyl at the 5-position of aminoglycoside antibiotics has been reversed. These publications, however, neither suggest nor disclose the anti-MRSA activity of 5-epi derivatives.

10 [0009] Japanese Patent Publication No. 10719/1988 discloses a process for producing 1-N-(L-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B having antimicrobial activity effective against various resistant bacteria.

[0010] The Journal of Antibiotics (1981), 34 (12), 1635-40
15 discloses a method for chemically modifying 5-deoxyarbekacin and further discloses 5-deoxyarbekacin and the like.

[0011] Carbohydrate Research 276 (1995), 75-89 discloses a process for producing 5-deoxy-5-epifluoroarbekacin and the like and the antimicrobial activity thereof.

20 [0012] The Journal of Antibiotics (1998), 51(8), 735-42 discloses a process for producing 3"-N-acetylarbekacin and the like and the antimicrobial activity thereof.

[0013] The Journal of Antibiotics(1975), 28(4), 340-343 discloses a process for producing a 1-acylated derivative of 3',4'-dideoxy-6'-N-methyl-kanamycin B and the antimicrobial activity thereof.
25

SUMMARY OF THE INVENTION

[0014] The present inventors have now found a group of compounds in aminoglycoside antibiotics, particularly arbekacin
30 derivatives, characterized by having such a structure that the steric configuration of the 5-position of arbekacin has been reversed and various substituents have been introduced, and further found that this group of compounds have significant antimicrobial activity against bacteria causative of infectious diseases, particularly against MRSA.
35 The present inventors have further found a group of compounds characterized by having such a structure that two substituents have been

[0016] According to a first aspect of the present invention, there are provided compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof:

(I)

20 R^{4'a} and R^{4'b}, which may be the same or different, represent a hydrogen atom or hydroxyl,

hydroxyl,

25 azide,

C₁₋₆ alkanoyloxy,

C₁₋₆ alkylsulfonyloxy,

C₁₋₆ alkanoylamino,

arylcarbonylamino,

di-C₁₋₆ alkylamino, or

C₁₋₆ alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl,

5 R^{6'a} represents C₁₋₆ alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, a halogen atom, or amino,

 R^{6'a} and R^{6'b}, which may be the same or different, represent a hydrogen atom or C₁₋₆ alkyl,

10 R^{3'a} represents a hydrogen atom or C₁₋₆ alkyl,
 the dashed line represents a single bond or a double bond,
 m represents an integer of 0 to 2,

 X represents a hydrogen atom or hydroxyl,

 n represents an integer of 1 to 3, and


15 * represents an R or S configuration, provided that

 R^{5'a} represents a group as defined above other than a fluorine atom when R^{4'a} represents a hydrogen atom, R^{4'b} represents hydroxyl, and, the dashed line represents a single bond; and R^{5'a} represents a group as defined above other than hydroxyl, amino, and azide when R^{3'a}
20 represents a hydrogen atom, R^{4'a} represents a hydrogen atom, R^{4'b} represents hydroxyl, R^{6'a} represents hydroxymethyl, both R^{6'a} and R^{6'b} represent a hydrogen atom, X represents a hydrogen atom, and, the dashed line represents a single bond.

[0017] Further, according to the first aspect of the present
25 invention, there is provided an antimicrobial agent comprising a compound according to the first aspect of the present invention or a pharmacologically acceptable salt or solvate thereof.

[0018] Furthermore, according to the first aspect of the present
invention, there is provided an anti-MRSA agent comprising a compound
30 represented by general formula (Ia) or a pharmacologically acceptable salt or solvate thereof:

[Chemical formula 2]



wherein

$R^{4'a}$ and $R^{4'b}$, which may be the same or different, represent a hydrogen atom or hydroxyl,

$R^{5'a}$ represents a halogen atom,

hydroxyl,

amino,

azide,

C_{1-6} alkanoyloxy,

C_{1-6} alkylsulfonyloxy,

C_{1-6} alkanoylamino,

arylcarbonylamino,

di- C_{1-6} alkylamino, or

C_{1-6} alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl,

$R^{6'a}$ represents C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, a halogen atom, or amino,

$R^{6'a}$ and $R^{6'b}$, which may be the same or different, represent a hydrogen atom or C_{1-6} alkyl,

$R^{3'a}$ represents a hydrogen atom or C_{1-6} alkyl,

the dashed line represents a single bond or a double bond,

m represents an integer of 0 to 2,

X represents a hydrogen atom or hydroxyl,


n represents an integer of 1 to 3, and

* represents an R or S configuration, provided that

$R^{5'a}$ represents a group as defined above other than a fluorine atom when $R^{4'a}$ represents a hydrogen atom, $R^{4'b}$ represents hydroxyl, and the dashed line represents a single bond.

[0019] According to a second aspect of the present invention, there are provided compounds represented by general formula (II) or pharmacologically acceptable salts or solvates thereof:

[Chemical formula 3]



5

wherein

R^{5C} represents C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by C_{1-6} alkoxy,

C_{2-6} alkenyl, or

10 amino C_{1-6} alkyl wherein one or more hydrogen atoms in the amino group are optionally substituted by C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by amino, hydroxyl, or heteroaryl, and

n represents an integer of 1 to 3.


15 [0020] According to the second aspect of the present invention, there is provided an antimicrobial agent comprising a compound according to the second aspect of the present invention or a pharmacologically acceptable salt or solvate thereof.

[0021] Further, according to the second aspect of the present invention, there is provided an anti-MRSA agent comprising a compound according to the second aspect of the present invention or a pharmacologically acceptable salt or solvate thereof.

20 [0022] According to a third aspect of the present invention, there are provided compounds represented by general formula (III) or pharmacologically acceptable salts or solvates thereof:

25

[Chemical formula 4]



wherein


R^{4c} represents a hydrogen atom or hydroxyl,

R^{4d} represents a hydrogen atom or hydroxyl wherein, when

5 R^{4c} represents hydroxyl, R^{4d} represents a hydrogen atom,

R^{6c} represents C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, amino, or azide; or a group of the formula:

[Chemical formula 5]



10

wherein R^{6d} and R^{6e} , which may be the same or different, represent a hydrogen atom or amino C_{1-6} alkyl, or R^{6d} and R^{6e} together may represent a six-membered cyclic group containing 1 to 4 heteroatom, Y represents a hydrogen atom or hydroxyl, and p represents an integer of 0 or 1,

15

R^{3c} and R^{3d} , which may be the same or different, represent a hydrogen atom,

C_{1-10} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl or aryl optionally substituted by hydroxyl or amino,

20

formimidoyl, or
amidino,

R^{6c} and R^{6d} , which may be the same or different, represent a hydrogen atom,

25

amino C_{1-6} alkyl,
formimidoyl,
amidino, or
benzyl optionally substituted by hydroxyl,

r represents an integer of 0 (zero) to 2,
 J represents a hydrogen atom or hydroxyl,
 s represents an integer of 1 to 3, and
 * represents an R or S configuration,

5 excluding compounds wherein

R^{4c} , R^{3c} , R^{3d} , R^{6c} , and R^{6d} simultaneously represent a hydrogen atom, R^{4d} represents hydroxyl, R^{6c} represents hydroxymethyl, r represents 0, X represents a hydrogen atom, and s represents 2.

[0023] According to the third aspect of the present invention,
 10 there is provided an antimicrobial agent comprising a compound according to the third aspect of the present invention or a pharmacologically acceptable salt or solvate thereof.

[0024] Further, according to the third aspect of the present invention, there is provided an anti-MRSA agent comprising a compound
 15 according to the third aspect of the present invention or a pharmacologically acceptable salt or solvate thereof.

[0025] The present invention provides novel aminoglycoside antibiotics that have excellent antimicrobial activity even against arbekacin resistant bacteria which are clinically obtained only in rare
 20 cases. The novel aminoglycoside antibiotics according to the present invention also have significant antimicrobial activity against bacteria causative of infectious diseases, for example, escherichia coli and Pseudomonas aeruginosa.

25 DETAILED DESCRIPTION OF THE INVENTION

[0026] The term "alkyl," "alkoxy," or "alkenyl" as used herein as a group or a part of a group respectively mean straight chain, branched chain or cyclic alkyl, alkoxy, and alkenyl unless otherwise specified. The term "aryl" as used herein means phenyl or naphthyl unless
 30 otherwise specified, and the term "heteroaryl" as used herein means five- or six-membered heteroaryl (five- or six-membered cyclic aromatic heterocyclic group) containing 1 to 3 nitrogen, oxygen, or sulfur atoms unless otherwise specified.

[0027] 5-Epiarbekacin analogues

35 In the first aspect of the present invention, halogen atoms represented by R^{5a} include, for example, fluorine, chlorine,

bromine, and iodine atoms. More preferred are fluorine and chlorine atoms.

[0028] In the first aspect of the present invention, C₁₋₆ alkanoyloxy represented by R^{5a} is preferably C₁₋₃ alkanoyloxy, and
 5 specific examples thereof include formyloxy, acetyloxy, propionyloxy, butyryloxy, and isobutyryloxy. Among them, acetyloxy is more preferred.

[0029] In the first aspect of the present invention, C₁₋₆ alkylsulfonyloxy represented by R^{5a} is preferably C₁₋₃ alkylsulfonyloxy, and specific examples thereof include methylsulfonyloxy, ethylsulfonyloxy,
 10 propylsulfonyloxy, isopropylsulfonyloxy, and butylsulfonyloxy. Methylsulfonyloxy is more preferred.

[0030] In the first aspect of the present invention, C₁₋₆ alkanoylamino represented by R^{5a} is preferably C₁₋₃ alkanoylamino, and specific examples thereof include formylamino, acetylamino,
 15 propionylamino, butyrylamino, and isobutyrylamino. Among them, acetylamino is more preferred.

[0031] In the first aspect of the present invention, arylcarbonylamino represented by R^{5a} is preferably C₆₋₁₀ arylcarbonylamino, and specific examples thereof include
 20 phenylcarbonylamino and naphthylcarbonylamino. Phenylcarbonylamino is more preferred.

[0032] In the first aspect of the present invention, di-C₁₋₆ alkylamino represented by R^{5a} is preferably di-C₁₋₃ alkylamino, and specific examples thereof include dimethylamino, diethylamino, and
 25 methylethylamino. Dimethylamino is more preferred.

[0033] In the first aspect of the present invention, C₁₋₆ alkylamino represented by R^{5a} is preferably C₁₋₃ alkylamino, and specific examples thereof include methylamino, ethylamino, propylamino, isopropylamino, butylamino, tert-butylamino. Methyl amino is more
 30 preferred.

[0034] Further, one or more hydrogen atoms in the C₁₋₆ alkylamino group represented by R^{5a} are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl. Specific examples of substituted alkylamino include hydroxymethylamino, 2-
 35 hydroxyethylamino, 3-hydroxypropylamino, benzylamino, phenethylamino, 3-phenylpropyl, 4-phenylbutyl, arylamino,

aminomethylamino, (2-aminoethyl)amino, and (2-hydroxy-1-hydroxymethylethyl)amino.

[0035] In the first aspect of the present invention, C₁₋₆ alkyl represented by R^{6'a} is preferably C₁₋₃ alkyl, and specific examples thereof include straight chain or branched chain C₁₋₆ alkyl, for example, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, s-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, and 2-ethylbutyl. Methyl or ethyl is more preferred.

[0036] Further, one or more hydrogen atoms in the C₁₋₆ alkyl group represented by R^{6'a} are optionally substituted by hydroxyl, a halogen atom, or amino. Specific examples of substituted C₁₋₆ alkyl include 2-amino-1-hydroxyethyl, hydroxymethyl, hydroxyethyl, and fluoromethyl.

[0037] In the first aspect of the present invention, C₁₋₆ alkyl represented by R^{6'a}, R^{6'b}, and R^{3'a} is preferably C₁₋₃ alkyl.

[0038] In a preferred embodiment of the present invention, compounds represented by formula (I) are those wherein

R^{5a} represents a halogen atom, hydroxyl, amino, azide, C₁₋₃ alkanoyloxy, C₁₋₃ alkylsulfonyloxy, C₁₋₃ alkanoylamino, phenylcarbonylamino, naphthylcarbonylamino, di-C₁₋₃ alkylamino, or C₁₋₃ alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl,

R^{6'a} represents C₁₋₃ alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, a halogen atom, or amino,

R^{6'a} and R^{6'b}, which may be the same or different, represent a hydrogen atom or C₁₋₃ alkyl, and

R^{3'a} represents a hydrogen atom or C₁₋₃ alkyl.

[0039] In another preferred embodiment of the present invention, compounds represented by formula (I) are those wherein

$R^{4'a}$ represents a hydrogen atom or hydroxyl,
 $R^{4'b}$ represents a hydrogen atom,
 $R^{6'a}$ represents hydroxymethyl,
 either one of $R^{6'a}$ and $R^{6'b}$ represents a hydrogen atom,
 the dashed line represents a single bond,
 m represents 0,
 X represents a hydrogen atom, and
 n represents an integer of 1 to 3.

[0040] In still another preferred embodiment of the present invention, compounds represented by formula (I) are those wherein

R^{5a} represents a chlorine atom, hydroxyl, amino, azide, C_{1-6} alkanoyloxy, C_{1-6} alkylsulfonyloxy, C_{1-6} alkanoylamino, arylcarbonylamino, di- C_{1-6} alkylamino, or, C_{1-6} alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl,

$R^{6'a}$ represents hydroxymethyl,
 either one of $R^{6'a}$ and $R^{6'b}$ represents a hydrogen atom,
 the dashed line represents a single bond,
 m represents 0,
 X represents a hydrogen atom, and
 n represents 2.

[0041] In a further preferred embodiment of the present invention, compounds represented by formula (I) are those wherein

$R^{6'a}$ represents hydroxymethyl or fluoromethyl,
 both $R^{6'a}$ and $R^{6'b}$ represent a hydrogen atom,
 $R^{3'a}$ represents a hydrogen atom,
 the dashed line represents a double bond,
 m represents 0,
 X represents a hydrogen atom, and
 n represents 1 or 2.

[0042] 5-Disubstituted arbekacin analogues

In the second aspect of the present invention, C_{1-6} alkyl represented by R^{5c} is preferably C_{1-3} alkyl.

[0043] One or more hydrogen atoms in the C_{1-6} alkyl group (preferably C_{1-3} alkyl group) represented by R^{5c} are optionally substituted

by C₁₋₆ alkoxy, preferably C₁₋₃ alkoxy, and specific examples of substituted alkyl include methoxymethyl, and ethoxymethyl. Methoxymethyl is more preferred.

[0044] In the second aspect of the present invention, C₂₋₆ alkenyl represented by R^{5c} is preferably C₂₋₄ alkenyl, and specific examples thereof include vinyl, 2-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-ethyl-2-propenyl, 2-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 1-ethyl-2-butenyl, 3-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, and 1-ethyl-3-butenyl.

[0045] In the second aspect of the present invention, amino C₁₋₆ alkyl represented by R^{5c} is preferably amino C₁₋₃ alkyl, and specific examples thereof include aminomethyl, 2-aminoethyl, and 3-aminopropyl. Aminomethyl is more preferred.

[0046] Further, one or more hydrogen atoms in the amino group in the amino C₁₋₆ alkyl group (preferably amino C₁₋₃ alkyl group) represented by R^{5c} are optionally substituted by C₁₋₆ alkyl, preferably C₁₋₃ alkyl. Methylaminomethyl is more preferred.

[0047] Further, one or more hydrogen atoms in the C₁₋₆ alkyl group (preferably C₁₋₃ alkyl group) as a substituent for one or more hydrogen atoms in the amino group in the amino C₁₋₆ alkyl group (preferably amino C₁₋₃ alkyl group) represented by R^{5c} are optionally substituted by amino, hydroxyl, or heteroaryl (preferably pyrrolyl or pyridyl), and examples of such R^{5c} include (2-aminoethyl)aminomethyl, (3-aminopropyl)aminomethyl, (3-amino-2-hydroxypropyl)aminomethyl, (2-hydroxyethyl)aminomethyl, arylaminomethyl, and (2-pyridylmethyl)amino. More preferred are (2-aminoethyl)aminomethyl, (3-amino-2-hydroxypropyl)aminomethyl, (2-hydroxyethyl)aminomethyl, and (2-pyridylmethyl)amino.

[0048] In another preferred embodiment of the present invention, compounds represented by formula (II) are those wherein R^{5c} represents C₁₋₃ alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by C₁₋₆ alkoxy; C₂₋₄ alkenyl; or amino C₁₋₃ alkyl wherein one or more hydrogen atoms in the amino group are optionally substituted by C₁₋₆ alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by amino, hydroxyl or heteroaryl.

[0049] In still another preferred embodiment of the present

invention, compounds represented by formula (II) are those wherein R^{5c} represents C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by C_{1-3} alkoxy; C_{2-6} alkenyl; or amino C_{1-6} alkyl wherein one or more hydrogen atoms in the amino group are optionally substituted by C_{1-3} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by amino, hydroxyl, pyrrolyl, or pyridyl.

[0050] In a further preferred embodiment of the present invention, compounds represented by formula (II) are those wherein R^{5c} represents C_{1-3} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by C_{1-3} alkoxy; C_{2-4} alkenyl; or amino C_{1-3} alkyl wherein one or more hydrogen atoms in the amino group are optionally substituted by C_{1-3} alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by amino, hydroxyl, pyrrolyl, or pyridyl.

[0051] Arbekacin derivatives wherein derivatization occurs at 6'-, 3''-, 4''-, and 6''-positions

In the third aspect of the present invention, C_{1-6} alkyl represented by R^{6c} is preferably C_{1-3} alkyl.

[0052] Further, one or more hydrogen atoms in the C_{1-6} alkyl group (preferably C_{1-3} alkyl group) represented by R^{6c} are optionally substituted by hydroxyl, amino, or azide. Examples of substituted alkyl include hydroxymethyl, aminomethyl, aminoethyl, azidomethyl, and azidoethyl. More preferred are hydroxymethyl, aminomethyl, and azidomethyl.

[0053] In the third aspect of the present invention, amino C_{1-6} alkyl represented by R^{6d} and R^{6e} is preferably amino C_{1-3} alkyl, and aminoethyl is more preferred.

[0054] In the third aspect of the present invention, the six-membered cyclic group containing 1 to 4 heteroatoms which R^{6d} and R^{6e} together represent includes six-membered heterocyclic saturated rings containing one or two heteroatoms selected from N and O. Specific examples thereof include morpholinyl, piperazyl, and piperidyl. Morpholinyl is more preferred.

[0055] In the third aspect of the present invention, C_{1-10} alkyl represented by R^{3c} and R^{3d} is preferably C_{1-6} alkyl. Specific examples thereof include straight chain or branched chain C_{1-10} alkyl, for example,

methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, s-butyl, tert-butyl, n-pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl,
 5 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2-ethylbutyl, n-hexyl, n-heptyl, n-octyl, and n-nonyl. Preferred are methyl, ethyl, propyl, n-butyl, n-pentyl, and n-hexyl. Methyl or ethyl is more preferred.

[0056] Further, one or more hydrogen atoms in the C₁₋₁₀ alkyl group (preferably C₁₋₆ alkyl) represented by R^{3'c} and R^{3'd} are optionally
 10 substituted by hydroxyl or aryl optionally substituted by hydroxyl or amino. Specific examples of substituted alkyl include hydroxymethyl, hydroxyethyl, benzyl, phenethyl, (m-hydroxy)benzyl, (p-hydroxy)benzyl, and (m-amino)benzyl. Preferred are hydroxyethyl, hydroxyethyl, benzyl, phenethyl, (m-hydroxy)benzyl, (p-hydroxy)benzyl, and (m-amino)benzyl.

15 [0057] In the third aspect of the present invention, amino C₁₋₆ alkyl represented by R^{6'c} and R^{6'd} is preferably amino C₁₋₃ alkyl. Aminoethyl is more preferred.

[0058] In the third aspect of the present invention, specific examples of benzyl, which is optionally substituted by hydroxyl,
 20 represented by R^{6'c} and R^{6'd} include (o-hydroxy)benzyl, (m-hydroxy)benzyl, and (p-hydroxy)benzyl. (o-Hydroxy)benzyl is more preferred.

[0059] In a preferred embodiment of the present invention, compounds represented by formula (III) are those wherein R^{6'c}
 25 represents C₁₋₃ alkyl wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, amino, or azide; or a group of formula:

[Chemical formula 6]



30 wherein R^{6'd} and R^{6'e}, which may be the same or different, represent a hydrogen atom or amino C₁₋₃ alkyl, or R^{6'd} and R^{6'e} together may represent a six-membered cyclic group containing 1 to 4 heteroatom, Y represents a hydrogen atom or hydroxyl, and p represents an integer of 0 or 1,

R^{3^c} and R^{3^d} , which may be the same or different, represent
a hydrogen atom,

C_{1-6} alkyl wherein one or more hydrogen atoms in the alkyl
group are optionally substituted by hydroxyl; phenyl optionally
5 substituted by hydroxyl or amino; or naphthyl optionally substituted by
hydroxyl or amino,

formimidoyl, or
amidino,

R^{6^c} and R^{6^d} , which may be the same or different, represent

10 a hydrogen atom,
amino C_{1-3} alkyl,
formimidoyl,
amidino, or
benzyl optionally substituted by hydroxyl.

15 [0060] In another preferred embodiment of the present invention,
compounds represented by formula (III) are those wherein R^{4^c}
represents a hydrogen atom, R^{4^d} represents hydroxyl, both R^{6^c} and R^{6^d}
represent a hydrogen atom, both R^{3^c} and R^{3^d} represent a hydrogen
atom, r represents 0, J represents a hydrogen atom, and s represents 2.

20 [0061] In still another preferred embodiment of the present
invention, compounds represented by formula (III) are those wherein R^{4^c}
represents a hydrogen atom, R^{4^d} represents hydroxyl, both R^{6^c} and R^{6^d}
represent a hydrogen atom, R^{6^c} represents hydroxymethyl, either one of
 R^{3^c} and R^{3^d} represent a hydrogen atom, r is 0 (zero), J represents a
25 hydrogen atom, and s is 2.

[0062] In a further preferred embodiment of the present invention,
compounds represented by formula (III) are those wherein R^{4^c}
represents a hydrogen atom, R^{4^d} represents hydroxyl, R^{6^c} represents
hydroxymethyl, both R^{3^c} and R^{3^d} represent a hydrogen atom, and s
30 represents 2.

[0063] Further, according to the present invention, there are
provided 5,4"-Diepiarbekacin, 5-deoxy-4"-epi-5-epifluoroarbekacin, 5-
deoxy-4"-epi-5-epichloroarbekacin, 5-deoxy-4"-epi-5-epiaminoarbekacin,
4"-deoxy-5-epiarbekacin, 1-N-[(S)-(3-amino-2-hydroxypropanoyl)]-5,4"-
diepidibekacin, 5,4"-diepi-3"-N-methylarbekacin, 5,4"-diepi-6'-N-
35 methylarbekacin, 5-epiarbekacin, 5-deoxy-5-epichloroarbekacin, 5-

deoxy-5-epiaminoarbakacin, 5-deoxy-5-epi(2-aminoethyl)aminoarbakacin, 5-epi-3"-N-methylarbakacin, 6"-aminomethyl-5-epiarbakacin, 3',4'-didehydro-5-epiarbakacin, 5-deoxy-3',4'-didehydro-5-epifluoroarbakacin, 5-deoxy-3',4'-didehydro-5-epiaminoarbakacin, 1-N-[(S)-(3-amino-2-hydroxypropanoyl)]-3',4'-didehydro-5-epidibekacin, 3',4'-didehydro-5,4"-diepiarbakacin, 5-deoxy-3',4'-didehydro-4"-epi-5-epifluoroarbakacin, 5-deoxy-3',4'-didehydro-4"-epi-5-epiaminoarbakacin, 4"-deoxy-3',4'-didehydro-5-epiarbakacin, and 6"-aminomethylarbakacin.


[0064] Production process

10 The compounds according to the first aspect of the present invention can be produced by the following processes A to Q.

Process A

In process A, compounds represented by general formula (A9) are produced by introducing substituent R^{5a} into the 5-position of compound (A1) in an axial configuration and then introducing substituent $R^{4'a}$ into the 4"-position in an axial configuration. Process A comprises the following steps. The compound represented by formula (A1) as a starting compound may be produced by the method described in Japanese Patent Laid-Open Nos. 62442/1974, 81897/1980, 164696/1980, and 10719/1988.

[Chemical formula 7]



[0065] Step A1

In step A1, a compound of general formula (A2) is produced by introducing protective group (A) into five amino groups in the compound of formula (A1). Step A1 is achieved by reacting the compound of formula (A1) with A₂O or ACl in the presence of a base, wherein A represents tert-butoxycarbonyl (Boc), benzyloxycarbonyl (group Z), p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl.

[0066] Solvents usable in step A1 include water, N,N-dimethylformamide, tetrahydrofuran, dioxane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of water and N,N-dimethylformamide. Bases usable herein include sodium hydroxide,

potassium carbonate, sodium carbonate, triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably triethylamine. The reaction temperature is 0°C to 40°C, and the reaction time is 1 to 24 hr.

[0067] Process A2

5 In step A2, a compound of general formula (A3) is produced by introducing a protective group into hydroxyl at the 4"-position and 6"-position of the compound of general formula (A2). This step is achieved by reacting the compound of general formula (A2) with E₂CO or E₂C(OMe)₂ in the presence of an acid, wherein E represents a
10 hydrogen atom, methyl, or phenyl or, as E₂C, cyclohexyl.

[0068] Solvents usable in this step include, for example, N,N-dimethylformamide, methylene chloride, chloroform, 1,2-dichloroethane, and ethyl acetate. The solvent is preferably N,N-dimethylformamide. Acids usable herein include, for example, p-toluenesulfonic acid,
15 pyridinium p-toluenesulfonate, camphorsulfonic acid, and hydrochloric acid. The acid is preferably p-toluenesulfonic acid. The reaction temperature is 20°C to 50°C. The reaction time is 1 to 8 hr.

[0069] Step A3

20 In step A3, a compound of general formula (A4) is produced by introducing a protective group into hydroxyl at the 2"-position and 2'''-position of the compound of general formula (A3). This step is achieved by reacting the compound of general formula (A3) with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

25 [0070] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, chloroform, and 1,2-dichloroethane. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to
30 30°C. The reaction time is 1 to 8 hr.

[0071] Step A4

35 In this step A4, a compound of general formula (A5) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (A4) and then subjecting the compound to a substitution reaction. This step is achieved by reacting the compound of general formula (A4) with WSO₂Cl, wherein W represents

methyl, phenyl, or p-tolyl, in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position, and then reacting the resultant compound with $R^{5a}M$ wherein R^{5a} represents acetoxyl, azide, a chlorine atom, or C_{1-6} alkylamino wherein one or more
 5 hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0072] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is
 10 preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

15 [0073] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

[0074] Step A5

20 In step A5, the protective group at the 4"-position and 6"-position of the compound of general formula (A5) is removed. This step is achieved by reacting the compound of general formula (A5) with an acid.

[0075] Solvents usable in this step include tetrahydrofuran, diethyl ether, dioxane, methanol, methylene chloride, chloroform, water, and mixed
 25 solvents thereof. The solvent is preferably a mixed solvent composed of methylene chloride and methanol. Acids usable herein include acetic acid, trifluoroacetic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, and boron trichloride. The acid is preferably trifluoroacetic acid. The reaction temperature is 0°C to 30°C. The reaction time is 0.1 to 8 hr.

30 [0076] In the compound of general formula (A5), when one of substituents E_2C is a hydrogen atom while the other substituent is phenyl, the protective group can also be removed by reacting the compound of general formula (A5) with hydrogen and a catalyst for catalytic hydrogen reduction. Catalysts for catalytic hydrogen reduction usable herein include
 35 palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The catalyst for catalytic hydrogen reduction is preferably a palladium-

carbon catalyst. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and a mixed solvent composed of an organic solvent and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0077] Step A6

In step A6, a compound of general formula (A7) is produced by introducing a protective group into hydroxyl at the 6"-position of the compound of general formula (A6). This step is achieved by reacting the compound of general formula (A6) with R¹³Cl wherein R¹³ represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, tert-butyldiphenylsilyl, or benzoyl, in the presence of a base.

[0078] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0079] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0080] Preferred solvents usable in the step of introducing benzoyl include acetonitrile, pyridine, N,N-dimethylformamide, and tetrahydrofuran. Preferred bases usable herein include triethylamine, tetramethylethylenediamine, and pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr. In this step, in addition to benzoyl chloride, for example, benzoic anhydride, benzoyl cyanide, or combinations of benzoic acid, diisopropyl azodicarboxylate, and triphenylphosphine may be used as the benzoylation reagent.

[0081] Step A7

In step A7, a compound of general formula (A8) is produced by introducing a leaving group into hydroxyl at the 4"-position of the compound of general formula (A7) and then subjecting the

compound to a substitution reaction. This step is achieved by reacting the compound of general formula (A7) with trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride in the presence of a base to synthesize a compound having trifluoromethanesulfonyloxy at the 4"-position, and then reacting the resultant compound with R^{4a}M wherein R^{4a} represents C₁₋₆alkanoyloxy, or benzoyloxy and M represents lithium, sodium, or cesium.

[0082] Solvents usable in the step of introducing a leaving group include methylene chloride, chloroform, tetrahydrofuran, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, lutidine, collidine, triethylamine, and diisopropylethylamine. The base is preferably pyridine. The reaction temperature is -30°C to 20°C. The reaction time is 1 to 6 hr.

[0083] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, methylene chloride, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 50°C. The reaction time is 1 to 6 hr.

[0084] Step A8

In step A8, a compound of general formula (A9) is produced by removing the protective group in the compound of general formula (A8). This step is achieved by reacting the compound of general formula (A8) with a base to remove the protective group of hydroxyl except for the protective group of hydroxyl at the 6"-position, and then reacting the resultant compound with an acid to remove the protective group of amino and hydroxyl at the 6"-position.

[0085] Solvents usable in the step of removing the protective group of hydroxyl except for the protective group of hydroxyl at the 6"-position include methanol, ethanol, isopropyl alcohol, tert-butylalcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C. The reaction time is 1 to 8 hr.

[0086] Solvents suitable in the step of removing the protective group of amino and hydroxyl at the 6"-position include ethyl acetate, methylene


chloride, acetonitrile, acetone, and water. The solvent is preferably water. Acids usable herein include p-toluenesulfonic acid, methanesulfonic acid, acetic acid, and trifluoroacetic acid. The acid is preferably trifluoroacetic acid. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 12 hr. When protective group A in the compound of general formula (A8) is benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl and, at the same time, the dashed line represents a single bond, the protective group may also be removed by reacting the compound with hydrogen and a catalytic hydrogen reduction catalyst. Catalytic hydrogen reduction catalysts usable herein include palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The catalyst is preferably palladium-carbon. The solvent is not particularly limited so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and a mixed solvent composed of these organic solvent and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0087] Process B

In process B, compounds of general formula (B6) are produced by introducing substituent $R^{4'a}$ into the 4"-position of a compound of general formula (B1) in an axial configuration and then introducing substituent R^{5a} into the 5-position in an axial configuration. Process B comprises the following steps. The compound of general formula (B1) as a starting compound may be produced in the same manner as in steps A1 to A3 in the above-described process A.

[Chemical formula 8]

Process B

[0088] Step B1

In step (B1), the protective group at the 4''-position and the 6''-position of the compound of general formula (B1) is removed.

- 5 This step is achieved by reacting the compound of general formula (B1) with an acid.

[0089] Solvents usable in this step include tetrahydrofuran, diethyl ether, dioxane, methanol, methylene chloride, chloroform, water, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methylene chloride and methanol. Acids usable herein include acetic acid, trifluoroacetic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, and boron trichloride. The acid is preferably trifluoroacetic acid. The reaction temperature is 0°C to 30°C. The reaction time is 0.1 to 8 hr.

- 15 [0090] In the compound of general formula (B1), when one of substituents of E₂C is a hydrogen atom while the other substituent is phenyl, the protective group can also be removed by reacting this compound with hydrogen and a catalyst for catalytic hydrogen reduction. Catalysts for catalytic hydrogen reduction usable herein include palladium-carbon,

palladium black, palladium hydroxide, and platinum oxide. The catalyst for catalytic hydrogen reduction is preferably palladium-carbon. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and a mixed solvent composed of these organic solvent and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0091] Process B2

In process B2, a protective group is introduced into hydroxyl at the 6"-position of the compound of general formula (B2). This step is achieved by reacting the compound of general formula (B2) with R¹³Cl wherein R¹³ represents triphenylmethyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, or benzoyl, in the presence of a base.

[0092] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0093] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, N,N-dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0094] Preferred solvents usable in the step of introducing benzoyl include acetonitrile, pyridine, N,N-dimethylformamide, and tetrahydrofuran. Preferred bases usable herein include triethylamine, tetramethylethylenediamine, and pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr. In this step, in addition to benzoyl chloride, for example, benzoic anhydride, benzoyl cyanide, or combinations of benzoic acid, diisopropyl azodicarboxylate, and triphenylphosphine may be used as the benzoylation reagent.

[0095] Step B3

In step B3, a compound of general formula (B4) is

produced by introducing a leaving group into hydroxyl at the 4"-position of the compound of general formula (B3) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (B3) with

5 trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride in the presence of a base to synthesize a compound having trifluoromethanesulfonyloxy at the 4"-position, and then reacting the resultant compound with $R^{4'a}M$ wherein $R^{4'a}$ represents C_1 - C_6 alkanoyl, or benzoyloxy and M represents lithium, sodium, or cesium.

10 [0096] Solvents usable in the step of introducing a leaving group include methylene chloride, chloroform, tetrahydrofuran, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, lutidine, collidine, triethylamine, and diisopropylethylamine. The base is preferably pyridine. The reaction

15 temperature is -30°C to 20°C . The reaction time is 1 to 6 hr.

[0097] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, methylene chloride, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 50°C . The reaction time is 1 to 6 hr.

20 [0098] Step B4

In step B4, a compound of general formula (B5) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (B4), and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting

25 the compound of general formula (B4) with $W\text{SO}_2\text{Cl}$, wherein W represents methyl, phenyl, or p-tolyl, in the presence of a base to synthesize of a compound having substituted sulfonyloxy at the 5-position, and then reacting the resultant compound with $R^{5a}M$ wherein R^{5a} represents acetoxy, azide, a chlorine atom, a bromine atom, or C_{1-6}

30 alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0099] Solvents usable in the step of introducing a leaving group include methylene chloride, chloroform, 1,2-dichloroethane,

35 tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine,

triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.


[0100] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, 1,2-dimethoxyethane, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 20°C to 120°C, preferably 80°C to 120°C. The reaction time is 1 to 12 hr. A compound of general formula (A9) may be produced by deprotecting the compound of general formula (B5) according to step A8 in process A.

[0101] Process C

In process C, a compound of general formula (C3) is produced by introducing fluoro into the 5-position of a compound of general formula (C1) in an axial configuration. The process C comprises the following steps. Each step constituting process C will be described in detail. The compound of general formula (C1) as a starting compound in process C can be produced according to steps B1 to B3 in the above-described process B.

[Chemical formula 9]

Process C



[0102] Step C1

In step C1, fluoro is introduced into the 5-position of the compound of general formula (C1) in an axial configuration. This step is achieved by reacting the compound of general formula (C1) with a fluorinating agent.

[0103] Fluorinating agents usable in this step include diethylamino sulfur trifluoride (DAST) and morpholino sulfur trifluoride. Solvents usable herein include tetrahydrofuran, dimethoxyethane, methylene chloride, and chloroform. The solvent is preferably methylene chloride. The reaction temperature is -40°C to 30°C. The reaction time is 1 to 8 hr.


[0104] Step C2

In step C2, a compound of general formula (C3) is produced by removing the protective group in the compound of general formula (C2). The protective group can be removed in the same manner as in step A8.

[0105] Process D

In process D, a compound of general formula (D2) is produced by reducing azide at the 5-position of a compound of general formula (D1) to amino. Process D comprises the following step. The compound of general formula (D1) as a starting compound may be produced according to processes A and B described above and processes E to H, J, and M to Q which will be described later.

[Chemical formula 10]



[0106] Step D1

In step D1, azide at the 5-position of a compound of general formula (D1) is reduced to amino. This step is achieved by reacting the compound of general formula (D1) with a reducing agent.

[0107] Reducing agents usable in this step include trimethylphosphine, tributylphosphine, triphenylphosphine, hydrogen and catalysts for catalytic hydrogen reduction such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. When the dashed line in the compound of general formula (D1) represents a double bond, tributylphosphine is preferred. On the other hand, when the dashed line represents a single bond, hydrogen and palladium-

30


carbon catalysts are suitable. Solvents usable herein include methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0108] Process E

In process E, a compound of general formula (E5) is produced by reducing the 4"-position of a compound of general formula (E1) and then introducing substituent R^{5a} into the 5-position in an axial configuration. This process comprises the following steps. The compound of general formula (E1) as a starting compound can be produced according to steps B1 to B2 in process B.

[Chemical formula 11]

Process E



15 [0109] Step E1

In step E1, a compound of general formula (E2) is produced by introducing a leaving group into hydroxyl at the 4"-position of a compound of general formula (E1) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (E1) with trifluoromethanesulfonyl

chloride or trifluoromethanesulfonic anhydride in the presence of a base to synthesize a compound having trifluoromethanesulfonyloxy at the 4"-position and then reacting the resultant compound with MX wherein X represents a chlorine atom or a bromine atom, and M represents lithium or sodium.

[0110] Solvents usable in the step of introducing a leaving group include methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, lutidine, collidine, triethylamine, and diisopropylethylamine. The base is preferably pyridine. The reaction temperature is -30°C to 20°C. The reaction time is 1 to 6 hr.

[0111] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, 1,2-dimethoxyethane, methylene chloride, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 50°C. The reaction time is 1 to 12 hr.

[0112] Step E2

In step E2, a compound of general formula (E3) is produced by reducing a halogen group at the 4"-position of the compound of general formula (E2). This step is achieved by reacting the compound of general formula (E2) with a reducing agent in the presence of a free radical initiator.

[0113] Reducing agents usable in this step include, for example, tri-n-butyltin hydride, di-n-butyltin hydride, triethyltin hydride, and triphenyltin hydride. The reducing agent is preferably tri-n-butyltin hydride. Free radical initiators usable herein include azobisisobutyronitrile. Solvents usable herein include tetrahydrofuran, dioxane, benzene, and toluene. The solvent is preferably dioxane. The reaction temperature is 20°C to 120°C. The reaction time is 1 to 8 hr.

[0114] Step E3

In step E3, a compound of general formula (E4) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (E3) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting

the compound of general formula (E3) with WSO_2Cl wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with R^{5a}M wherein R^{5a} represents acetoxy, azide, a chlorine atom, a bromine atom, or C_{1-6} alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0115] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C . The reaction time is 1 to 24 hr.

[0116] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C . The reaction time is 1 to 12 hr.

[0117] Step E4


In step E4, a compound of general formula (E5) is produced by removing the protective group in the compound of general formula (E4). The protective group can be removed in the same manner as in step A8.

[0118] Process F

In process F, a compound of general formula (F11) is produced by introducing substituent $\text{R}^{4'a}$ into the 4'-position of a compound of formula (F1) in an axial configuration, then introducing substituent R^{5a} into the 5-position in an axial configuration, and further introducing a side chain into amino at the 1-position. Process F comprises the following steps. The compound of formula (F1) as a starting compound can be produced according to the method described in Tetrahedron Lett., 4951-4954 (1979), and J. Med. Chem., 34, 1483-1492 (1991).

[Chemical formula 12]

Process F

[0119] Step F1

In step F1, a compound of general formula (F2) is produced by introducing a protective group into hydroxyl at the 4''-position and 6''-position of the compound of formula (F1). This step is achieved by reacting the compound of formula (F1) with E₂CO or E₂C(OMe)₂ in the presence of an acid, wherein E represents a hydrogen atom, methyl, or phenyl, or, as E₂C, cyclohexyl.

[0120] Solvents usable in this step include, for example, N,N-dimethylformamide, methylene chloride, and ethyl acetate. The solvent is preferably N,N-dimethylformamide. Acids usable herein include p-

toluenesulfonic acid, pyridinium p-toluenesulfonate, camphorsulfonic acid, and hydrochloric acid. The acid is preferably p-toluenesulfonic acid. The reaction temperature is 20°C to 50°C. The reaction time is 1 to 8 hr.

5 [0121] Step F2

In step F2, a compound of general formula (F3) is produced by introducing a protective group into hydroxyl at the 2"-position of the compound of general formula (F2). This step is achieved by reacting the compound of general formula (F2) with B₂O or BCl
10 wherein B represents acetyl or benzoyl in the presence of a base.

[0122] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, 4-dimethylaminopyridine. The base is preferably pyridine. The
15 reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0123] Step F3

In step F3, the compound of general formula (F3) is converted to a compound of general formula (F4). This step is achieved by reacting the compound of general formula (F3) with an acid.

20 [0124] Solvents usable in this step include tetrahydrofuran, diethyl ether, dioxane, methanol, methylene chloride, chloroform, water, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methylene chloride and methanol. Acids usable herein include acetic acid, trifluoroacetic acid, hydrochloric acid, sulfuric acid, p-toluenesulfonic acid, and boron trichloride. The acid is preferably
25 trifluoroacetic acid. The reaction temperature is 0°C to 30°C. The reaction time is 0.1 to 8 hr.

[0125] Sep F4

In step F4, a compound of general formula (F5) is
30 produced by introducing a protective group into hydroxyl at the 6"-position of the compound of general formula (F4). This step is achieved by reacting the compound of general formula (F4) with R¹³Cl wherein R¹³ represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, or tert-butyldiphenylsilyl, in the presence of a base.

35 [0126] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is

preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

5 [0127] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to
10 30°C. The reaction time is 1 to 12 hr.

[0128] Step F5

In step F5, a compound of general formula (F6) is produced by introducing a leaving group into hydroxyl at the 4"-position of the compound of general formula (F5) and then subjecting the
15 resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (F5) with trifluoromethanesulfonyl chloride or trifluoromethanesulfonic anhydride in the presence of a base to synthesize a compound having trifluoromethanesulfonyloxy at the 4"-position and then reacting the
20 resultant compound with $R^{4'a}M$ wherein $R^{4'a}$ represents C_1 - C_6 alkanoyloxy, or benzoyloxy, and M represents lithium, sodium, or cesium.

[0129] Solvents usable in the step of introducing a leaving group include methylene chloride, chloroform, tetrahydrofuran, and ethyl acetate. The solvent is preferably methylene chloride. Bases
25 usable herein include pyridine, lutidine, collidine, triethylamine, and diisopropylethylamine. The base is preferably pyridine. The reaction temperature is -30°C to 20°C. The reaction time is 1 to 6 hr.

[0130] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, methylene chloride, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide.
30 The reaction temperature is 0°C to 50°C. The reaction time is 1 to 6 hr.

[0131] Step F6

In step F6, a compound of general formula (F7) is produced by introducing a leaving group into hydroxyl at the 5-position of
35 the compound of general formula (F6) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting

the compound of general formula (F6) with WSO_2Cl wherein W represents methyl, phenyl, or p-tolyl, in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting, in the presence of a base, the resultant compound with R^{5a}M wherein R^{5a} represents acetoxy, azide, a chlorine atom, a bromine atom, or C_{1-6} alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0132] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C . The reaction time is 1 to 24 hr.

[0133] Solvents usable in the step of a substitution reaction include tetrahydrofuran, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C . The reaction time is 1 to 12 hr.

[0134] Step F7

In step F7, a compound of general formula (F8) is produced by removing the protective group of hydroxyl except for the protective group at the 6"-position of the compound of general formula (F7). This step is achieved by reacting the compound of general formula (F7) with a base.

[0135] Solvents usable in this step include methanol, ethanol, isopropyl alcohol, t-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C . The reaction time is 1 to 8 hr.

[0136] Step F8

In step F8, a compound of general formula (F9) is produced by removing the protective group in the compound of general formula (F8). This step is achieved by reacting the compound of general formula (F8) with a reducing agent.

5 [0137] Reducing agents usable in this step include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide, metallic sodium and metallic lithium. When the dashed line in the compound of general formula (F8) represents a double bond,
10 metallic sodium is preferred. On the other hand, when the dashed line represents a single bond, hydrogen and palladium-carbon catalysts are preferred. Solvents usable herein include, in the case of catalytic hydrogen reduction, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and
15 these organic solvents. When metallic sodium is used, liquid ammonia is preferred. The reaction temperature is -60°C to 30°C. The reaction time is generally 1 to 8 hr.

[0138] Step F9

In step F9, a compound of general formula (F10), wherein
20 A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl, is produced by introducing a side chain into amino at the 1-position of the compound of general formula (F9). This step is achieved by condensing, in the presence of a condensing agent, the compound of general formula (F9)
25 with a carbocyclic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$, wherein A is as defined above and n represents an integer of 1 to 3, or by reacting the compound of general formula (F9) with a derivative of a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$, wherein A is as defined above, in the absence of a condensing agent.

30 [0139] Condensing agents usable in this step include, for example, carbodiimides such as dicyclohexylcarbodiimide, diisopropylcarbodiimide, and N-ethyl-N'-3-dimethylaminopropylcarbodiimide, or these condensing agents to which, for example, 1-oxobenzotriazole or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine has been added as an additive. Carboxylic acid
35 derivatives usable herein include N-hydroxyphthalimide esters, N-

hydroxysuccinimide esters, p-nitrophenyl esters, and pentafluorophenyl esters. The carboxylic acid derivative is preferably an N-hydroxysuccinimide ester. Solvents usable herein include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0140] Step F10

In step F10, a compound of general formula (F11) is produced by removing the protective group in the compound of general formula (F10). The protective group can be removed in the same manner as in step A8.

10


[0141] Process G

In process G, a compound of general formula (G6) is produced by introducing substituent R^{6'a} into amino at the 6'-position of the compound of formula (G1). Process G comprises the following steps. A compound of general formula (G7) can be produced from the compound of general formula (G6) according to steps A3 to A8 in process A described above or steps B1 to B6 in process B described above, or process J which will be described later.

15

20 [Chemical formula 13]

Process G

[0142] Step G1

In step G1, a compound of formula (G2) is produced by protecting amino in the compound of formula (G1). This step is achieved by first reacting the compound of formula (G1) with N-benzyloxycarbonyloxysuccinimide in the presence of zinc acetate to give the compound in which the amino group at the 6'-position has been protected by benzyloxycarbonyl (group Z), and then reacting the amino groups in the 3-position, 2'-position, 3''-position, 4'''-position of the resultant compound with di-tert-butyl dicarbonate in the presence of a base to protect the amino groups with tert-butoxycarbonyl (group Boc).

[0143] Solvents usable in the step of protecting the 6'-position include tetrahydrofuran, dioxane, water, N,N-dimethylformamide, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of water and N,N-dimethylformamide. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0144] Solvents usable in the step of protecting the 3-position, 2'-position, 3"-position, and 4'''-position include water, N,N-dimethylformamide, tetrahydrofuran, dioxane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of water and dioxane. Bases usable herein include sodium hydroxide, potassium carbonate, sodium carbonate, triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably triethylamine. The reaction temperature is 0°C to 40°C. The reaction time is 1 to 24 hr.

Step G2

10 In step G2, a compound of formula (G3) is produced by removing the protective group in the compound of formula (G2) and then protecting the compound with benzyl. This step is achieved by subjecting the compound of formula (G2) to catalytic hydrogen reduction with hydrogen and then reacting the resultant compound having amino at the 6'-position with benzaldehyde in the presence of a reducing agent.

15 [0145] Reducing agents usable in the step of deprotection include hydrogen and catalysts for catalytic hydrogen reduction, such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide, metallic sodium and metallic lithium. When the dashed line in the compound represented by general formula (G2) represents a double bond, metallic sodium is preferable. On the other hand, when the dashed line represents a single bond, hydrogen and palladium-carbon catalysts are preferable. Solvents usable herein include, in the case of catalytic hydrogen reduction, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. When metallic sodium is used, liquid ammonia is preferable. The reaction temperature is -60°C to 30°C. The reaction time is generally 1 to 8 hr.

20 [0146] Reducing agents usable in the step of benzylation include sodium borohydride, sodium cyanoborohydride, and lithium cyanoborohydride. The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr. This step may also be achieved by a reaction with benzyl bromide in the

25
30
35

presence of a base.

Step G3

In step G3, a compound of general formula (G4) is produced by introducing a substituent into amino at the 6'-position of the compound of formula (G3). This step is achieved by reacting the
5 compound of formula (G3) with $R^{01}CHO$ wherein R^{01} represents a hydrogen atom or C_{1-5} alkyl in the presence of a reducing agent.

[0147] Reducing agents usable in this step include sodium borohydride, sodium cyanoborohydride, and lithium cyanoborohydride.
10 The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. The reaction temperature is $0^{\circ}C$ to $30^{\circ}C$. The reaction time is 1 to 8 hr.

Step G4

15 In step G4, the benzyl group at the 6'-position of the compound of general formula (G4) is converted to tert-butoxycarbonyl. This step is achieved by reacting the compound of general formula (G4) with di-tert-butyl dicarbonate and a reducing agent.

20 [0148] Solvents usable in this step include, for example, methanol, ethanol, tetrahydrofuran, dioxane, tetrahydrofuran, or mixed solvents composed of these organic solvents and water. The solvent is preferably a mixed solvent composed of water and tetrahydrofuran. Reducing agents usable herein include hydrogen and catalysts for
25 catalytic hydrogen reduction such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The reducing agent is preferably, hydrogen and palladium-carbon. The reaction temperature is $10^{\circ}C$ to $30^{\circ}C$. The reaction time is generally 1 to 8 hr.

Step G5

30 In step G5, a compound of general formula (G6) is produced by introducing a protective group into hydroxyl at the 4"-position and 6"-position of the compound of general formula (G5). This step is achieved by reacting the compound of general formula (G5) with E_2CO or $E_2C(OMe)_2$ wherein E represents a hydrogen atom, methyl, or phenyl or, as E_2C , cyclohexyl in the presence of an acid.
35

[0149] Solvents usable in this step include, for example, N,N-


dimethylformamide, methylene chloride, and ethyl acetate. The solvent is preferably N,N-dimethylformamide. Acids usable herein include p-toluenesulfonic acid, pyridinium p-toluenesulfonate, camphorsulfonic acid, and hydrochloric acid. The acid is preferably p-toluenesulfonic acid. The reaction temperature is 20°C to 50°C. The reaction time is 1 to 8 hr.

[0150] Process H

In process H, a compound of general formula (G6) is produced by introducing substituents R^{5a} and $R^{4'a}$ into the 5-position and 4"-position of the compound of formula (H1) in an axial configuration and then introducing substituent $R^{3'a}$ into amino at the 3"-position. Process H comprises the following steps. The compound of formula (H1) as a starting compound can be produced by the method described in Japanese Patent Laid-Open No. 1319/1988, Japanese Patent Laid-Open No. 82290/1995, and U.S Patent No. 4297485.

[Chemical formula 14]

Process H

[0151] Step H1

In step H1, a compound of formula (H2) is produced by selectively protecting hydroxyl at the 6"-position of the compound of formula (H1). This step is achieved by reacting the compound of formula (H1) with R¹³Cl wherein R¹³ represents triphenylmethyl, tert-butyl dimethylsilyl, triisopropylsilyl, or tert-butyl diphenylsilyl in the presence of a base.

[0152] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The

reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0153] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0154] Step H2

10 In step H2, a compound of general formula (H3) is produced by introducing a protective group into hydroxyl at the 2"-position of the compound of formula (H2). This step is achieved by reacting the compound of formula (H2) with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

15 [0155] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

20 [0156] Step H3

In step H3, a compound of general formula (H4) is produced by introducing a leaving group into hydroxyl at the 5-position and 4"-position of the compound of general formula (H3) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (H3) with WSO₂Cl wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and 4"-position and then reacting the resultant compound with R^{4'a}M wherein R^{4'a} represents C₁-C₆ alkanoyloxy or benzoyloxy, and M represents lithium, sodium, or cesium. Substituent R^{5a} at the 5-position of the compound of general formula (H4) is as defined in R^{4'a}.

25 [0157] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The

35

base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

[0158] Solvents usable in the step of a substitution reaction include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

[0159] Step H4

In step H4, a compound of general formula (H5) is produced by removing the protective group of hydroxyl except for the protective group at the 6"-position of the compound of general formula (H4). This step is achieved by reacting the compound of general formula (H4) with a base.

[0160] Solvents usable in this step include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C. The reaction time is 1 to 8 hr.

[0161] Step H5

In step H5, a compound of general formula (H6) is produced by removing the protective group of amino at the 1-position and 3"-position of the compound of general formula (H5) and then selectively protecting amino at the 3"-position. This step is achieved by reacting the compound of general formula (H5) with a reducing agent and then reacting the resultant compound having amino at the 1- and 3"-positions with trifluoroethyl acetate in the presence of a base.

[0162] Reducing agents usable in the step of deprotection include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide, or metallic sodium and metallic lithium. When the dashed line in the compound of general formula (H5) represents a double bond, metallic sodium is preferred. On the other hand, when the dashed line represents a single bond, hydrogen and a

palladium-carbon catalyst are preferred. Solvents usable herein include, in the case of catalytic hydrogen reduction, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. When metallic sodium is used, liquid ammonia is preferred. The reaction temperature is -60°C to 30°C. The reaction time is generally 1 to 8 hr.

[0163] Solvents usable in the step of protection include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide.

Bases usable herein include triethylamine, diisopropylethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0164] Step H6

In step H6, a compound of general formula (H7), wherein A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl, is produced by introducing a side chain into amino at the 1-position of the compound of general formula (H6). This step is achieved by reacting the compound of general formula (H6) with a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$, wherein A is as defined above and n represents an integer of 1 to 3, in the presence of a condensing agent, or by reacting the compound of general formula (H6) with a derivative of a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$, wherein A is as defined above, in the absence of a condensing agent.

[0165] Condensing agents usable in this step include, for example, carbodiimides such as dicyclohexylcarbodiimide, diisopropylcarbodiimide and N-ethyl-N'-3-dimethylaminopropylcarbodiimide, or these condensing agents to which, for example, 1-oxobenzotriazole or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine has been added as an additive. Carboxylic acid derivatives usable herein include N-hydroxyphthalimide esters, N-hydroxysuccinimide esters, p-nitrophenyl esters, and pentafluorophenyl esters. The carboxylic acid derivative is preferably an N-hydroxysuccinimide ester. Solvents usable herein include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide.

The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.
[0166] Step H7

In step H7, a compound of general formula (H8) is produced by converting the protective group at the 3"-position of the compound of general formula (H7) from trifluoroacetyl to di(4-methoxyphenyl)methyl (group PDMD). This step is achieved by reacting the compound of general formula (H7) with a base and then reacting the resultant compound having amino at the 3"-position with di(4-methoxyphenyl)methyl chloride in the presence of a base.

[0167] Bases usable in the step of deprotection include potassium carbonate, sodium carbonate, barium hydroxide, and ammonium hydroxide. Among them, ammonium hydroxide is preferred. Solvents usable herein include methanol, ethanol, isopropyl alcohol, tetrahydrofuran, dioxane, methylene chloride, chloroform, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of tetrahydrofuran and ethanol. The reaction temperature is 0°C to 50°C. The reaction time is 1 to 8 hr.

[0168] Bases usable in the step of protection include triethylamine, diisopropylethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably triethylamine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 24 hr.

[0169] Step H8

In Step H8, a compound of general formula (H9) is produced by introducing a substituent into amino at the 3"-position of the compound of general formula (H8). This step is achieved by reacting the compound of general formula (H8) with $R^{01}CHO$ wherein R^{01} represents a hydrogen atom or C_{1-5} alkyl in the presence of a reducing agent.

[0170] Reducing agents usable in this step include sodium borohydride, sodium cyanoborohydride, and lithium cyanoborohydride. The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0171] Step H9


In step H9, a compound of general formula (H10) is produced by removing the protective group in the compound of general formula (H9). The protective group can be removed in the same manner as in step A8.

5 [0172] Process I

In process I, a compound of general formula (I8) is produced by introducing a side chain into the 1-position of the compound of formula (I1) and then introducing fluoro into the 5-position and 6"-position. Process I comprises the following steps. Each step in

10 [Chemical formula 15]

Process I



[0173] Step I1

15 In step I1, a compound of formula (I2) is produced by removing the protective group of amino at the 1-position and 3"-position of the compound of formula (I1) and then selectively protecting amino at the 3"-position. This step is achieved by reacting the compound of

formula (I1) with a reducing agent and then reacting the resultant compound having amino at the 1,3"-position with trifluoroethyl acetate in the presence of a base.

[0174] Reducing agents usable in the step of deprotection include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide, or metallic sodium and metallic lithium. When the dashed line in the compound of general formula (I1) represents a double bond, metallic sodium is preferred. On the other hand, when the dashed line represents a single bond, hydrogen and palladium-carbon catalysts are preferred. Solvents usable herein include, in the case of catalytic hydrogen reduction, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. When metallic sodium is used, liquid ammonia is preferred. The reaction temperature is -60°C to 30°C. The reaction time is generally 1 to 8 hr.

[0175] Solvents usable in the step of protection include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. Bases usable herein include triethylamine, diisopropylethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0176] Step I2

In step I2, a compound of general formula (I3) wherein A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl, is produced by introducing a side chain into amino at the 1-position of the compound of formula (I2). This step is achieved by reacting the compound of formula (I2) with a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$ wherein A is as defined above in the presence of a condensing agent, or by reacting the compound of formula (I2) with a derivative of a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$ wherein A is as defined above and n represents an integer of 1 to 3 in the absence of a condensing agent.

[0177] Condensing agents usable in this step include, for example, carbodiimides such as dicyclohexylcarbodiimide, diisopropylcarbodiimide and N-ethyl-N'-3-

dimethylaminopropylcarbodiimide, or these condensing agents to which, for example, 1-oxobenzotriazole or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine has been added as an additive. Carboxylic acid derivatives usable herein include N-hydroxyphthalimide esters, N-hydroxysuccinimide esters, p-nitrophenyl esters, and pentafluorophenyl esters. The carboxylic acid derivative is preferably an N-hydroxysuccinimide ester. Solvents usable herein include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0178] Step I3

In step I3, a compound of general formula (I4) is produced by introducing a protective group into hydroxyl at the 6"-position of the compound of general formula (I3). This step is achieved by reacting the compound of general formula (I3) with $R^{13}Cl$ wherein R^{13} represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, or tert-butyldiphenylsilyl in the presence of a base.

[0179] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0180] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0181] Step I4

In step I4, a compound of general formula (I5) is produced by introducing a protective group into hydroxyl at the 2"-position, 4"-position, and 2'''-position of the compound of general formula (I4). This step is achieved by reacting the compound of general formula (I4) with B_2O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

[0182] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0183] Step I5

In step I5, a compound of general formula (I6) is produced by removing triphenylmethyl or silyl as the protective group of hydroxyl at the 6"-position of the compound of general formula (I5). This step is achieved by reacting the compound of general formula (I5) with an acid or a base.

[0184] Solvents usable in the step of deprotection of triphenylmethyl group include diethyl ether, tetrahydrofuran, dimethoxyethane, and water. The solvent is preferably diethyl ether. Acids usable herein include formic acid and acetic acid. The acid is preferably formic acid. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0185] Preferred solvents usable in the step of deprotection of silyl group include acetonitrile, tetrahydrofuran, and methylene chloride. Reagents usable in the deprotection include tetrabutylammonium fluoride, hydrogen fluoride-pyridine, hydrogen fluoride-triethylamine, and hydrogen fluoride. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0186] Step I6

In step I6, a compound of general formula (I7) is produced by fluorinating the 5-position and 6"-position of the compound of general formula (I6). This step is achieved by reacting the compound of general formula (I6) with a fluorinating reagent.

[0187] Fluorinating reagents usable in this step include diethylaminosulfur trifluoride (DAST) and morpholinosulfur trifluoride. Solvents usable herein include tetrahydrofuran, dimethoxyethane, methylene chloride, and chloroform. The solvent is preferably methylene chloride. The reaction temperature is -40°C to 30°C. The reaction time is 1 to 8 hr.

[0188] Step I7


In step I7, a compound of general formula (I8) is produced

by removing the protective group in the compound of general formula (17). The protective group can be removed in the same manner as in step A8.

[0189] Process J

In process J, a compound of general formula (J4) is produced by introducing substituent R^{5a} into the 5-position of the compound of formula (J1) in an axial configuration. Process J comprises the following steps. Each step in process J will be described. [Chemical formula 16]

Process J



10 [0190] Step J1

In step J1, a protective group is introduced into all hydroxyl and amino except for the 5-position of the compound of formula (J1). This step is achieved by first reacting a compound of formula (J1) with A_2O or ACl wherein A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl in the presence of a base to introduce a protective group into amino and then reacting the resultant compound with B_2O or BCl wherein B represents acetyl or benzoyl in the presence of a base to introduce a protective group into hydroxyl.

20 [0191] Solvents usable in the step of protecting amino include water, N,N-dimethylformamide, tetrahydrofuran, dioxane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of water and N,N-dimethylformamide. Bases usable herein include sodium hydroxide, potassium carbonate, sodium carbonate, triethylamine,

pyridine, and 4-dimethylaminopyridine. The base is preferably triethylamine. The reaction temperature is 0°C to 40°C. The reaction time is 1 to 24 hr.

[0192] Solvents usable in the step of protecting hydroxyl include
5 pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

10 [0193] Step J2

In step J2, a compound of general formula (J3) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (J2) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting
15 the compound of general formula (J2) with WSO₂Cl wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with R^{5a}M wherein R^{5a} represents acetoxy, azide, a chlorine atom, a bromine atom, or C₁₋₆
20 alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0194] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane,
25 tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

30 [0195] Solvents usable in the step of a substitution reaction include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

35 [0196] Step J3

In step J3, a compound of general formula (J4) is


produced by removing the protective group in the compound of general formula (J3). The protective group can be removed in the same manner as in step A8.

[0197] Process K

5 In process K, a compound of general formula (K4) is produced by reducing azide in an axial configuration at the 5-position of the compound of general formula (K1) to amino and introducing a substituent into the amino group. Process K comprises the following steps. The compound of general formula (K1) as a starting compound
10 can be produced according to steps J1 and J2 in the above process J.

[Chemical formula 17]

Process K



[0198] Step K1

15 In step K1, a compound of general formula (K2) is produced by removing the protective group of hydroxyl in the compound of general formula (K1). This step is achieved by reacting the compound of general formula (K1) with a base.

[0199] Solvents usable in this step include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is

0°C to 60°C. The reaction time is 1 to 8 hr.

[0200] Step K2

In step K2, azide at the 5-position of the compound of general formula (K2) is reduced to amino. This step is achieved by reacting the compound of general formula (K2) with a reducing agent.

[0201] Reducing agents usable in this step include trimethylphosphine, tributylphosphine, triphenylphosphine, and catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. When the dashed line in the compound of general formula (K2) represents a double bond, tributylphosphine is preferred. When the dashed line represents a single bond, hydrogen and palladium-carbon catalysts are preferred. Solvents usable herein include methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0202] Step K3

In step K3, a compound of general formula (K4) is produced by introducing a substituent into amino at the 5-position of the compound of general formula (K3) and then removing the protective group. This step is achieved by either reacting, in the presence of a base, the compound of general formula (K3) with $R^{02}COCl$ wherein R^{02} represents C_{1-5} alkyl or aryl, or $R^{03}X$ wherein R^{03} represents C_{1-6} alkyl or aralkyl, and X represents a halogen, or reacting the compound of general formula (K3) with $R^{04}CHO$ wherein R represents a hydrogen atom, C_{1-5} alkyl, or aryl, and then reacting the resultant compound with a base or an acid in the presence of a reducing agent, and then removing the protective group.

[0203] Solvents usable in the step of the reaction with $R^{02}COCl$ include methylene chloride, chloroform, 1,2-dichloroethane, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, diisopropylethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0204] Solvents usable in the step of the reaction with $R^{03}X$

include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, methylene chloride, chloroform, 1,2-dichloroethane, methanol, ethanol, acetonitrile, and water. The solvent is preferably N,N-dimethylformamide. Bases usable herein include potassium carbonate, sodium carbonate, triethylamine, and 4-dimethylaminopyridine. The base is preferably potassium carbonate. The reaction temperature is 20°C to 60°C. The reaction time is 1 to 12 hr.

[0205] Solvents usable in the step of the reaction with $R^{O4}CHO$ include, methanol, ethanol, isopropyl alcohol, dioxane, water, acetic acid, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol, dioxane, and acetic acid. Reducing agents usable herein include sodium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, and sodium triacetoxo borohydride. The reducing agent is preferably sodium triacetoxo borohydride. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0206] Solvents usable in the step of deprotection with a base include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C. The reaction time is 1 to 8 hr.

[0207] Solvents usable in the step of deprotection with an acid include ethyl acetate, methylene chloride, acetonitrile, acetone, and water. The solvent is preferably water. Acids usable herein include p-toluenesulfonic acid, methanesulfonic acid, acetic acid, and trifluoroacetic acid. The acid is preferably trifluoroacetic acid. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 12 hr. When the protective group A in the compound of general formula (K3) is benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl, the protective group can also be removed by reacting this compound with hydrogen and a catalyst for catalytic hydrogen reduction. Catalysts for catalytic hydrogen reduction usable


herein include palladium-carbon and platinum oxide. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred solvents are methanol, ethanol, tetrahydrofuran, dioxane, and a mixed solvent composed of these organic solvent and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0208] Process L

In Process L, a compound of general formula (L5) is produced by introducing substituted sulfonyloxy into the 5-position of the compound of general formula (L1), wherein R^{5a} represents C_{1-6} alkanoyloxy, in an axial configuration. Process L comprises the following steps. The compound of general formula (L1) as a starting compound can be produced according to the steps J1 and J2 in the above process J.

[Chemical formula 18]

Process L



[0209] Step L1

In step L1, a compound of general formula (L2) is

produced by removing the protective group of hydroxyl in the compound of general formula (L1). This step is achieved by reacting the compound of general formula (L1) with a base.

[0210] Solvents usable in this step include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C. The reaction time is 1 to 8 hr.

[0211] Step L2

In step L2, a compound of general formula (L3) is produced by introducing a protective group into hydroxyl in the compound of general formula (L2) except for hydroxyl at the 5-position. This step is achieved by reacting the compound of general formula (L2) with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

[0212] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0213] Step L3

In step L3, hydroxyl at the 5-position of the compound of general formula (L3) is sulfonated. This step is achieved by reacting the compound of general formula (L3) with R⁰⁵SO₂Cl wherein R⁰⁵ represents C₁₋₆ alkyl in the presence of a base.

[0214] Solvents usable in this step include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.


[0215] Step L4

In step L4, a compound of general formula (L5) is produced by removing the protective group in the compound of general formula (L4). The protective group can be removed in the same manner as in step A8.

5 [0216] Process M

In process M, a compound of general formula (M6) is produced by introducing substituent R^{5a} into the 5-position of the compound of general formula (M1) in an axial configuration and then introducing a side chain into the 1-position. Process M comprises the following steps. The compound of general formula (M1) as a starting compound can be produced according to step I1 in the above process I.

10 [Chemical formula 19]



15 [0217] Process M1

In step M1, a compound of general formula (M2) is produced by introducing a protective group into hydroxyl in the compound of general formula (M1) except for hydroxyl at the 5-position. This step is achieved by reacting the compound of general formula (M1) with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

20

[0218] Solvents usable in this step include pyridine, N,N-

dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

5 [0219] Step M2

In step M2, a compound of general formula (M3) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (M2) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting
10 the compound of general formula (M2) with $W\text{SO}_2\text{Cl}$ wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with R^{5a}M wherein R^{5a} represents acetoxy, azide, a chlorine atom, or C_{1-6} alkylamino wherein
15 one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0220] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane,
20 tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

25 [0221] Solvents usable in the step of a substitution reaction include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

30 [0222] Step M3

In step M3, the protective group of hydroxyl in the compound of general formula (M3) is removed, and the protective group of amino in the 1-position is then removed. This step is achieved by reacting the compound of general formula (M3) with a base and then
35 reacting the resultant compound with a reducing agent.

[0223] Solvents usable in the step of removing the protective

group of hydroxyl include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 60°C. The reaction time is 1 to 8 hr.

[0224] Reducing agents usable in the step of removing the protective group of amino include hydrogen and catalysts for catalytic hydrogen reduction such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide, or metallic sodium and metallic lithium. When the dashed line in the compound of general formula (M3) represents a double bond, metallic sodium is preferred. On the other hand, when the dashed line represents a single bond, hydrogen and palladium-carbon catalysts are preferred. Solvents usable herein include, in the case of catalytic hydrogen reduction, methanol, ethanol, tetrahydrofuran, dioxane, N,N-dimethylformamide, water, or mixed solvents composed of water and these organic solvents. When metallic sodium is used, liquid ammonia is preferred. The reaction temperature is -60°C to 30°C. The reaction time is generally 1 to 8 hr.

[0225] Step M4

In step M4, a compound of general formula (M5) wherein A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl, is produced by introducing a side chain into amino at the 1-position of the compound of general formula (M4). This step is achieved by condensing the compound of general formula (M4) with a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$ wherein A is as defined above and n represents an integer of 1 to 3 in the presence of a condensing agent, or by reacting the compound of general formula (M4) with a derivative of a carboxylic acid $\text{ANH}(\text{CH}_2)_n\text{CH}(\text{OH})\text{COOH}$ wherein A is as defined above in the absence of a condensing agent.

[0226] Condensing agents usable in this step include, for example, carbodiimides such as dicyclohexylcarbodiimide, diisopropylcarbodiimide and N-ethyl-N'-3-

dimethylaminopropylcarbodiimide, or these condensing agents to which, for example, 1-oxobenzotriazole or 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine has been added as an additive. Carboxylic acid derivatives usable herein include N-hydroxyphthalimide esters, N-hydroxysuccinimide esters, p-nitrophenyl esters, and pentafluorophenyl esters. The carboxylic acid derivative is preferably an N-hydroxysuccinimide ester. Solvents usable herein include tetrahydrofuran, dioxane, methylene chloride, chloroform, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide.

10 The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.
[0227] Step M5


In step M5, a compound of general formula (M6) is produced by removing the protective group in the compound of general formula (M5). The protective group can be removed in the same
15 manner as in step A8.

[0228] Process N

In process N, a compound of general formula (N6) is produced by introducing substituent R^{3a} into the 3"-position in the compound of general formula (N1) and then introducing substituent R^{5a}
20 into the 5-position in an axial configuration. Process N comprises the following steps. The compound of formula (N1) as a starting compound can be produced by the method described in Japanese Patent Laid-Open No. 164696/1980.

[Chemical formula 20]

Process N

[0229] Step N1

In step N1, benzyl is introduced into amino at the 3"-position of the compound of general formula (N1). This step is achieved by reacting the compound of general formula (N1) with benzyl bromide in the presence of a base. This step can also be achieved by reacting the compound of general formula (N1) with benzaldehyde in the presence of a reducing agent.

[0230] Solvents usable in this step include tetrahydrofuran, dioxane, 1,2-dimethoxyethane, N,N-dimethylformamide, dimethylsulfoxide, and methylene chloride. The solvent is preferably N,N-dimethylformamide. Bases usable herein include potassium carbonate, sodium carbonate, triethylamine, and 4-dimethylaminopyridine. The base is preferably potassium carbonate. The reaction temperature is 20°C to 60°C. The reaction time is 1 to 12 hr.

[0231] Step N2

In step N2, a compound of general formula (N3) is

produced by introducing a substituent into amino at the 3"-position of the compound of general formula (N2). This step is achieved by reacting the compound of general formula (N2) with $R^{01}CHO$ wherein R^{01} represents a hydrogen atom or C_{1-5} alkyl in the presence of a reducing agent.

[0232] Reducing agents usable in this step include sodium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, and sodium triacetoxymethylborohydride. The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. The reaction temperature is $0^{\circ}C$ to $30^{\circ}C$. The reaction time is 1 to 8 hr.

[0233] Step N3

In step N3, benzyl at the 3"-position of the compound of general formula (N3) is converted to tert-butoxycarbonyl. This step is achieved by reacting the compound of general formula (N3) with di-tert-butyl dicarbonate and a reducing agent.

[0234] Solvents usable in this step include, for example, methanol, ethanol, tetrahydrofuran, dioxane, tetrahydrofuran, or mixed solvents composed of these organic solvents and water. The solvent is preferably a mixed solvent composed of water and tetrahydrofuran. Reducing agents usable herein include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The reducing agent is preferably hydrogen and palladium-carbon. The reaction temperature is $10^{\circ}C$ to $30^{\circ}C$. The reaction time is generally 1 to 8 hr.

[0235] Step N4

In step N4, a compound of general formula (N5) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (N4) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (N4) with WSO_2Cl wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with $R^{5a}M$ wherein R^{5a}

represents acetoxy, azide, a chlorine atom, a bromine atom, or C₁₋₆ alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

5 [0236] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The
10 base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

[0237] Solvents usable in the step of a substitution reaction include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably
15 N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

[0238] Step N5


In step N5, a compound of general formula (N6) is produced by removing the protective group in the compound of general
20 formula (N5). The protective group can be removed in the same manner as in step A8.

[0239] Process O

In process O, a compound of general formula (O9) is produced by introducing a side chain into the 6'-position of the
25 compound of general formula (O1) and then introducing a substituent R^{5a} into the 5-position in an axial configuration. Process O comprises the following steps. The compound of general formula (O1) as a starting compound can be produced according to step G1 in the above process G.

30 [Chemical formula 21]

Process O

[0240] Step O1

In step O1, a protective group is introduced into the 4"-position and 6"-position of the compound of general formula (O1), and the protective group at the 6'-position is then removed. This step is achieved by reacting the compound of general formula (O1) with E₂CO or E₂C(OMe)₂ wherein E represents a hydrogen atom, methyl, or phenyl or, as E₂C, cyclohexyl in the presence of an acid and then reacting the resultant compound with a reducing agent.

[0241] Solvents usable in the step of protection include, for example, N,N-dimethylformamide, methylene chloride, and ethyl acetate. The solvent is preferably N,N-dimethylformamide. Acids usable herein

include p-toluenesulfonic acid, pyridinium p-toluenesulfonate, camphorsulfonic acid, and hydrochloric acid. The acid is preferably p-toluenesulfonic acid. The reaction temperature is 20°C to 50°C. The reaction time is 1 to 8 hr.

5 [0242] Reducing agents usable in the step of deprotection include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The reducing agent is preferably hydrogen and palladium-carbon. Any solvent may be used without
10 particular limitation so far as the solvent is inert to this reaction. Preferred solvents are methanol, ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

15 [0243] Step O2

In step O2, amino at the 6'-position of the compound of general formula (O2) is oxidized to aldehyde. This step is achieved by reacting the compound of general formula (O2) with an oxidizing agent in the presence of a base.

20 [0244] A mixed solvent composed of water and chloroform is preferred as a solvent used in this step. The oxidizing agent is preferably ninhydrin. Bases usable herein include sodium hydrogencarbonate. The reaction temperature is 0°C to 30°C. The reaction time is 12 to 48 hr.

25 [0245] Step O3

In step O3, a compound of general formula (O4) is produced. This step is achieved by reacting the compound of general formula (O3) with nitromethane in the presence of a base. Solvents usable in this step include methanol, ethanol, tert-butyl alcohol,
30 methylene chloride, dichloroethane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 30°C. The reaction
35 time is 1 to 6 hr.

[0246] Step O4

In step O4, a compound of general formula (O5) is produced. This step is achieved by reacting the compound of general formula (O4) with a reducing agent. Reducing agents usable in this step include hydrogen and catalysts for catalytic hydrogen reduction such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. Preferred are hydrogen and platinum oxide. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0247] Step O5

In step O5, a compound of formula (O6) is produced by removing the protective group in general formula (O5). The protective group can be removed in the same manner as in step A8.

[0248] Step O6

In step O6, a protective group is introduced into all hydroxyl and amino in the compound of formula (O6) except for the 5-position of the compound. This step is achieved by first reacting the compound of formula (O6) with A₂O or ACl wherein A represents tert-butoxycarbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, or p-nitrobenzyloxycarbonyl in the presence of a base to introduce a protective group into amino and then reacting the resultant compound with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base to introduce a protective group into hydroxyl.

[0249] Solvents usable in the step of protecting amino include water, N,N-dimethylformamide, tetrahydrofuran, dioxane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of water and N,N-dimethylformamide. Bases usable herein include sodium hydroxide, potassium carbonate, sodium carbonate, triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably triethylamine. The reaction temperature is 0°C to 40°C. The reaction time is 1 to 24 hr.

[0250] Solvents usable in the step of protecting hydroxyl include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include

triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0251] Step O7

5 In step O7, a compound of general formula (O8) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (O7) and then subjecting the resultant compound to a substitution reaction. This step is achieved by reacting the compound of general formula (O7) with WSO₂Cl wherein W
10 represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with R^{5a}M wherein R^{5a} represents acetoxy, azide, a chlorine atom, a bromine atom, or C₁₋₆ alkylamino wherein one or more hydrogen atoms in the alkyl group are
15 optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0252] Solvents usable in the step of introducing a leaving group include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is
20 preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

[0253] Solvents usable in the step of a substitution reaction
25 include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

[0254] Step O8

30 In step O8, a compound of general formula (O9) is produced by removing the protective group in the compound of general formula (O8). The protective group can be removed in the same manner as in step A8.


[0255] Process P

35 In process P, a compound of general formula (P6) is produced by reducing hydroxyl at the 6^o-position of the compound of

general formula (P1) and then introducing substituent R^{5a} into the 5-position in an axial configuration. This process comprises the following steps. The compound of general formula (P1) as a starting compound can be produced according to step A1 in the above process A.

5 [Chemical formula 22]

Process P



[0256] Step P1

In step P1, a protective group is introduced into hydroxyl in the compound of general formula (P1) except for hydroxyl at the 5-position of the compound. This step is achieved by reacting the compound of general formula (P1) with $\text{PhCH}(\text{OR}^{06})_2$ wherein R^{06} represents methyl or ethyl in the presence of an acid to protect the 4'-position and 6''-position and then reacting the resultant compound with B_2O or BCl wherein B represents acetyl or benzoyl in the presence of a base to protect the 2''-position and 2'''-position.

[0257] Solvents usable in the step of protecting 4''-position and 6''-position include, for example, N,N-dimethylformamide, methylene chloride, and ethyl acetate. The solvent is preferably N,N-dimethylformamide. Acids usable herein include p-toluenesulfonic acid, pyridinium p-toluenesulfonate, camphorsulfonic acid, and hydrochloric

acid. The acid is preferably p-toluenesulfonic acid. The reaction temperature is 0°C to 10°C. The reaction time is 1 to 8 hr.

[0258] Solvents usable in the step of protecting the 2"-position and 2'''-position include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0259] Step P2

10 In step P2, a compound of general formula (P3) is produced. This step is achieved by reacting the compound of general formula (P2) with a halogenating agent. Carbon tetrachloride is a preferred solvent usable in this step. Halogenating agents usable herein include N-bromosuccinimide. The reaction temperature is 20°C to 60°C. The reaction time is 1 to 12 hr.

[0260] Step P3

20 In step P3, a compound of general formula (P4) is produced. This step is achieved by reacting the compound of general formula (P3) with a reducing agent in the presence of a free radical initiator, or by catalytic hydrogen reduction of the compound of general formula (P3).

[0261] Reducing agents usable in this step include, for example, tri-n-butyltin hydride, di-n-butyltin hydride, triethyltin hydride, and triphenyltin hydride. The reducing agent is preferably tri-n-butyltin hydride. Azobisisobutylnitrile may be mentioned as the free radical initiator. Solvents usable herein include tetrahydrofuran, dioxane, and benzene, and toluene. The solvent is preferably dioxane. The reaction temperature is 20°C to 120°C. The reaction time is 1 to 8 hr.

[0262] Catalysts usable in the catalytic hydrogen reduction include palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. The catalyst is preferably palladium-carbon. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0263] Step P4

In step P4, a compound of general formula (P5) is produced by introducing a leaving group into hydroxyl at the 5-position of the compound of general formula (P4) and then subjecting the resultant
5 compound to a substitution reaction. This step is achieved by reacting the compound of general formula (P4) with WSO_2Cl wherein W represents methyl, phenyl, or p-tolyl in the presence of a base to synthesize a compound having substituted sulfonyloxy at the 5-position and then reacting the resultant compound with R^{5a}M wherein R^{5a}
10 represents acetoxy, azide, a chlorine atom, a bromine atom, or C_{1-6} alkylamino wherein one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl, phenyl, vinyl, amino, or hydroxymethyl, and M represents lithium, sodium, cesium, or a hydrogen atom.

[0264] Solvents usable in the step of introducing a leaving group
15 include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature
20 is generally 0°C to 30°C . The reaction time is 1 to 24 hr.

[0265] Solvents usable in the step of a substitution reaction
include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C .
25 The reaction time is 1 to 12 hr.

[0266] Step P5

In step P5, a compound of general formula (P6) is produced by removing the protective group in the compound of general formula (P5). The protective group can be removed in the same
30 manner as in step A8.


[0267] Process Q

In process Q, a compound of general formula (Q7) is produced by introducing a side chain $\text{R}^{6'a}$ wherein $\text{R}^{6'a}$ represents 2-amino-1-hydroxyethyl into the 6"-position of the compound of general
35 formula (Q1). Process Q comprises the following steps. The compound of general formula (Q1) as a starting compound can be

produced according to steps J1 and J2 in the above process J.

[Chemical formula 23]

Process Q



[0268] Process Q1

- 5 In process Q1, the protective group of hydroxyl in the compound of general formula (Q1) is removed. This step is achieved by reacting the compound of general formula (Q1) with a base. Solvents usable in this step include methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, methylene chloride, chloroform, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of
- 10 methanol and methylene chloride. Bases usable herein include potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C
- 15 to 60°C. The reaction time is 1 to 8 hr.

[0269] Step Q2

A compound of general formula (Q3) is produced by protecting hydroxyl at the 6"-position of the compound of general formula (Q2) by triphenylmethyl or silyl and then protecting the remaining
5 hydroxyl in the compound by acyl. This step is achieved by reacting the compound of general formula (Q2) with $R^{13}Cl$ wherein R^{13} represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, or tert-butyldiphenylsilyl in the presence of a base and then reacting the resultant compound with B_2O or BCl wherein B represents acetyl or
10 benzoyl in the presence of a base.

[0270] Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine.
15 The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0271] Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile, and pyridine. Bases usable herein include 4-dimethylaminopyridine,
20 triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0272] Solvents usable in the step of introducing acyl include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform.
25 The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0273] Step Q3

30 In step Q3, a compound of general formula (Q4) is produced by removing the protective groups of hydroxyl, i.e., triphenylmethyl or silyl, at the 6"-position of the compound of general formula (Q3). This step is achieved by reacting the compound of general formula (Q3) with an acid or a base.

35 [0274] Solvents usable in the step of deprotection of triphenylmethyl group include diethyl ether, tetrahydrofuran, 1,2-

dimethoxyethane, and water. The solvent is preferably diethyl ether. Acids usable herein include formic acid and acetic acid. The acid is preferably formic acid. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

5 [0275] Preferred solvents usable in the step of deprotection of silyl group include acetonitrile, tetrahydrofuran, and methylene chloride. Reagents usable in the deprotection include tetrabutylammonium fluoride, hydrogen fluoride-pyridine, hydrogen fluoride-triethylamine, and hydrogen fluoride. The reaction temperature is 0°C to 30°C. The
10 reaction time is 1 to 12 hr.

[0276] Step Q4

In step Q4, hydroxyl at the 6"-position of the compound of general formula (Q4) is oxidized to aldehyde. This step is achieved by reacting the compound of general formula (Q3) with an oxidizing agent.

15 [0277] Pyridine may be mentioned as a preferred solvent used in this step. Oxidizing agents usable in this step include dimethylsulfoxide, dicyclohexylcarbodiimide, and hydrogen donating compounds. Hydrogen donating compounds include phosphoric acid and trifluoroacetic acid. The hydrogen donating compound is preferably
20 trifluoroacetic acid. The reaction temperature is 0°C to 30°C. The reaction time is 6 to 24 hr.

[0278] Step Q5

In step Q5, a compound of general formula (Q6) is produced. This step is achieved by reacting the compound of general
25 formula (Q5) with nitromethane in the presence of a base and then reacting the resultant nitro compound with a reducing agent.

[0279] Solvents usable in the step of the reaction with nitromethane include methanol, ethanol, tert-butyl alcohol, methylene chloride, 1,2-dichloroethane, and mixed solvents thereof. The solvent is
30 preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 6 hr.

[0280] Reducing agents usable in the step of reduction include
35 catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide,

and platinum oxide, or iron. When the dashed line in the compound of general formula (Q5) represents a single bond, hydrogen and platinum oxide are preferred. On the other hand, when the dashed line represents a double bond, iron is preferred. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred solvents include methanol, ethanol, tetrahydrofuran, dioxane, acetic acid, or mixed solvents composed of these organic solvents and water. The reaction temperature is 0°C to 30°C. The reaction time is generally 1 to 8 hr.

10 [0281] Step Q6

In step Q6, a compound of general formula (Q7) is produced by removing the protective group in the compound of general formula (Q6). The protective group can be removed in the same manner as in step A8.


15 [0282] The compounds of general formula (II) according to the second aspect of the present invention can be produced by the following process R.

Process R

20 In process R, a compound of general formula (R4) is produced by introducing a substituent into the 5-position of a compound of general formula (R1) in an axial configuration. Process R comprises the following steps. The compound of general formula (R1) as a starting compound can be produced according to step J1 in the above process J.

25 [Chemical formula 24]

Process R



[0283] Step R1

In step R1, a compound of general formula (R2) is produced. This step is achieved by reacting the compound of general formula (R1) with an oxidizing agent. The oxidizing agents is preferably a combination of dimethylsulfoxide with acetic anhydride. The reaction temperature is 0°C to 30°C. The reaction time is 48 to 72 hr.

[0284] Step R2

In step R2, a compound of general formula (R3) is produced. This step is achieved by either reacting the compound of general formula (R2) with R⁰⁷MgX wherein R⁰⁷ represents C₁₋₆ alkyl or C₂₋₆ alkenyl, and X represents a halogen, or reacting the compound of general formula (R2) with diazomethane and then reacting the resultant epoxy compound with NaN₃; R⁰⁸NH₂ wherein R⁰⁸ represents C₁₋₆ alkyl, in which one or more hydrogen atoms in the alkyl group are optionally substituted by amino or hydroxyl, or aralkyl; or R⁰⁹ONa wherein R⁰⁹ represents C₁₋₆ alkyl. The azide compound produced by the reaction with NaN₃ can be converted to an amino compound by a reaction with a reducing agent.

[0285] Solvents usable in the step of the reaction with R⁰⁷MgX include diethyl ether, tetrahydrofuran, dimethoxyethane, dioxane, benzene, and toluene. The solvent is preferably tetrahydrofuran. The reaction temperature is -40°C to 30°C. The reaction time is 1 to 8 hr.

[0286] Solvents usable in the step of the reaction with diazomethane include methanol, ethanol, methylene chloride, and dichloroethane. The solvent is preferably methanol. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 4 hr.

5 [0287] Solvents usable in the step of the reaction with NaN_3 , R^{08}NH_2 , and R^{09}ONa include tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, dimethylsulfoxide, methanol, and ethanol. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 0°C to 80°C. The reaction time is 1 to 12 hr.

10 [0288] Reducing agents usable in the step of reducing the azide compound include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. Preferred are hydrogen and palladium-carbon. The solvent is not particularly limited so far as it is
15 inert to this reaction. Preferred solvents include methanol, ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0289] Step R3

20 In step R3, a compound of general formula (R4) is produced by removing the protective group in the compound of general formula (R3). The protective group can be removed in the same manner as in step A8.


[0290] The compounds of general formula (III) according to the
25 third aspect of the present invention can be produced by the following processes S to X.

[0291] Process S

In process S, a compound of general formula (S3) is produced by introducing substituent $\text{R}^{3'c}$ into the 3"-position of the
30 compound of general formula (S1). Process S comprises the following steps. Each step constituting this process will be described in detail. The compound of general formula (S3) can also be produced by removing the protective group in the compound of general formula (N4).

[Chemical formula 25]

Process S

[0292] Step S1

In step S1, a compound of general formula (S2) is produced by introducing substituent R^3C into amino at the 3''-position of the compound of general formula (S1). This step is achieved by reacting, in the presence of a reducing agent, the compound of general formula (S1) with $R^{10}CHO$ wherein R^{10} represents C_{1-9} alkyl in which one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl; aryl; or aralkyl. This step can also be achieved by reacting, in the presence of a base, the compound of general formula (S1) with $R^{14}X$ wherein R^{14} represents C_{1-10} alkyl in which one or more hydrogen atoms in the alkyl group are optionally substituted by hydroxyl; or OR^{15} in which R^{15} represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, tert-butyldiphenylsilyl, or tetrahydropyranyl; or aralkyl. Further, this step can be achieved by reacting the compound of general formula (S1) with an imidoylating agent or an amidinoylating agent for introducing formimidoyl or amidino.

[0293] Reducing agents usable in the step of the reaction with $R^{10}CHO$ include sodium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, and sodium triacetoxyborohydride. The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. The reaction temperature is 0°C to 30°C . The

reaction time is 1 to 8 hr.

[0294] Solvents usable in the step of the reaction with $R^{14}X$ include diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of N,N-dimethylformamide and water. Bases usable herein include sodium carbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide. The base is preferably potassium carbonate. The reaction temperature is 20°C to 80°C. The reaction time is 1 to 16 hr.

[0295] Preferred imidoylating agents usable in the step of introducing formimidoyl include imidate hydrochlorides and $EtOCH=NH \cdot HCl$. Solvents usable herein include methylene chloride, dichloroethane, acetonitrile, methanol, ethanol, and tetrahydrofuran. The solvent is preferably methanol. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0296] Preferred amidinoylating agents usable in the step of introducing amidino include 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. Solvents usable herein include tetrahydrofuran, dioxane, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. Bases usable herein include triethylamine. Mercury chloride may be included as an additive. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 6 hr.

[0297] Step S2


In step S2, a compound of general formula (S3) is produced by removing the protective group in the compound of general formula (S2). The protective group can be removed in the same manner as in step A8.

[0298] Process T

A compound of general formula (T4) is produced by introducing substituent $R^{6'c}$ into the 6'-position of the compound of general formula (T1). This process comprises the following steps. The compound of general formula (T1) can be produced according to step G1 in the above process G.

[Chemical formula 26]

Process T

[0299] Step T1

In step T1, a compound of general formula (T2) is produced. This step is achieved by first removing the protective group at the 6'-position and then reacting the compound of general formula (T1) with $R^{11}CHO$ wherein R^{11} represents C_{1-5} alkyl in which one or more hydrogen atoms in the alkyl group are optionally substituted by amino protected by tert-butoxycarbonyl, p-methoxybenzyloxycarbonyl or the like; or aryl, in the presence of a reducing agent, or by reacting the compound of general formula (T1) with a formimidoylating agent or an amidinoylating agent when the introduction of formimidoyl and amidino is contemplated.

[0300] Solvents usable in the step of the reaction with $R^{11}CHO$ include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane. Reducing agents usable herein include sodium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, and sodium triacetoxyborohydride. The reducing agent is preferably sodium borohydride. The reaction temperature is 0°C to 30°C . The reaction time is 1 to 8 hr.

[0301] Preferred imidoylating agents usable in the step of introducing formimidoyl include imidate hydrochlorides and $\text{EtOCH}=\text{NH}\cdot\text{HCl}$. Solvents usable herein include methylene chloride, dichloroethane, acetonitrile, methanol, ethanol, and tetrahydrofuran. The solvent is preferably methanol. The reaction temperature is 0°C to 30°C . The reaction time is 1 to 12 hr.

[0302] Preferred amidinoylating agents usable in the step of

introducing amidino include 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea. Solvents usable herein include tetrahydrofuran, dioxane, and N,N-dimethylformamide. The solvent is preferably N,N-dimethylformamide. Bases usable herein include triethylamine.

5 Mercury chloride may be included as an additive. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 6 hr.

[0303] Step T2

In step T2, a compound of general formula (T3) is produced by removing the protective group in the compound of general formula (T2). The protective group can be removed in the same manner as in step A8.

10


[0304] Process U

In process U, a compound of general formula (U4) is produced by introducing a side chain into the 6'-position of the compound of general formula (U1). This process comprises the following steps. The compound of general formula (U1) as a starting compound can be produced according to steps O1 and O2 in the above process O.

15

[Chemical formula 27]

Process U



20

[0305] Step U1

In step U1, a compound of general formula (U2) is produced. This step is achieved by reacting the compound of general formula (U1) with $\text{Ph}_3\text{P}=\text{CHCN}$, or by reacting the compound of general formula (U1) with $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{CN}$ in the presence of a base.

25

[0306] Solvents usable in the step of the reaction with

Ph₃P=CHCN include methylene chloride, 1,2-dichloroethane, chloroform, benzene, and toluene. The solvent is preferably chloroform. The reaction temperature is 20°C to 60°C. The reaction time is 1 to 24 hr. Solvents usable in the step of the reaction with (EtO)₂P(O)CH₂CN
 5 include diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, and N,N-dimethylformamide. The solvent is preferably tetrahydrofuran. Bases usable herein include sodium hydride, potassium hydride, and tert-BuOK. The base is preferably sodium hydride. The reaction temperature is 0°C to 30°C. The reaction time
 10 is 1 to 8 hr.

[0307] Step U2

In step U2, a compound of general formula (U3) is produced. This step is achieved by reacting the compound of general formula (U2) with a reducing agent. Reducing agents usable in this
 15 step include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. Preferred are hydrogen and platinum oxide. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred solvents include methanol,
 20 ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.


[0308] Step U3

In step U3, a compound of general formula (U4) is
 25 produced by removing the protective group in the compound of general formula (U3). The protective group can be removed in the same manner as in step A8.

[0309] Process V

In process V, a compound of general formula (V6) is
 30 produced by introducing a side chain into the 6"-position of the compound of general formula (V1). This process comprises the following steps. The compound of general formula (V1) as a starting compound can be produced according to step A1 in the above process A.
 [Chemical formula 28]

Process V



[0310]

Step V1

In step V1, a compound of general formula (V2) is produced by protecting hydroxyl at the 6''-position of the compound of general formula (V1) by triphenylmethyl or silyl and then protecting the remaining hydroxyl in the compound by acyl. This step is achieved by reacting the compound of general formula (V1) with $R^{13}Cl$ wherein R^{13} represents triphenylmethyl, tert-butyldimethylsilyl, triisopropylsilyl, or tert-butyldiphenylsilyl in the presence of a base, and then reacting the resultant compound with B_2O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

[0311]

Solvents usable in the step of introducing triphenylmethyl include methylene chloride, acetonitrile, and pyridine. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 20°C to 80°C. The reaction time is generally 2 to 10 hr.

[0312]

Preferred solvents usable in the step of introducing silyl include methylene chloride, chloroform, dimethylformamide, acetonitrile,

and pyridine. Bases usable herein include 4-dimethylaminopyridine, triethylamine, imidazole, and diisopropylethylamine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

5 [0313] Solvents usable in the step of introducing acyl include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The
10 reaction time is 1 to 8 hr.

[0314] Step V2

In step V2, a compound of general formula (V3) is produced by removing the protective group of hydroxyl, that is, triphenylmethyl or silyl, at the 6"-position of the compound of general
15 formula (V2). This step is achieved by reacting the compound of general formula (V2) with an acid or a base.

[0315] Solvents usable in the step of deprotection of triphenylmethyl group include diethyl ether, tetrahydrofuran, and water. The solvent is preferably diethyl ether. Acids usable herein include
20 formic acid and acetic acid. The acid is preferably formic acid. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0316] Preferred solvents usable in the step of deprotection of silyl group include acetonitrile, tetrahydrofuran, and methylene chloride. Reagents usable in the deprotection include tetrabutylammonium
25 fluoride, hydrogen fluoride-pyridine, hydrogen fluoride-triethylamine, and hydrogen fluoride. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 12 hr.

[0317] Step V3

In step V3, hydroxyl at the 6"-position of the compound of
30 general formula (V3) is oxidized to aldehyde. This step is achieved by reacting the compound of general formula (V3) with an oxidizing agent. The solvent used in this step is preferably pyridine. Dimethylsulfoxide, dicyclohexylcarbodiimide, and a hydrogen donating compound may be used in combination as the oxidizing agent. Hydrogen donating
35 compounds usable herein include phosphoric acid and trifluoroacetic acid. The hydrogen donating compound is preferably trifluoroacetic

acid. The reaction temperature is 0°C to 30°C. The reaction time is 6 to 24 hr.

[0318] Step V4

5 In step V4, a compound of general formula (V5) is produced. This step can be achieved by reacting the compound of general formula (V4) with nitromethane in the presence of a base and then reacting the resultant nitro compound with a reducing agent. This step can also be achieved by reacting, in the presence of a reducing agent, the compound of general formula (V4) with $R^{12}NH_2$ wherein R^{12} represents C_{1-6} alkyl, wherein one or more hydrogen atoms in the alkyl group are optionally substituted by amino protected by tert-butoxycarbonyl, p-methoxybenzyloxycarbonyl or the like, or by reacting, in the presence of a reducing agent, the compound of general formula (V4) with morpholine.

15 [0319] Solvents usable in the step of the reaction with nitromethane include methanol, ethanol, tert-butyl alcohol, methylene chloride, dichloroethane, and mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and methylene chloride. Bases usable herein include sodium methoxide, sodium ethoxide, and tert-BuOK. The base is preferably sodium methoxide. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 6 hr. Reducing agents usable in the next step of reduction include hydrogen and catalysts for catalytic hydrogen reduction such as palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. Preferred are hydrogen and platinum oxide. Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred are methanol, ethanol, tetrahydrofuran, dioxane, and mixed solvent composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

30 [0320] Reducing agents usable in the step of the reaction with the amino compound include sodium borohydride, sodium cyanoborohydride, lithium cyanoborohydride, and sodium triacetoxyborohydride. The reducing agent is preferably sodium borohydride. Solvents usable herein include methanol, ethanol, isopropyl alcohol, dioxane, water, or mixed solvents thereof. The solvent is preferably a mixed solvent composed of methanol and dioxane.

The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0321] Step V5


In step V5, a compound of general formula (V6) is produced by removing the protective group in the compound of general formula (V5). The protective group can be removed in the same manner as in step A8.

[0322] Process W

In process W, a compound of general formula (W5) wherein $R^{6''c}$ represents azidomethyl or aminomethyl, is produced by introducing a side chain into the 6''-position of the compound of general formula (W1). This process comprises the following steps. The compound of the general formula (W1) as a starting compound can be produced according to step A1 in the above process A.

[Chemical formula 29]

Process W



[0323] Step W1

In step W1, a compound of general formula (W2) is produced. This step is achieved by reacting the compound of general formula (W1) with WSO₂Cl wherein W represents methyl, phenyl, or p-

tolyl.

[0324] Solvents usable in this step include, for example, methylene chloride, chloroform, 1,2-dichloroethane, tetrahydrofuran, acetonitrile, and ethyl acetate. The solvent is preferably methylene chloride. Bases usable herein include pyridine, triethylamine, diisopropylethylamine, and 4-dimethylaminopyridine. The base is preferably 4-dimethylaminopyridine. The reaction temperature is generally 0°C to 30°C. The reaction time is 1 to 24 hr.

[0325] Step W2

In step W2, a compound of general formula (W3) is produced by introducing a protective group into hydroxyl at the 2"-position, 4"-position, and 2'''-position of the compound of general formula (W2). This step is achieved by reacting the compound of general formula (W2) with B₂O or BCl wherein B represents acetyl or benzoyl in the presence of a base.

[0326] Solvents usable in this step include pyridine, N,N-dimethylformamide, methylene chloride, and chloroform. The solvent is preferably pyridine. Bases usable herein include triethylamine, pyridine, and 4-dimethylaminopyridine. The base is preferably pyridine. The reaction temperature is 0°C to 30°C. The reaction time is 1 to 8 hr.

[0327] Step W3

In step W3, a compound of general formula (W4) is produced. This step is achieved by reacting the compound of general formula (W3) with sodium azide and then reacting the resultant azide compound with a reducing agent.

[0328] Solvents usable in the step of azidation include tetrahydrofuran, dioxane, 1,2dimethoxyethane, N,N-dimethylformamide, and dimethylsulfoxide. The solvent is preferably N,N-dimethylformamide. The reaction temperature is 60°C to 90°C. The reaction time is 1 to 12 hr.

[0329] Reducing agents usable in the step of reduction include catalysts for catalytic hydrogen reduction used together with hydrogen, for example, palladium-carbon, palladium black, palladium hydroxide, and platinum oxide. Preferred are hydrogen and palladium-carbon.

Any solvent may be used without particular limitation so far as the solvent is inert to this reaction. Preferred solvents include methanol,

ethanol, tetrahydrofuran, dioxane, and mixed solvents composed of these organic solvents and water. The reaction temperature is 10°C to 30°C. The reaction time is generally 1 to 8 hr.

[0330] Step W4

5 In step W4, a compound of general formula (W5) is produced by removing the protective group in the compound of general formula (W4). The protective group can be removed in the same manner as in step A8.

[0331] Salt

10 The compounds according to the present invention may form salts. Such salts include pharmaceutically acceptable nontoxic salts. Specific examples thereof include hydrohalogenic acid salts such as hydrofluoric acid salt, hydrochloric acid salts, hydrobromic acid salts, and hydroiodic acid salts, inorganic acid salts such as sulfuric acid salts,
15 nitric acid salts, phosphoric acid salts, perchloric acid salts, and carbonic acid salts, carboxylic acid salts such as acetic acid salts, trichloroacetic acid salts, trifluoroacetic acid salts, hydroxyacetic acid salts, lactic acid salts, citric acid salts, tartaric acid salts, oxalic acid salts, benzoic acid salts, mandelic acid salts, butyric acid salts, maleic acid salts, propionic
20 acid salts, forming acid salts, and malic acid salts, amino acid salts such as alginic acid salts, aspartic acid salts, and glutamic acid salts, and organic acid salts such as methanesulfonic acid salts and p-toluenesulfonic acid salts. Preferred are inorganic acid salts such as sulfuric acid salts.

25 [0332] Solvate

 The compounds according to the present invention may form solvates. Preferred solvates include, for example, hydrates and ethanolates.

[0333] Antimicrobial activity

30 The compounds according to the present invention or pharmacologically acceptable salts or solvates thereof have potent antimicrobial activity against bacteria causative of infectious diseases, for example, MRSA, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa and thus can be used as antimicrobial agents,
35 especially anti-MRSA agents. Thus, according to another aspect of the present invention, there is provided use of a compound according to

the present invention or a pharmacologically acceptable salt or solvate thereof, for the manufacture of an antimicrobial agent.

[0334] Medicament

5 The compounds according to the present invention or
pharmacologically acceptable salts or solvates thereof may also be
utilized as medicaments. Specifically, the compounds according to the
present invention or pharmacologically acceptable salts or solvates
thereof may be used for preventing or treating infectious diseases.
Such infectious diseases include, for example, septicemia, infectious
10 endocarditis, dermatological infections, surgical infections, orthopaedic
infections, respiratory tract infections, urinary-tract infections, enteric
infections, peritonitis, meningitis, ophthalmologic infections, and otologic
infections. More specific examples of infectious diseases include skin
suppuration, burn/operation wound secondary infections, pneumonia,
15 endobronchial infections, tuberculosis, pyelonephritis, enteritis including
food poisoning, conjunctivitis, and tympanitis. Thus, according to
another aspect of the present invention, there is provided a composition,
especially a pharmaceutical composition, comprising a compound
according to the present invention or a pharmacologically acceptable salt
20 or solvate thereof. Further, according to still another aspect of the
present invention, there is provided a method for treating or preventing
an infectious disease, comprising the step of administering a compound
according to the present invention or a pharmacologically acceptable salt
or solvate thereof to an animal including a human. According to a
25 further aspect of the present invention, there is provided use of a
compound according to the present invention or a pharmacologically
acceptable salt or solvate thereof, for the manufacture of a
pharmaceutical composition.

[0335] Pharmaceutical compositions comprising compounds of
30 the present invention or pharmacologically acceptable salts thereof as an
active ingredient can be administered to all mammals including humans
orally or parenterally by administration routes, for example, intravenous
administration, intramuscular administration, subcutaneous
administration, rectal administration, percutaneous administration, ocular
35 topical administration, or pulmonic administration. Therefore, the
pharmaceutical composition comprising a compound according to the

present invention as an active ingredient may be formulated into suitable dosage forms according to the administration routes. Specifically, the pharmaceutical composition may be mainly formulated into any of injections such as intravenous injections and intramuscular injections, oral preparations such as capsules, tablets, granules, powders, pills, fine
 5 subtles, and troches, ointments, eye drops, dry powders, or atomized aerosol formulations. These preparations may be prepared by conventional methods, for example, with commonly used additives for preparations, such as excipients, extenders, binders, wetting agents,
 10 disintegrants, surfactants, lubricants, dispersants, buffering agents, preservatives, solubilizers, antiseptics, corrigents, deodorants, soothing agents, stabilizers, tonicity adjusting agents, and pH adjustors. Nontoxic additives usable herein include, for example, lactose, D-mannitol, fructose, glucose, starches, gelatin, methylcellulose or its salts,
 15 gum arabics, polyethylene glycols, syrup, vaseline, lanoline, glycerin, ethanol, propylene glycol, citric acid or its salts, sodium chloride, sodium sulfite, benzalconium chloride, sodium phosphate, methyl p-oxybenzoate, propyl p-oxybenzoate, β -cyclodextrin, hydroxypropyl- β -cyclodextrin, Tween 80, sodium hydroxide, and sulfuric acid. The dose
 20 may be appropriately determined in consideration of particular conditions, for example, dose regimen, the age, sex, and severity of condition of patients.

EXAMPLES

[0336] The present invention is further illustrated by the following
 25 Examples that are not intended as a limitation of the invention.


In the following Examples, arbekacin, 3,2',6'-tri-N-t-butoxycarbonyl-4''-N-p-methoxybenzyloxycarbonylarbekacin, and 3,2',6'-tri-N-t-butoxycarbonyl-3''-trifluoroacetyl-dibekacin were synthesized according to the method described in Japanese Patent Laid-Open No.
 30 164696/1980. 2',3,6'-Tri-N-(t-butoxycarbonyl)-3''-N-trifluoroacetyl-3',4'-didehydrodibekacin was synthesized using 3',4'-didehydrodibekacin according to the method described in Japanese Patent Laid-Open No. 164696/1980. 2',3,6'-Tri-N-(t-butoxycarbonyl)-3''-N-trifluoroacetyl-3',4'-didehydrodibekacin was synthesized, by using 3',4'-didehydrodibekacin,
 35 according to the method described in Japanese Patent Laid-Open No. 164696/1980. 3',4'-Didehydroarbekacin was synthesized according to

the method described in Japanese Patent Publication No. 10719/1988. 3,2',6',3"-Tetra-N-t-butoxycarbonyl-3',4'-didehydro-4'''-p-methoxybenzyl-oxy-carbonylarbekacin was synthesized according to the method described in Japanese Patent Laid-Open No. 81897/1980.

5 [0337] Example 1

5,4"-Diepiarbekacin


[Chemical formula 30]



[0338] Production step 1-(a)

10 N,N-Dimethylformamide (900 mL) was added to a solution of 100 g of arbekacin dissolved in 450 mL of water. Di-t-butyl dicarbonate (250 g) was added thereto under an ice bath, and the mixture was stirred at room temperature overnight. Ethyl acetate was added to the reaction solution, and the mixture was washed with a
15 saturated aqueous sodium hydrogencarbonate solution and a saturated aqueous sodium chloride solution in that order and was dried over anhydrous magnesium sulfate. This solution was concentrated to dryness to give 188 g of the following compound as a solid.


[Chemical formula 31]



20 [0339] Production step 1-(b)

The compound (40 g) prepared in production step 1-(a) was dissolved in 360 mL of N,N-dimethylformamide, 11.6 mL of 1,1-dimethoxycyclohexane and 1.3 g of p-toluenesulfonic acid monohydrate
25 were added to the solution, and the mixture was allowed to react under conditions of 50°C and 46 to 48 mbar for 5 hr. Ethyl acetate was added thereto, and the mixture was washed with water and was concentrated to dryness to give 45 g of the following compound.

[Chemical formula 32]




FABMS: m/z 1155 $[M+Na]^+$, 1171 $[M+Na]^+$.

[0340] Production step 1-(c)

- 5 The compound (25 g) prepared in production step 1-(b) was dissolved in 500 mL of pyridine, and benzoyl chloride was added dropwise to the solution at an internal temperature of 4 to 6°C over a period of 20 min. This solution was stirred for 2 hr while maintaining the internal temperature of the solution at 4 to 6°C, and the temperature was
- 10 raised to room temperature, followed by stirring for 1 hr. Water (0.75 mL) was added to this solution, and the mixture was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water, a 10% aqueous potassium hydrogensulfate solution, a saturated aqueous sodium
- 15 hydrogencarbonate solution, and a saturated aqueous sodium chloride solution in that order, dried over anhydrous magnesium sulfate, and then concentrated to dryness to give 30 g of the following compound.

[Chemical formula 33]




- 20 FABMS: m/z 1363 $[M+Na]^+$, 1379 $[M+K]^+$.

[0341] Production step 1-(d)

- The compound (11.6 g) prepared in production step 1-(c) was dissolved in 150 mL of methylene chloride. 4-Dimethylaminopyridine (18 g) was added to the solution at room
- 25 temperature, 4.5 mL of mesyl chloride was added thereto under an ice bath, and the mixture was stirred under an ice bath for 1 hr. The temperature was then raised to room temperature before stirring for 4 hr.

Water (100 mL) was added to this reaction solution under an ice bath, and 240 mL of methylene chloride was added thereto. This solution was washed with a 10% aqueous potassium hydrogensulfate solution, a saturated aqueous sodium hydrogencarbonate solution, and a saturated aqueous sodium chloride solution in that order and was dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 1 to 1 : 2) to give 7.4 g of the following compound.


[Chemical formula 34]



[0342] Production step 1-(e)

The compound (6.0 g) prepared in production step 1-(d) was dissolved in 60 mL of N,N-dimethylformamide. Cesium acetate (6.4 g) dried at 120°C in a sample dryer for 2 hr was added to the solution, and a reaction was allowed to proceed at 100°C for 2 hr. This solution was cooled to room temperature and was concentrated under the reduced pressure. Methylene chloride (300 mL) was added to the residue, and the mixture was washed with water and was dried over anhydrous magnesium sulfate. The solution was then concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 1 to 2 : 3) to give 4.6 g of the following compound.

[Chemical formula 35]




FABMS: m/z 1405 $[M+Na]^+$, 1421 $[M+K]^+$.

[0343] Production step 1-(f)

The compound (1.13 g) prepared in production step 1-(e)

was dissolved in a mixed solution composed of 40 mL of methylene chloride and 4 mL of methanol. A 90% aqueous trifluoroacetic acid solution (4 mL) was added to the solution, and the mixture was stirred for 1 hr. Water (20 mL) was added to the reaction solution, and the organic layer was washed with a saturated aqueous sodium hydrogencarbonate solution, dried over anhydrous magnesium sulfate, and then concentrated under the reduced pressure to give 1.03 g of the following compound.


[Chemical formula 36]



[0344] Production step 1-(g)

The compound (1.03 g) prepared in production step 1-(f) was dissolved in 8 mL of pyridine. Triphenylmethyl chloride (0.56 g) was added to the solution, and the mixture was stirred at 60°C overnight. After the completion of this reaction, 0.15 mL of methanol was added thereto, and the mixture was stirred for 1 hr. This reaction solution was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and then concentrated under the reduced pressure to give 0.99 g of the following compound.

[Chemical formula 37]




FABMS: m/z 1567 $[M+Na]^+$.

[0345] Production step 1-(h)


The compound (0.84 g) prepared in production step 1-(g) was dissolved in 8 mL of methylene chloride, and 0.54 mL of pyridine was added to the solution. The mixture was cooled to -18°C, 0.24 mL of trifluoromethanesulfonic anhydride was added thereto, and the mixture was stirred at -5°C for 2 hr. After six drops of methanol were added to this reaction solution, the mixture was extracted with ethyl acetate. The organic layer was washed with ice water, a saturated aqueous sodium

hydrogencarbonate solution, and a 10% aqueous potassium hydrogensulfate solution, dried over anhydrous magnesium sulfate, and then concentrated under the reduced pressure. Further, toluene was added to the residue, and the mixture was concentrated under the reduced pressure. The residue was dissolved in 9 mL of N,N-dimethylformamide. Cesium acetate (0.59 g) dried at 120°C for 2 hr in a sample dryer was added to this solution, and the mixture was allowed to react at room temperature for 2 hr. This reaction solution was extracted with ethyl acetate, and the extract was dried over anhydrous magnesium sulfate to give 0.93 g of the following compound.
[Chemical formula 38]



[0346] Production step 1-(i)

The compound (0.92 g) prepared in production step 1-(h) was dissolved in 15 mL of methylene chloride, 5 mL of a 0.5 M sodium methoxide-methanol solution was added to the solution, and the mixture was stirred at room temperature for 3 hr. Dry ice was added to the reaction solution, and the mixture was stirred for 30 min and concentrated under the reduced pressure to give the following compound (0.72 g) as a crude product.
[Chemical formula 39]



[0347] Production step 1-(i)

A 90% aqueous trifluoroacetic acid solution (15 mL) was added to 0.72 g of the crude product prepared in production step 1-(i), and the mixture was stirred at room temperature overnight. Water (10 mL) was added to the reaction solution, and the aqueous layer was washed three times with 5 mL of diethyl ether. The aqueous layer was

neutralized and adjusted to pH 7 by the addition of aqueous ammonia and was purified by Bio-Rex70(NH_4^+ , 110 mL, 100-200 mesh) to give the title compound: 5,4''-diepiarbekacin (0.16 g).


TSPMS: m/z 553 $[\text{M}+\text{H}]^+$;

5 ^1H -NMR ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.54 (1H, m), 1.60 (1H, m), 1.93 (4H, m), 2.11 (1H, m), 2.22 (1H, ddd, $J = 4.4, 4.6, 12.9$ Hz), 2.85 (2H, m), 2.94 (2H, m), 3.02 (1H, m), 3.17 (1H, dd, $J = 2.9, 10.7$ Hz), 3.41 (1H, m), 3.67 (1H, dd, $J = 2.4, 10.0$ Hz), 3.76 (1H, dd, $J = 3.9, 10.7$ Hz), 3.92 (2H, m), 4.00 (1H, dd, $J = 2.6, 10.5$ Hz), 4.02 (1H, m), 4.07 (1H, brd), 4.27 (1H, m), 4.38
10 (1H, dd, $J = 3.6, 9.2$ Hz), 4.46 (1H, m), 4.75 (1H, dd, $J = 2.3$ Hz), 5.14 (1H, d, $J = 3.4$ Hz), 5.27 (1H, d, $J = 3.9$ Hz).

[0348] Example 2

5-Deoxy-4''-epi-5-epifluoroarbekacin

[Chemical formula 40]




15

[0349] Production step 2-(a)

The compound (2.5 g) prepared in production step 1-(b) of Example 1 was dissolved in 7.0 mL of pyridine, 3.0 mL of acetic anhydride was added to the solution, and the mixture was stirred at room
20 temperature overnight. The reaction solution was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and was then concentrated under the reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 2) to give 1.9 g of the following compound.

25 [Chemical formula 41]




ESIMS: m/z 1217 $[\text{M}+\text{H}]^+$.

[0350] Production step 2-(b)

1.0 g of the compound prepared in production step 2-(a) was used in the same manner as in production step 1-(f) in Example 1 to give the following compound (0.91 g).

[Chemical formula 42]



5


FABMS: m/z 1159 $[M+Na]^+$

[0351] Production step 2-(c)

2.4 g of the compound prepared in production step 2-(b) was used in the same manner as in production step 1-(g) to give the following compound (2.2 g).

10

[Chemical formula 43]




FABMS: m/z 1379 $[M+H]^+$.

[0352] Production step 2-(d)

15

0.74 g of the compound prepared in production step 2-(c) was used in the same manner as in production step 1-(h) in Example 1 to give the following compound (0.25 g).

[Chemical formula 44]



20 FABMS: m/z 1443 $[M+Na]^+$.


[0353] Production step 2-(e)

The compound (0.18 g) prepared in production step 2-(d) was dissolved in 5.0 mL of methylene chloride. Under cooling at -50°C , 0.058 mL of diethylamino sulfur trifluoride (DAST) was added to the solution, and the mixture was stirred at room temperature for 3 hr. Thereafter, under ice cooling, 5 mL of saturated aqueous sodium

25

hydrogencarbonate solution was added thereto, and the mixture was stirred for 5 min and was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and was then concentrated under the reduced pressure to give the following compound as a crude product. The crude product as such was used in the next step, production step 2-(f), without isolation and purification.

[Chemical formula 45]



[0354] Production step 2-(f)

170 mg of the crude product prepared in production step 2-(e) was used in the same manner as in production steps 1-(i) and (j) in Example 1 to give the title compound: 5-deoxy-4''-epi-5-epifluoroarbakacin (7.3 mg).


FABMS: m/z 555 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.88 (2H, m), 2.12 (4H, m), 2.20 (3H, m), 2.37 (1H, m), 2.52 (1H, m), 3.12 (2H, m), 3.23 (3H, m), 3.40 (1H, dd, $J = 3.0, 10.7$ Hz), 3.66 (1H, m), 4.03 (1H, dd, $J = 3.9, 10.7$ Hz), 4.03 (1H, dd, $J = 10.3, 27.1$ Hz), 4.18 (2H, m), 4.28 (1H, m), 4.32 (1H, m), 4.38 (1H, dd, $J = 11.0, 27.3$ Hz), 4.52 (1H, m), 4.63 (1H, dd, $J = 3.6, 9.3$ Hz), 4.67 (1H, ddd, $J = 4.7, 11.0$ Hz), 5.43 (1H, d, $J = 3.2$ Hz), 5.52 (1H, d, $J = 3.6$ Hz), 5.88 (1H, d, $J = 52.2$ Hz).

[0355] Example 3

5-Deoxy-4''-epi-5-epichloroarbakacin

[Chemical formula 46]




Production step 3-(a)

0.28 g of the compound prepared in production step 2-(d) was used in the same manner as in production step 1-(d) to give the

following compound (0.21 g).


[Chemical formula 47]



[0356] Production step 3-(b)

5 0.21 g of the compound prepared in production step 3-(a) was used in the same manner as in production step 1-(e) in Example 1 except that lithium chloride was used instead of cesium acetate, to give the following compound (0.13 g).

[Chemical formula 48]



10

FABMS: m/z 1461 $[M+Na]^+$, 1477 $[M+K]^+$.

[0357] Production step 3-(c)

15 130 mg of the compound prepared in production step 3-(b) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-4"-epi-5-epichloroarbekacin (14.0 mg)


FABMS: m/z 571 $[M+H]^+$

20 1H -NMR (D_2O+ND_3) δ : 1.60 (2H, m), 1.92 (4H, m), 2.11 (1H, m), 2.26 (1H, m), 2.85 (2H, m), 2.98 (3H, m), 3.16 (1H, dd, $J = 2.9, 10.7$ Hz), 3.52 (1H, m), 3.77 (1H, dd, $J = 3.9, 10.7$ Hz), 3.92 (3H, m), 4.02 (1H, m), 4.07 (1H, brd, $J = 2.9$ Hz), 4.24 (1H, dd, $J = 3.1, 10.5$ Hz), 4.33 (1H, m), 4.38 (1H, dd, $J = 3.6, 9.2$ Hz), 4.53 (1H, m), 5.10 (1H, d, $J = 3.4$ Hz), 5.23 (1H, brs, $J = 3.7$ Hz), 5.27 (1H, d, $J = 3.9$ Hz).

[0358] Example 4

5-Deoxy-4"-epi-5-epiazidoarbekacin


25 [Chemical formula 49]



Production step 4-(a)

100 mg of the compound prepared in production step 3-(a) was used in the same manner as in production step 1-(e) except that sodium azide was used instead of cesium acetate, to give the following compound (57 mg).

[Chemical formula 50]



FABMS: m/z 1446 $[M+H]^+$.

10 [0359] Production step 4-(b)

The compound (52 mg) prepared in step 4-(a) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-4"-epi-5-epiazidoarbekacin (6.3 mg).

FABMS: m/z 578 $[M+H]^+$

15 $^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.54 (1H, m), 1.60 (1H, m), 1.92 (4H, m), 2.12 (1H, m), 2.19 (1H, ddd, $J = 4.5, 12.9$ Hz), 2.86 (2H, m), 2.95 (2H, m), 3.04 (1H, m), 3.14 (1H, dd, $J = 3.0, 10.7$ Hz), 3.34 (1H, m), 3.78 (2H, m), 3.95 (2H, m), 4.00 (1H, m), 4.09 (2H, brd), 4.24 (2H, m), 4.37 (1H, dd, $J = 3.6, 9.3$ Hz), 4.46 (1H, ddd, $J = 3.6, 1.5$ Hz), 4.61 (1H, brs), 5.16 (1H, d, $J = 3.4$ Hz), 5.30 (1H, d, $J = 3.9$ Hz).

[0360] Example 5

5-Deoxy-4"-epi-5-epiaminoarbekacin

[Chemical formula 51]

The compound produced in Example 4: 5-deoxy-4"-epi-5-epiazidoarbekacin (8.3 mg) was dissolved in 5.0 mL of water. Under an argon gas stream, 10% Pd-C (8.0 mg) was added thereto. The air in the system was then replaced by hydrogen and the mixture was stirred at room temperature for 5 hr. The reaction solution was filtered through Celite and was then purified by CM-Sephadex (NH₄⁺) to give the title compound: 5-deoxy-4"-epi-5-epiaminoarbekacin (5.7 mg).


¹H-NMR (D₂O+ND₃): δ 1.57 (1H, m), 1.62 (1H, m), 1.97 (4H, m), 2.15 (1H, m), 2.23 (1H, m), 2.89 (2H, m), 2.98 (2H, m), 3.05 (1H, m), 3.20 (1H, dd, J = 3.2, 11.0 Hz), 3.47 (1H, ddd, J = 4.4, 11.7 Hz), 3.74 (1H, dd, J = 3.4, 10.3 Hz), 3.79 (1H, dd, J = 3.9, 11.0 Hz), 3.94 (2H, m), 4.04 (2H, m), 4.12 (2H, m), 4.22 (1H, dd, J = 6.1 Hz), 4.41 (1H, dd, J = 3.4, 9.3 Hz), 4.52 (1H, ddd, J = 3.6, 7.3 Hz), 5.16 (1H, d, J = 3.2 Hz), 5.30 (1H, d, J = 3.9 Hz).

5-Deoxy-4''-epi-5-epi(2-hydroxyethyl)aminoarbakacin

The chemical structure shows a complex oligosaccharide with multiple amino and hydroxyl groups. It features a central pyranose ring with various substituents, including amino groups (H₂N) and hydroxyl groups (OH), and is connected to other sugar units via glycosidic bonds.

The compound (100 mg) produced in production step 3-(a) was used in the same manner as in production step 1-(e) except that 2-aminoethanol instead of cesium acetate, to give the following compound as a crude product. This crude product was used in production step 6-(b) without isolation and purification.

[Chemical formula 53]



[0362] Production step 6-(b)

72 mg of the compound produced in production step 6-(a) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-4"-epi-5-epi(2-hydroxyethyl)aminoarbakacin (13 mg).


FABMS: m/z 596 $[M+H]^+$

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$): δ 1.56 (1H, m), 1.65 (1H, m), 1.99 (4H, m), 2.17 (1H, m), 2.26 (1H, ddd, $J = 4.9, 13.2$ Hz), 2.90 (2H, m), 3.00 (2H, m), 3.08 (2H, m), 3.17 (1H, m), 3.27 (1H, m), 3.46 (1H, m), 3.80 (1H, m), 4.00 (5H, m), 4.13 (1H, m), 4.15 (1H, dd, $J = 3.2, 11.0$ Hz), 4.27 (1H, dd, $J = 5.8, 5.9$ Hz), 4.41 (1H, dd, $J = 3.4, 9.2$ Hz), 4.65 (1H, ddd, $J = 4.2, 11.7$ Hz), 5.17 (1H, d, $J = 3.2$ Hz), 5.30 (1H, d, $J = 3.9$ Hz).

[0363] Example 7

15 4"-Epiarbakacin

[Chemical formula 54]



Production step 7-(a)

75 mg of the compound produced in production step 2-(d) was used in the same manner as in production steps 1-(i) and (j) to give the title compound: 4"-epiarbakacin (24 mg).

[0364] FABMS: m/z 553 $[M+H]^+$


$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$): δ 1.70 (2H, m), 1.90 (1H, m), 2.00 (3H, m), 2.19 (2H, m), 2.92 (2H, m), 3.02 (2H, m), 3.12 (1H, ddd, $J = 3.7, 12.4$ Hz), 3.18 (1H, m), 3.20 (1H, m), 3.61 (1H, dd, $J = 9.1$ Hz), 3.85 (1H, dd, $J = 3.8, 10.7$ Hz), 3.97 (4H, m), 4.13 (1H, m), 4.16 (1H, brd), 4.22 (1H, ddd, $J = 4.3, 9.7, 13.4$ Hz), 4.44 (1H, dd, $J = 3.6, 9.2$ Hz), 4.51 (1H, m), 5.39 (1H, d, $J = 3.8$ Hz), 5.41 (1H, d, J

= 3.9 Hz).

[0365] Example 8

4"-Deoxy-5-epiarbekacin

[Chemical formula 55]




5

Production step 8-(a)

560 mg of the compound produced in production step 2-(c) was used in the same manner as in production step 2-(d) except that lithium chloride was used instead of cesium acetate, to give the following compound (284 mg)

10

[Chemical formula 56]



FABMS: m/z 1435 $[M+K]^+$.


[0366] Production step 8-(b)

15

The compound (140 mg) prepared in production step 8-(a) was dissolved in 7.0 mL of dioxane. Tri-*n*-butyltin hydride (0.43 mL) and 15 mg of azobisisobutyronitrile were added to the solution, and the mixture was stirred at 80°C overnight. The reaction solution was concentrated under the reduced pressure, and the residue was washed with hexane and was purified by preparative TLC (hexane : ethyl acetate = 5 : 7) to give 109 mg of the following compound.

20

[Chemical formula 57]




FABMS: m/z 1385 $[M+Na]^+$, 1401 $[M+K]^+$

[0367] Production step 8-(c)


95 mg of the compound prepared in production step 8-(b) was used in the same manner as in production step 1-(d) to give the following compound as a crude product. This compound as such was used in the next step without isolating and purifying the compound.

[Chemical formula 58]

[0368] Production step 8-(d)

The compound produced in production step 8-(c) was used in the same manner as in production step 1-(e) to give the following compound (25 mg).

[Chemical formula 59]

FABMS: m/z 1427 $[M+Na]^+$.15 [0369] Production step 8-(e)

25 mg of the compound produced in production step 8-(d) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 4"-deoxy-5-epiarbekacin (10 mg).


FABMS: m/z 537 $[M+H]^+$

20 1H -NMR (D_2O+ND_3): δ 1.30 (1H, m), 1.40 (1H, m), 1.47 (1H, m), 1.78 (4H, m), 1.91 (1H, m), 2.00 (1H, m), 2.08 (1H, m), 2.72 (2H, m), 2.83 (2H, m), 2.89 (1H, m), 3.16 (1H, m), 3.28 (1H, m), 3.33 (1H, dd, J = 3.8, 10.2 Hz), 3.52 (1H, dd, J = 2.2, 10.3 Hz), 3.60 (1H, dd, J = 7.6, 12.1 Hz), 3.70 (1H, dd, J = 2.7, 12.1 Hz), 3.84 (1H, m), 3.92 (1H, m), 4.16 (1H, m), 4.25 (1H, dd, J = 3.6, 9.5 Hz), 4.31 (1H, ddd, J = 4.6, 12.2 Hz), 4.57 (1H, brs), 5.01 (1H, d, J = 3.4 Hz), 5.12 (1H, d, J = 3.8 Hz).

[0370] Example 9

1-N-[(S)-(3-amino-2-hydroxypropanoyl)]-5,4"-diepidibekacin


[Chemical formula 60]



Production step 9-(a)

3,2',6'-Tri-N-t-butoxycarbonyl-3''-trifluoroacetyl-dibekacin (5 g) was dissolved in 100 mL of 1,4-dioxane and 50 mL of water. Triethylamine (0.44 mL) and 2 g of benzyloxycarbonyloxysuccinimide were added to the solution, and the mixture was stirred for one hr. The reaction solution was concentrated under the reduced pressure, and the residue was washed with hexane, diisopropyl ether, and diethyl ether and was dried to give the following compound.


[Chemical formula 61]



[0371] Production step 9-(b)

The compound produced in production step 9-(a) was dissolved in 150 mL of methanol. 150 mL of aqueous ammonia was added to the solution, and the mixture was stirred at room temperature overnight. This reaction solution was concentrated under the reduced pressure to give the following compound.

[Chemical formula 62]




[0372] Production step 9-(c)

The compound produced in production step 9-(b) was dissolved in 100 mL of tetrahydrofuran and 50 mL of water. Triethylamine (0.66 mL) and 1.9 mL of t-butyl dicarbonate were added to the solution, and the mixture was stirred overnight. The reaction solution was concentrated under the reduced pressure, and the residue

was purified by column chromatography on silica gel (methylene chloride : methanol : aqueous ammonia = 300 : 10 : 1) to give 2.8 g of the following compound.

[Chemical formula 63]




5

[0373] Production step 9-(d)

The compound produced in production step 9-(c) was used in the same manner as in production step 1-(b) to give the following compound.

10 [Chemical formula 64]




[0374] Production step 9-(e)

The compound produced in production step 9-(d) was used in the same manner as in production step 2-(a) to give the following compound.

15

[Chemical formula 65]




[0375] Production step 9-(f)

The compound produced in production step 9-(e) was used in the same manner as in production step 1-(f) to give the following compound.

20


[Chemical formula 66]



[0376] Production step 9-(g)


3 g of the compound produced in production step 9-(f) was used in the same manner as in production step 1-(g) to give the following compound (1.2 g).

5 [Chemical formula 67]

[0377] Production step 9-(h)

1.2 g of the compound produced in production step 9-(g) was used in the same manner as in production step 1-(h) to give the following compound (1.2 g).

[Chemical formula 68]

[0378] Production step 9-(i)


1.2 g of the compound produced in production step 9-(h) was used in the same manner as in production step 1-(d) to give the following compound (0.35 g).

[Chemical formula 69]

[0379] Production step 9-(j)

0.35 g of the compound produced in production step 9-(i) was used in the same manner as in production step 1-(e) to give the following compound (0.20 g).


[Chemical formula 70]



25 [0380] Production step 9-(k)

0.20 g of the compound produced in production step 9-(j) was used in the same manner as in production step 1-(i) to give the following compound (0.17 g).

[Chemical formula 71]




5

[0381] Production step 9-(l)

The compound (75 mg) produced in production step 9-(k) was dissolved in methanol. 0.23 mL of formic acid and 145 mg of palladium-carbon were added to the solution, and the mixture was stirred for 5 hr. The reaction solution was filtered through Celite, and the filtrate was concentrated under the reduced pressure. Methylene chloride was added to the residue, and the mixture was washed with a 5% aqueous sodium hydrogencarbonate solution and was dried over magnesium sulfate. This solution was concentrated to dryness to give 46 mg of the following compound.

10
15

[Chemical formula 72]




[0382] Production step 9-(m)

(s)-3-Benzyloxycarbonylamino-2-hydroxypropionic acid (30 mg) was dissolved in 1 mL of tetrahydrofuran. DCC (25 mg) and 14 mg of hydroxysuccinimide were added to the solution, and the mixture was stirred for 5 hr to give an active ester solution. The compound (67 mg) produced in production step 9-(l) was dissolved in 1 mL of a tetrahydrofuran/water solution (tetrahydrofuran : water = 3 : 1), and 13 mg of sodium carbonate was added to the solution. The active ester solution prepared above was added to this solution, and the mixture was stirred for one hr. Thereafter, 80 mL of methylene chloride was added to the reaction solution, and the mixture was washed with saturated brine and dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure, and the residue was purified

20
25
30

by column chromatography on silica gel (methylene chloride : methanol : aqueous ammonia = 100 : 10 : 1) to give 20 mg of the following compound.

[Chemical formula 73]



5

[0383] Production step 9-(n)

The compound (20 mg) produced in production step 9-(m) was dissolved in 2 mL of 90% aqueous trifluoroacetic acid solution, and the mixture was stirred for 4 hr. The reaction solution was concentrated under the reduced pressure. Thereafter, the concentrate was dissolved in 2 mL of water, 20 mg of palladium-carbon was added to the solution, and the mixture was stirred in a hydrogen atmosphere for 4 hr. This solution was filtered through Celite and was concentrated under the reduced pressure. The residue was purified by CM-Sephadex(NH₄⁺) to give the title compound: 1-N-[(S)-(3-amino-2-hydroxypropanoyl)]-5,4"-diepidibekacin (10 mg).


FABMS: m/z 539 [M+H]⁺;

¹H-NMR (D₂O+ND₃) δ: 1.33 - 1.54 (2H, m), 1.75 - 1.88 (3H, m), 2.05 - 2.13 (1H, m), 2.69 - 2.83 (2H, m), 2.86 - 2.95 (2H, m), 3.00 - 3.09 (2H, m), 3.20 - 3.33 (1H, m), 3.54 (1H, dd, J = 2.5), 3.64 (1H, dd, J = 4.0, 10.8 Hz), 3.79 - 4.00 (3H, m), 3.86 (1H, dd, J = 2.3, 10.8 Hz), 3.96 (1H, d, J = 1.9 Hz), 4.12 - 4.18 (1H, m), 4.22 (1H, dd, J = 3.9, 6.9 Hz), 4.30 - 4.38 (1H, m), 4.56 (1H, s), 5.02 (1H, d, J = 3.2 Hz), 5.14 (1H, d, J = 4.1 Hz).

25 [0384] Example 10

1-N-[(S)-(5-Amino-2-hydroxypentanoyl)]-5,4"-diepidibekacin

[Chemical formula 74]




[0385] Production step 10-(a)

(s)-5-benzyloxycarbonylamino-2-hydroxypentanoic acid was used in the same manner as in Example 9 to give the title compound: 1-N-[(S)-(5-amino-2-hydroxypentanoyl)]-5,4"-diepidibekacin.

5 FABMS: m/z 567 [M+H]⁺.


[0386] Example 115,4"-Diepi-3"-N-methylarbekacin

[Chemical formula 75]

10 Production step 11-(a)

3,2',6'-Tri-N-t-butoxycarbonyl-4''-N-p-methoxybenzyloxy-carbonyl-arbekacin (3.0 g) was dissolved in 30 mL of a methanol/dioxane solution (methanol : dioxane = 1 : 1) . 0.84 mL of triethylamine and 0.46 mL of benzaldehyde were added to the solution, and the mixture was stirred at room temperature for 2 hr. The reaction solution was concentrated under the reduced pressure, followed by washing with diisopropyl ether. The residue was dissolved in 30 mL of a methanol/dioxane solution (methanol : dioxane = 1 : 1). Sodium borohydride (113 mg) was added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated under the reduced pressure, the concentrate was extracted with methylene chloride, and the extract was dried over anhydrous magnesium sulfate and was then concentrated under the reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride : methanol = 9 : 1) to give 0.87 g of the following compound.


[Chemical formula 76]



FABMS: m/z 1107 $[M+H]^+$.

[0387] Production step 11-(b)

1.40 g of the compound produced in production step 11-(a) was used in the same manner as in production step 11-(a) except that formaldehyde was used instead of benzaldehyde, to give the following compound (0.99 g).
[Chemical formula 77]



FABMS: m/z 1121 $[M+H]^+$.

10 [0388] Production step 11-(c)


A reaction was allowed to proceed in the same manner as in production steps 1-(b) to 1-(j), except that the compound produced in the above step (b) was used. The compound thus obtained was dissolved in water. 1 M hydrochloric acid was added to the solution, and 10%Pd-C was added thereto under an argon gas stream. The air in the system was then replaced by hydrogen, followed by stirring at room temperature overnight. The reaction solution was filtered through Celite and was then purified by CM-Sephadex(NH_4^+) to give the title compound: 5,4''-diepi-3''-N-methylarbekacin.

20 FABMS: m/z 567 $[M+H]^+$.

Example 12

5,4''-Diepi-6'-N-methylarbekacin


[Chemical formula 78]



25 Production step 12-(a)

Arbekacin (22 g) was dissolved in 116 mL of water, and 772 mL of N,N-dimethylformamide was added to the solution. Zinc acetate

(14.7 g) was added thereto, and the mixture was stirred for 1 hr. Benzyloxycarbonyloxysuccinimide was added thereto, and the mixture was stirred for 5 hr. The reaction solution was concentrated under the reduced pressure, and the residue was purified by Amberlite CG-50(NH₄⁺) to give 4.9 g of the following compound.
[Chemical formula 79]




FABMS: m/z 687 [M+H]⁺.

[0389] Production step 12-(b)

The compound (4.9 g) produced in production step 12-(a) was dissolved in 100 mL of water. Methanol (150 mL) and 25 mL of 1,4-dioxane were added to the solution, 0.8 mL of triethylamine and 9.5 mL of di-t-butyl dicarbonate were further added thereto, and the mixture was stirred overnight. The reaction solution was concentrated under the reduced pressure. The residue was washed with hexane, diisopropyl ether and diethyl ether, and concentrated to dryness to give 8.0 g of the following compound.


[Chemical formula 80]



[0390] Production step 12-(c)

The compound produced in production step 12-(b) was dissolved in 80 mL of 1,4-dioxane, 16 mL of water was added to the solution, 0.5 g of 10%Pd-C was added thereto, and a catalytic hydrogen reduction reaction was carried out under a hydrogen atmosphere. After filtration through Celite, the filtrate was concentrated to dryness to give 6.0 g of the following compound.


[Chemical formula 81]



[0391] Production step 12-(d)

The compound (6.0 g) produced in production step 12-(c) was dissolved in 100 mL of 1,4-dioxane. Methanol (100 mL) was added to the solution, 1.8 mL of triethylamine and 1.0 mL of benzaldehyde were added thereto, and the mixture was stirred for 2 hr. The reaction solution was concentrated under the reduced pressure. The residue was washed with diisopropyl ether and was then concentrated to dryness. The residue was dissolved in 100 mL of 1,4-dioxane. Methanol (100 mL) was added to the solution, 0.24 g of sodium borohydride was added thereto, and the mixture was stirred for 2 hr. The reaction solution was concentrated under the reduced pressure, and 100 mL of water was added to the residue. The mixture was extracted with methylene chloride, and the extract was dried over anhydrous magnesium sulfate and then concentrated to dryness to give 4.0 g of the following compound.


[Chemical formula 82]



[0392] Production step 12-(e)

6.58 g of the compound produced in production step 12-(d) was used in the same manner as in production step 12-(d) except that formaldehyde was used instead of benzaldehyde, to give the following compound (6.74 g).


[Chemical formula 83]



[0393] Production step 12-(f)

Water (20 mL) was added to a solution of 4 g of the compound produced in production step 12-(e) dissolved in 140 mL of tetrahydrofuran, 1 g of palladium hydroxide was added thereto, and the mixture was stirred under a hydrogen atmosphere for 3 hr. The mixture was filtered through Celite, and the filtrate was concentrated to dryness. The residue was dissolved in 100 mL of tetrahydrofuran. Triethylamine (1.2 mL) and 2.9 mL of di-*t*-butyl dicarbonate were added to the solution, and the mixture was stirred for 3 hr. The reaction solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (methylene chloride : methanol : aqueous ammonia = 100 : 10 : 1) to give 1.0 g of the following compound.


15 [Chemical formula 84]



[0394] Production step 12-(g)

1 g of the compound produced in production step 12-(f) was used in the same manner as in production step 1-(b) to give the following compound (1.2 g).


[Chemical formula 85]



[0395] Production step 12-(h)

The compound (1.2 g) produced in production step 12-(g) was dissolved in 7 mL of pyridine, 0.25 mL of acetic anhydride was added to the solution, and a reaction was allowed to proceed for 2 hr.


- 5 The reaction solution was concentrated under the reduced pressure, 30 mL of water was added to the residue, and the mixture was extracted with methylene chloride, followed by washing with a 10% potassium hydrogensulfate solution and a saturated aqueous sodium carbonate solution. The extract was then dried over anhydrous magnesium sulfate.
- 10 This solution was then concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 1 : 2) to give 0.38 g of the following compound.
- [Chemical formula 86]

15 [0396] Production step 12-(i)

The compound (0.38 g) produced in production step 12-(h) was dissolved in a mixed solution composed of 10 mL of methylene chloride and 1 mL of methanol, 1 mL of a 90% aqueous trifluoroacetic acid solution was added to the solution, and the mixture was stirred for 1


20 hr. The mixture was then neutralized by the addition of triethylamine under an ice bath. The reaction solution was concentrated under the reduced pressure, the residue was extracted with methylene chloride, and the extract was dried over anhydrous magnesium sulfate and was concentrated to dryness to give 0.34 g of the following compound.

25 [Chemical formula 87]

[0397] Production step 12-(j)

250 mg of the compound produced in production step 12-(i) was used in the same manner as in production step 1-(g) to give the following compound (70 mg).

[Chemical formula 88]




5

[0398] Production step 12-(k)

70 mg of the compound produced in production step 12-(j) was used in the same manner as in production step 1-(h) to give the following compound (66 mg).


10 [Chemical formula 89]



[0399] Production step 12-(l)

50 mg of the compound produced in production step 12-(k) was used in the same manner as in production step 1-(d) to give the following compound (50 mg).

[Chemical formula 90]




[0400] Production step 12-(m)

70 mg of the compound produced in production step 12-(l) was used in the same manner as in production step 1-(e) to give the following compound (60 mg).

[Chemical formula 91]

20



[0401] Production step 12-(n)

35 mg of the compound produced in production step 12-(m) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5,4''-diepi-6'-N-methylarbekacin (3 mg).


FABMS: m/z 567 $[M+H]^+$;

1H -NMR (D_2O+DCI) δ : 1.62 (1H, m), 1.88 (1H, m), 1.99 (1H, m), 2.04 (1H, m), 2.10 (2H, m), 3.26 (2H, m), 2.82 (3H, s), 3.16 (1H, dd, $J = 9.0, 13.0$ Hz), 3.25 (2H, m), 3.30 (1H, dd, $J = 2.0, 13.0$ Hz), 3.59 (1H, m), 3.62 (1H, dd, $J = 3.1, 11.2$ Hz), 3.73 (1H, m), 3.80 (1H, dd, $J = 8.8, 12.0$ Hz), 3.87 (1H, dd, $J = 2.7, 12.0$ Hz), 4.05 (2H, m), 4.22 (3H, m), 4.36 (1H, dd, $J = 3.8, 9.3$ Hz), 4.41 (1H, m), 4.80 (1H, m), 5.26 (1H, d, $J = 4.0$ Hz), 5.47 (1H, d, $J = 3.7$ Hz).

Example 13

5-Epiarbekacin


[Chemical formula 92]



Production step 13-(a)

14 g of the compound produced in production step 1-(a) was used in the same manner as in Production step 2-(a) to give the following compound (11.6 g).

[Chemical formula 93]




FABMS: m/z 1259 $[M+K]^+$.

[0402] Production step 13-(b)

11.6 g of the compound produced in production step 13-(a) was used in the same manner as in production step 1-(d) to give the following compound (7.4 g).

5 [Chemical formula 94]




FABMS: m/z 1321 $[M+Na]^+$, 1337 $[M+K]^+$.

[0403] Production step 13-(c)

7.4 g of the compound produced in production step 13-(b) was used in the same manner as in production step 1-(e) to give the following compound (3.6 g).

[Chemical formula 95]



FABMS: m/z 1263 $[M+H]^+$.

15 [0404] Production step 13-(d)


5.1 g of the compound produced in production step 13-(c) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-epiarbekacin(1.3 g).

FABMS: m/z 553 $[M+H]^+$;

20 1H -NMR (D_2O+ND_3) δ : 1.27 - 1.48 (2H, m), 1.64 - 1.80 (4H, m), 1.85 - 1.95 (1H, m), 1.98 - 2.07 (1H, m), 2.60 - 2.86 (5H, m), 3.02 (1H, dd, J = 10.3 Hz), 3.17 - 3.26 (2H, m), 3.39 (1H, ddd, J = 1.2, 3.9, 10.3 Hz), 3.46 (1H, dd, J = 1.2, 10.3 Hz), 3.67 (1H, dd, J = 6.9, 12.1 Hz), 3.77 - 3.93 (4H, m), 4.17 (1H, dd, J = 3.7, 9.3 Hz), 4.25 (1H, dd, J = 4.4, 11.7 Hz),
 25 4.50 (1H, s), 4.94 (1H, d, J = 3.2 Hz), 5.40 (1H, d, J = 3.9 Hz).

[0405] Example 145-Deoxy-5-epiacetylaminoarbekacin


[Chemical formula 96]



Production step 14-(a)

12 mL of isopropyl alcohol, 60 mL of tetrahydrofuran, and 2.4 mL of triethylamine were added to a solution of 3.36 g of arbekacin in 30 mL of water. A solution of S-p-methoxybenzyloxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine (10.86 g) in isopropyl alcohol/tetrahydrofuran (18 mL of isopropyl alcohol and 30 mL of tetrahydrofuran) was added dropwise thereto at room temperature, and the mixture was stirred at 60°C for 3 hr. Diethyl ether (100 mL) was added thereto, and the mixture was allowed to stand at 6°C for 14 hr. The precipitated solid was collected by filtration, was washed with diethyl ether and water, was dried under the reduced pressure to give 6.61 g of the following compound as a solid.

[Chemical formula 97]




[0406] Production step 14-(b)

The compound (4.11 g) prepared in production step 14-(a) was dissolved in 50 mL of pyridine. A solution of 2.05 g of benzoyl chloride in 9 mL of methylene chloride was added to the solution under ice cooling, and the mixture was stirred under ice cooling for 0.5 hr. Thereafter, the temperature was raised to room temperature, followed by stirring for 4 hr. Water (0.1 mL) was added, and the mixture was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water, a 10% aqueous potassium hydrogensulfate solution, a saturated aqueous sodium hydrogencarbonate solution, and a saturated aqueous sodium chloride

solution in that order, dried over anhydrous magnesium sulfate, and then concentrated to dryness to give 5.22 g of the following compound.


[Chemical formula 98]



5 [0407] Production step 14-(c)

The compound produced in production step 14-(b) was used in the same manner as in production step 4-(a) to give the following compound.

[Chemical formula 99]



10

[0408] Production step 14-(d)

The compound (103 mg) produced in production step 14-(c) was dissolved in a mixed solvent composed of 2 mL of tetrahydrofuran and 0.2 mL of water, and the solution was stirred in the presence of Raney nickel at atmospheric hydrogen pressure for 3 hr. The catalyst was removed by filtration, and the filtrate was concentrated under the reduced pressure. The residue was dissolved in 2 mL of a solution of chloroform : methanol = 5 : 1. Triethylamine (0.03 mL) and 30 mg of acetic anhydride were added to the solution, and the mixture was stirred at room temperature overnight. The residue was subjected to deprotection treatment in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-5-epiacetylaminorabekacin (6 mg).

15

20


FABMS: m/z 594 $[M+H]^+$.

25

[0409] Example 15

5-Deoxy-5-epimethanesulfonyloxylarabekacin

[Chemical formula 100]



Production step 15-(a)

The compound produced in production step 13-(c) was allowed to react in the same manner as in production step 1-(i) and was further allowed to react in the same manner as in production step 2-(a). The compound thus obtained was allowed to react in the same manner as in production step 1-(d), followed by deprotection in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-5-epimethanesulfonyl-arbekacin.


FABMS: m/z 631 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.69 (1H, m), 1.92 (3H, m), 2.15 (3H, m), 2.34 (1H, m), 3.12 (3H, m), 3.41 (2H, m), 3.47 (3H, s), 3.67 (3H, m), 3.95 (5H, m), 4.27 (1H, m), 4.35 (2H, m), 4.44 (1H, m), 5.18 (1H, d, $J = 3.6$ Hz), 5.50 (1H, brs), 5.58 (1H, brs).

[0410] Example 16

5-Deoxy-5-epichloroarbekacin


[Chemical formula 101]



Production step 16-(a)

The compound produced in production step 13-(b) was used in the same manner as in production step 3-(b) to give the following compound.

[Chemical formula 102]



[0411] Production step 16-(b)


The compound produced in production step 15-(a) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-5-epichloroarbekacin.

5 FABMS: m/z 571 $[M+H]^+$;

1H -NMR (D_2O+ND_3) δ : 1.62 (1H, dddd, $J = 3.90, 13.67, 13.67, 13.67$ Hz), 1.85 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.90 - 2.10 (4H, m), 2.17 (1H, ddt, $J = 3.42, 7.81, 14.16$ Hz), 2.34 (1H, ddd, $J = 4.39, 4.39, 12.7$ Hz), 3.09 (1H, dd, $J = 7.33, 13.19$ Hz), 3.17 (2H, dd, $J = 6.84, 6.84$ Hz), 3.27 (1H, dd, $J = 2.93, 13.18$ Hz), 3.38 (1H, dd, $J = 10.26, 10.26$ Hz), 3.58 (1H, dd, $J = 9.77, 9.77$ Hz), 3.58 - 3.63 (1H, m), 3.69 (1H, dd, $J = 7.33, 12.21$ Hz), 3.81 (1H, dd, $J = 3.90, 11.23$ Hz), 3.87 - 3.97 (3H, m), 4.05 - 4.13 (1H, m), 4.28 (1H, dd, $J = 3.41, 9.27$ Hz), 4.30 (1H, dd, $J = 2.93, 9.77$ Hz), 4.38 - 4.45 (1H, m), 4.42 (1H, dd, $J = 2.93, 10.74$ Hz), 5.15 (1H, dd, $J = 2.93, 2.93$ Hz), 5.17 (1H, d, $J = 3.91$ Hz), 5.35 (1H, d, $J = 3.42$ Hz).


[0412] Example 175-Deoxy-5-epiazidoarbekacin

20 [Chemical formula 103]

Production step 17-(a)

25 The compound produced in production step 13-(b) was used in the same manner as in production step 4-(a) to give the following compound.

[Chemical formula 104]

[0413] Production step 17-(b)


The compound produced in production step 17-(a) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-5-epiazidoarbakacin.

FABMS: 578 $[M+H]^+$.

5 [0414] Example 18

5-Deoxy-5-epiaminoarbakacin

[Chemical formula 105]



Production step 18-(a)

10 The compound produced in Example 17 was used in the same manner as in Example 5 to give the title compound: 5-deoxy-5-epiaminoarbakacin.


FABMS: m/z 552 $[M+H]^+$;

15 1H -NMR (D_2O+ND_3) δ : 1.27 - 1.48 (1H, m), 1.33 (1H, q, $J = 12.8$ Hz), 1.67 - 1.80 (4H, m), 1.87 - 1.97 (1H, m), 2.01 (1H, dt, $J = 4.7, 12.8$ Hz), 2.62 - 2.87 (5H, m), 3.02 (1H, t, $J = 10.1$ Hz), 3.15 - 3.30 (1H, m), 3.38 (1H, dd, $J = 3.9$ Hz, $J = 10.1$ Hz), 3.52 (1H, dd, $J = 3.1$ Hz, $J = 10.3$ Hz), 3.73 - 3.87 (6H, m), 4.19 (1H, dd, $J = 3.6, 9.5$ Hz), 4.26 - 4.35 (1H, m), 4.93 (1H, d, $J = 3.4$ Hz), 5.17 (1H, d, $J = 3.9$ Hz).

20 [0415] Example 19

5-Deoxy-5-epidimethylaminoarbakacin


[Chemical formula 106]



Production step 19-(a)

25 288 mg of the compound produced in production step 17-(a) was used in the same reaction as in production step 1-(i) to give the following compound (250 mg).


[Chemical formula 107]



[0416] Production step 19-(b)

The compound (220 mg) produced in production step 19-
 5 (a) was dissolved in 4 mL of a solution (water : ethanol = 1 : 1).
 10%Pd-C (200 mg) was added to the solution under an argon gas
 stream, and the mixture was stirred at room temperature overnight.
 The reaction solution was filtered through Celite and was purified by P-
 TLC (developing solvent: acetone) to give 120 mg of the following
 10 compound.

[Chemical formula 108]



[0417] Production step 19-(c)


A reaction was carried out in the same manner as in
 15 production step 11-(b), except that 90 mg of the compound produced in
 production step 19-(b) was used. Further, deprotection was carried out
 in the same manner as in production step 1-(j) to give the title
 compound: 5-deoxy-5-epidimethylaminoarbekacin (8 mg).

FABMS: m/z 580 $[M+H]^+$.

20 [0418] Example 20

5-Deoxy-5-epibenzoylaminoarbekacin

[Chemical formula 109]



Production step 20-(a)


A reaction was carried out in the same manner as in production step 1-(c), except that 50 mg of the compound produced in production step 19-(b) was used. Further, deprotection was carried out in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-deoxy-5-epibenzoylaminoarbakacin (8 mg).

FABMS: 656 [M+H]⁺.

[0419] Example 21

5-Deoxy-5-epibenzylaminoarbakacin

[Chemical formula 110]



Production step 21-(a)


This compound (100 mg) produced in production step 19-(b) was dissolved in 3 mL of N,N-dimethylformamide. Potassium carbonate (13 mg) and 0.066 mL of benzyl bromide were added to the solution, and the mixture was stirred at room temperature overnight. The reaction solution was concentrated under the reduced pressure and then extracted with methylene chloride, and the extract was washed with a saturated aqueous sodium hydrogencarbonate solution, was then dried over anhydrous magnesium sulfate and concentrated to dryness to give a compound (64 mg). This compound was used for deprotection in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epibenzylaminoarbakacin (30 mg).

FABMS: m/z 642 [M+H]⁺.

[0420] Example 22

5-Deoxy-5-epimethylaminoarbakacin

[Chemical formula 111]




Production step 22-(a)

500 mg of the compound produced in production step 13-

(b) was used in the same manner as in production step 1-(i) to give the following compound (406 mg).


[Chemical formula 112]



5 [0421] Production step 22-(b)

A methylamine-methanol solution (5.0 mL) was added to 100 mg of the compound produced in production step 22-(a), and the mixture was stirred in a sealed tube at 60°C for 4 days. The reaction solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (chloroform : methanol = 9 : 1) to give 27.0 mg of the following compound.

[Chemical formula 113]



FABMS: m/z 1088 [M+Na]⁺.

15 [0422] Production step 22-(c)

23.0 mg of the compound produced in production step 22-(b) was used in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epimethylaminoarbekacin (12.0 mg).


FABMS: m/z 566 [M+H]⁺;

20 ¹H-NMR (D₂O+ND₃) δ: 1.48 (1H, m), 1.60 (1H, m), 1.90 (4H, m), 2.09 (1H, m), 2.19 (1H, m), 2.74 (3H, s), 2.84 (2H, m), 2.94 (2H, m), 3.01 (1H, m), 3.15 (1H, dd, J = 9.7, 10.5 Hz), 3.32 (1H, m), 3.40 (1H, dd, J = 9.8, 10.0 Hz), 3.56 (2H, m), 3.72 (1H, dd, J = 3.0, 10.0 Hz), 3.88 (2H, m), 3.99 (2H, m), 4.08 (1H, m), 4.35 (1H, dd, J = 3.4, 9.3 Hz), 4.52 (1H, ddd, J = 4.8, 12.0 Hz), 5.12 (1H, d, J = 3.4 Hz), 5.20 (1H, d, J = 4.0 Hz).

[0423] Example 23


5-Deoxy-5-epiallylaminoarbekacin

[Chemical formula 114]



Production step 23-(a)

100 mg of the compound produced in production step 22-(a) was used in the same manner as in production step 22-(b) except that allylamine was used instead of the methylamine-methanol solution, to give the following compound (21 mg).
[Chemical formula 115]



FABMS: m/z 1092 $[M+H]^+$.


10 [0424] Production step 23-(b)

21 mg of the compound produced in production step 23-(a) was used in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epiallylaminoarbakacin (12.0 mg).
FABMS: m/z 592 $[M+H]^+$.

15 [0425] Example 24

5-Deoxy-5-epi(2-aminoethyl)aminoarbakacin


[Chemical formula 116]



Production step 24-(a)

20 100 mg of the compound produced in production step 22-(a) was used in the same manner as in production step 1-(e) except that ethylenediamine was used instead of cesium acetate, to give the following compound (21 mg).

[Chemical formula 117]



FABMS: m/z 1095 $[M+H]^+$.

[0426] Production step 24-(b)

5 The compound produced in production step 24-(a) was used in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epi(2-aminoethyl)aminoarbakacin (16.0 mg).


FABMS: m/z 595 $[M+H]^+$;

10 $^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.48 (1H, m), 1.59 (1H, m), 1.90 (4H, m), 2.08 (1H, m), 2.18 (1H, m), 2.83 (2H, m), 2.92 (4H, m), 3.00 (2H, m), 3.13 (1H, dd, $J = 10.2$ Hz), 3.20 (1H, m), 3.35 (1H, m), 3.40 (1H, dd, $J = 10.2$ Hz), 3.55 (1H, dd, $J = 3.9, 10.2$ Hz), 3.65 (1H, brs), 3.71 (1H, dd, $J = 3.0, 10.1$ Hz), 3.87 (1H, m), 3.97 (2H, m), 4.06 (2H, m), 4.34 (1H, dd, $J = 3.5, 9.8$ Hz), 4.59 (1H, m), 5.10 (1H, d, $J = 3.4$ Hz), 5.19 (1H, d, $J = 3.9$ Hz).

15 [0427] Example 25

5-Deoxy-5-epi(2-hydroxyethyl)aminoarbakacin


[Chemical formula 118]



Production step 25-(a)

20 100 mg of the compound produced in production step 22-(a) was used in the same manner as in production step 1-(e) except that 2-aminoethanol was used instead of cesium acetate, to give the following compound (25.0 mg).

[Chemical formula 119]



FABMS: m/z 1096 $[M+H]^+$.

[0428] Production step 25-(b)


25.0 mg of the compound produced in production step 25-
 5 (a) was used in the same manner as in production step 1-(j) to give the
 title compound: 5-deoxy-5-epi(2-hydroxyethyl)aminoarbekacin (11.4 mg).
 FABMS: m/z 596 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.26 (1H, m), 1.35 (1H, m), 1.69 (4H, m), 1.87
 (1H, m), 1.96 (1H, m), 2.61 (2H, m), 2.70 (3H, m), 2.80 (1H, m), 2.89 (1H,
 10 dd, $J = 9.6$ Hz), 3.09 (1H, m), 3.17 (1H, dd, $J = 9.6, 10.0$ Hz), 3.32 (1H,
 dd, $J = 3.6, 9.6$ Hz), 3.43 (1H, brs), 3.52 (1H, m), 3.65 (3H, m), 3.74 (2H,
 m), 3.85 (2H, m), 4.12 (1H, dd, $J = 3.6, 10.0$ Hz), 4.39 (1H, m), 4.87 (1H,
 d, $J = 3.2$ Hz), 4.97 (1H, d, $J = 3.8$ Hz).

[0429] Example 26

15 5-Deoxy-5-epi(3-hydroxypropyl)aminoarbekacin


[Chemical formula 120]



Production step 26-(a)

100 mg of the compound produced in production step 22-
 20 (a) was used in the same manner as in production step 1-(e) except that
 3-amino-1-propanol was used instead of cesium acetate, to give the
 following compound (43.0 mg).

[Chemical formula 121]



FABMS: m/z 1110 $[M+H]^+$.

[0430] Production step 26-(b)


43.0 mg of the compound produced in production step 26-(a) was used in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epi(3-hydroxypropyl)aminoarbakacin (18.5 mg).

ESIMS: m/z 610 $[M+H]^+$.

[0431] Example 27

5-Deoxy-5-epi(2-hydroxy-1-hydroxymethyl-ethyl)aminoarbakacin


[Chemical formula 122]



Production step 27-(a)

100 mg of the compound produced in production step 22-(a) was used in the same manner as in production step 1-(e), except that 2-amino-1,3-propanediol was used instead of cesium acetate, to give the following compound (13.8 mg).

[Chemical formula 123]



[0432] Production step 27-(b)

13.8 mg of the compound produced in production step 27-(a) was used in the same manner as in production step 1-(j) to give the title compound: 5-deoxy-5-epi(2-hydroxy-1-hydroxymethyl-ethyl)aminoarbakacin (6.0 mg).

FABMS: m/z 626 $[M+H]^+$;


$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.49 (1H, m), 1.60 (1H, m), 1.95 (4H, m), 2.09 (1H, m), 2.20 (1H, m), 2.84 (2H, m), 2.93 (2H, m), 3.03 (1H, m), 3.11 (1H, dd, $J = 10.1$ Hz), 3.34 (1H, m), 3.43 (1H, dd, $J = 9.7, 10.1$ Hz), 3.48 (1H, m), 3.57 (1H, dd, $J = 3.8, 10.1$ Hz), 3.70 - 4.09 (11H, m), 4.36 (1H, dd, $J =$

3.4, 9.5 Hz), 4.81 (1H, m), 5.17 (1H, d, J = 3.4 Hz), 5.22 (1H, d, J = 3.8 Hz).

[0433] Example 28

5-Epi-3''-N-methylarbekacin


5 [Chemical formula 124]



Production step 28-(a)

3,2',6'-Tri-N-t-butoxycarbonyl-4'''-N-p-methoxybenzyloxycarbonyl-arbekacin (3.0 g) was dissolved in 30 mL of a methanol/dioxane solution (methanol : dioxane = 1 : 1), 0.84 mL of triethylamine and 0.46 mL of benzaldehyde were added to the solution, and the mixture was stirred at room temperature for 2 hr. The reaction solution was concentrated under the reduced pressure and was then washed with diisopropyl ether. The residue was dissolved in 30 mL of a methanol/dioxane solution (methanol : dioxane = 1 : 1), 113 mg of sodium borohydride was added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated under the reduced pressure, the residue was extracted with methylene chloride, and the extract was dried over anhydrous magnesium sulfate and was concentrated under the reduced pressure. The residue was purified by column chromatography on silica gel (methylene chloride : methanol = 9 : 1) to give 0.87 g of the following compound.

[Chemical formula 125]




25

FABMS: m/z 1107 [M+H]⁺

[0434] Production step 28-(b)

1.40 g of the compound produced in production step 28-(a) was used as a starting compound in the same manner as in production step 28-(a) except that formaldehyde was used instead of benzaldehyde, to give the following compound (0.99 g).

5 [Chemical formula 126]




FABMS: m/z 1121 [M+H]⁺

[0435] Production step 28-(c)

370 mg of the compound produced in production step 28-(b) was used in the same manner as in production step 2-(a) to give the following compound (200 mg).

[Chemical formula 127]




FABMS: m/z 1289 [M+H]⁺

15 [0436] Production step 28-(d)

200 mg of the compound produced in production step 28-(c) was used in the same manner as in production steps 1-(d) and 1-(e) to give the following compound (134 mg).

[Chemical formula 128]



20


FABMS: m/z 1331 [M+H]⁺

[0437] Production step 28-(e)

130 mg of the compound produced in production step 28-(d) was used in the same manner as in production steps 1-(i) and 1-(j) to

give the following compound (19 mg).

[Chemical formula 129]



FABMS: m/z 657 $[M+H]^+$

5 [0438] Production step 28-(f)

The compound (19.0 mg) produced in production step 28-
(e) was dissolved in 5.0 mL of water, and 0.5 mL of 1 N hydrochloric acid
was added to the solution. Under an argon gas stream, 5 mg of
10%Pd-C was added thereto, the air in the system was replaced by
hydrogen, and the mixture was stirred at room temperature overnight.
The reaction solution was filtered through Celite and was purified by CM-
Sephadex(NH₄⁺) to give the title compound: 5-epi-3"-N-methylarbakacin
(16.0 mg).


FABMS: 567 [M+H]⁺

15 ¹H-NMR (D₂O+ND₃) δ: 1.40 (2H, m), 1.77 (4H, m), 1.95 (1H, m), 2.05 (1H,
ddd, J = 4.2, 5.1, 13.2 Hz), 2.47 (3H, s), 2.70 (2H, m), 2.83 (4H, m), 3.26
(1H, m), 3.40 (1H, dd, J = 9.8, 10.0 Hz), 3.50 (1H, dd, J = 2.2, 10.3 Hz),
3.57 (1H, dd, J = 3.9, 10.5 Hz), 3.70 (1H, dd, J = 7.0, 12.0 Hz), 3.85 (3H,
m), 3.93 (1H, dd, J = 2.0, 12.0 Hz), 4.23 (1H, dd), 4.31 (1H, m), 4.54 (1H,
20 dd), 4.98 (1H, d, J = 3.6 Hz), 5.07 (1H, d, J = 3.9 Hz).

[0439] Example 29

5-Epi-6'-N-methylarbekacin

[Chemical formula 130]



25 Production step 29-(a)

The compound produced in production step 12-(f) was used in the acetylation of a hydroxyl group carried out in the same manner as in production step 2-(a). The compound thus obtained was used in the reversal reaction of the hydroxyl group at the 5-position


carried out in the same manner as in production steps 1-(d) and 1-(e), followed by deprotection in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-epi-6'-N-methylarbekacin.

FABMS: m/z 567 $[M+H]^+$

5 [0440] Example 30

6'-Aminomethyl-6'-deamino-5-epi-6'-hydroxyarbekacin


[Chemical formula 131]



Production step 30-(a)

10 A catalytic amount of p-TsOH·H₂O and 210 mg of 2,2-dimethoxypropane were added to a solution of 620 mg of the compound produced in production step 12-(b) dissolved in 10 mL of N,N-dimethylformamide, and the mixture was stirred at room temperature for 20 hr. Triethylamine was added to the reaction solution, and the mixture was concentrated under the reduced pressure. The residue was washed with isopropyl ether and was then dried under the reduced pressure to give 640 mg of the following compound as a solid.


[Chemical formula 132]



20 [0441] Production step 30-(b)

The compound (640 mg) produced in production step 30-(a) was dissolved in 10 mL of dioxane, 10 mL of methanol, and 8 mL of water, 170 mg of palladium hydroxide was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction at a hydrogen pressure of 30 lbs for 16 hr. The reaction solution was filtered through Celite and was washed with a solution of methanol : water = 1 : 1, and the filtrate was concentrated to dryness to give 560 mg of the following compound.


[Chemical formula 133]



[0442] Production step 30-(c)

The compound (500 mg) produced in production step 30-
 5 (b) was dissolved in 12 mL of chloroform and 6 mL of water. Ninhydrin (440 mg) and 210 mg of sodium hydrogencarbonate were added to the solution, and the mixture was stirred at room temperature for 16 hr. Methylene chloride was added to the reaction solution. The mixture was washed with water, was dried over anhydrous magnesium sulfate,
 10 and was then concentrated under the reduced pressure. The residue was purified by column chromatography on silica gel (development system, methylene chloride : methanol = 15 : 1) to give 256 mg of the following compound.

[Chemical formula 134]




15

[0443] Production step 30-(d)

The compound (100 mg) produced in production step 30-(c) was dissolved in 5 mL of methylene chloride, 2 mL of tetrahydrofuran, and 1 mL of methanol. Nitromethane (60 mg), and 100 mg of a
 20 methanol solution of sodium methoxide (1 M) were added to the solution, and the mixture was stirred for 1 hr. This reaction solution was neutralized with a 1 M hydrochloric acid solution. Chloroform was added thereto, and the mixture was washed with water and was then dried over anhydrous magnesium sulfate. The solution thus obtained
 25 was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system,

methylene chloride : methanol = 15 : 1) to give 82 mg of the following compound.

[Chemical formula 135]



5 [0444] Production step 30-(e)


The compound (82 mg) produced in production step 30-(d) was dissolved in 7 mL of methanol, 3 mL of water, and 0.2 mL of acetic acid. Platinum oxide (50 mg) was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction at a hydrogen pressure of 40 lbs for 20 hr. The reaction solution was filtered through Celite, followed by washing with a solution of methanol : water = 1 : 1. The filtrate was then concentrated under the reduced pressure, and deprotection was carried out in the same manner as in production step 1-(j). The compound thus obtained was used for the protection of the amino group in the same manner as in production step 1-(a). Thereafter, a reaction was allowed to proceed in the same manner as in Example 13 to give the title compound: 6'-aminomethyl-6'-deamino-5-epi-6'-hydroxyarbekacin.

FABMS: m/z 583 [M+H]⁺

20 [0445] Example 31

6'-Aminomethyl-6'-deamino-5-deoxy-5-epiacetoxy-6'-hydroxy-arbekacin

[Chemical formula 136]



Production step 31-(a)


25 A reaction was allowed to proceed in the same manner as in Example 30 to give 6'-aminomethyl-6'-deamino-5-epi-6'-hydroxyarbekacin and the title compound: 6'-aminomethyl-6'-deamino-5-deoxy-5-epiacetoxy-6'-hydroxyarbekacin.

FABMS: m/z 625 $[M+H]^+$

[0446] Example 32

6"-Deoxy-5-epiarbekacin

[Chemical formula 137]



5

Production step 32-(a)


The compound (1.55 g) produced in production step 1-(a) was dissolved in 20 mL of dimethylformamide. p-TsOH·H₂O (100 mg) and 2 mL of benzaldehyde dimethylacetal were added to the solution, and the mixture was stirred at 5°C for 5 hr. Triethylamine was added to the reaction solution, and the mixture was neutralized and was concentrated under the reduced pressure. Pyridine (30 mL) and 1.5 mL of acetic anhydride were added to the residue, and the mixture was stirred at room temperature for 3 days. Methanol (20 mL) was added to the reaction solution, and the mixture was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with an aqueous potassium hydrogensulfate solution, an aqueous sodium hydrogencarbonate solution, and water in that order and dried over anhydrous magnesium sulfate. The solution thus obtained was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, ethyl acetate : n-hexane = 1 : 1) to give 1.13 g of the following compound .

10

15

20

[Chemical formula 138]




25

[0447] Production step 32-(b)

The compound (200 mg) produced in production step 32-

- (a) was dissolved in 6 mL of carbon tetrachloride, 50 mg of N-bromosuccinimide and 18 mg of barium carbonate were added to the solution, and the mixture was stirred under reflux for 3 hr. The reaction solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, ethyl acetate : toluene = 1 : 1) to give 154 mg of the following compound.


[Chemical formula 139]



- 10 [0448] Production step 32-(c)

67 mg of the compound produced in production step 32-(b) was used in the reduction of a halogen carried out in the same manner as in production step 8-(b), to give 65 mg of the following compound.

[Chemical formula 140]




15

- [0449] Production step 32-(d)

25 mg of the compound produced in Production step 32-(c) was used in the same manner as in production step 1-(d) to give the following compound (30 mg).

- 20 [Chemical formula 141]



TSPMS: m/z 1303 $[M+H]^+$

[0450] Production step 32-(e)


30 mg of the compound produced in production step 32-(d) was used in the same manner as in production step 1-(e). The compound thus obtained was then deprotected in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 6"-deoxy-5-epiarbekacin.

FABMS: m/z 537 $[M+H]^+$

10 [0451] Example 33

6"-Aminomethyl-5-epiarbekacin


[Chemical formula 142]



Production step 33-(a)

15 The compound produced in production step 13-(c) was subjected to the deprotection of the hydroxyl group in the same manner as in production step 1-(i). 0.33 g of the compound thus obtained was used in the same manner as in production step 1-(g) to give the following compound (0.32 g).

20 [Chemical formula 143]




[0452] Production step 33-(b)

0.32 g of the compound produced in production step 33-(a)

was used in the same manner as in production step 2-(a) to give the following compound (0.29 g).


[Chemical formula 144]



5 [0453] Production step 33-(c)

The compound (0.36 g) produced in production step 33-(b) was dissolved in 0.75 mL of diethyl ether and 0.75 mL of formic acid. The solution was stirred for 20 min and was then extracted with methylene chloride, followed by washing with an aqueous saturated sodium hydroxide solution. The extract was then dried over anhydrous magnesium sulfate and was then concentrated under the reduced pressure. The residue was dissolved in 12.3 mL of toluene and 1.6 mL of DMSO. Pyridine (0.085 mL), 0.027 mL of trifluoroacetic acid, and 0.26 g of 1,3-dicyclohexylcarbodiimide were added to the solution, and the mixture was stirred at room temperature overnight. The reaction solution was then extracted with ethyl acetate, and the extract was concentrated under the reduced pressure. The residue was then purified by column chromatography on silica gel (methylene chloride : methanol = 15 : 1) to give 0.05 g of the following compound.


20 [Chemical formula 145]



[0454] Production step 33-(d)

100 mg of the compound produced in production step 33-(c) was used in the same manner as in production step 30-(d) to give the following compound (38 mg).

[Chemical formula 146]



[0455] Production step 33-(e)


38 mg of the compound produced in production step 33-(d) was used in the same manner as in production step 30-(e) to give the title compound: 6''-aminomethyl-5-epi-*ar*bekacin (20 mg).

FABMS: m/z 582 $[M+H]^+$.

[0456] Example 34

5-Methylarbekacin


[Chemical formula 147]



Production step 34-(a)

The following compound (6.61 g) was produced in the same manner as in Example 14-(a).

[Chemical formula 148]




[0457] Production step 34-(b)

The compound (4.11 g) produced in production step 34-(a) was dissolved in 50 mL of pyridine, and, under ice cooling, a solution of 2.05 g of benzoyl chloride in 9 mL of methylene chloride was added to the solution. The mixture was stirred under ice cooling for 0.5 hr, and the temperature of the mixture was raised to room temperature before stirring for 4 hr. Thereafter, 0.1 mL of water was added thereto, followed by concentration under the reduced pressure. Ethyl acetate

was added to the residue, and the mixture was washed with water, a 10% aqueous potassium hydrogensulfate solution, a saturated aqueous sodium hydrogencarbonate solution, and a saturated aqueous sodium chloride solution in that order, was then dried over anhydrous magnesium sulfate, and was then concentrated to dryness to give 5.22 g of the following compound.


[Chemical formula 149]



[0458] Production step 34-(c)

The compound (1.197 g) produced in production step 34-(b) was dissolved in 5 mL of dimethylsulfoxide, 1.5 mL of acetic anhydride was added to the solution, and the mixture was stirred at room temperature for 3 days. A saturated aqueous sodium hydrogencarbonate solution (1 mL) was added thereto, and the mixture was stirred for 1 hr. Ethyl acetate was added thereto, and the mixture was washed with water, a saturated aqueous sodium hydrogencarbonate solution, and a saturated aqueous sodium chloride solution in that order, was dried over anhydrous sodium sulfate, and was then concentrated to dryness to give 1.20 g of the following compound.

[Chemical formula 150]




[0459] Production step 34-(d)

The compound (320 mg) produced in production step 34-(c) was dissolved in 4 mL of tetrahydrofuran, and 0.97 mL of a solution of methylmagnesium bromide (0.93 mmol/mL) in tetrahydrofuran was added to the solution under ice cooling, and the mixture was stirred under ice cooling for 3 hr. A saturated aqueous ammonium chloride solution was added to this reaction solution, and the mixture was extracted with ethyl acetate, followed by washing with saturated brine.

The extract was then dried over anhydrous sodium sulfate. The solution thus obtained was concentrated under the reduced pressure, and the residue was purified by preparative TLC (development system, chloroform : methanol = 30 : 1) to give 100 mg of the following compound.

[Chemical formula 151]



[0460] Production step 34-(e)

100 mg of the compound produced in production step 34-(d) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-methylarbakacin (5.1 mg).


FABMS: m/z 567 $[M+H]^+$;

1H -NMR (D_2O+DCI) δ : 1.63 - 1.73 (1H, m), 1.86 (1H, ddd, $J = 12.4, 12.4, 12.4$ Hz), 1.96 - 2.03 (2H, m), 2.05 - 2.15 (2H, m), 2.21 (1H, ddt, $J = 3.7, 7.1, 14.7$ Hz), 2.31 (1H, ddd, $J = 4.4, 4.4, 13.0$ Hz), 3.21 (2H, d, $J = 7.1, 7.1$ Hz), 3.21 (1H, dd, $J = 6.8, 13.1$ Hz), 3.32 (1H, dd, $J = 3.5, 13.5$ Hz), 3.37 (3H, s), 3.42 (1H, dd, $J = 10.5, 10.5$ Hz), 3.47 - 3.56 (1H, m), 3.63 - 3.68 (1H, m), 3.75 (1H, dd, $J = 10.0, 10.0$ Hz), 3.79 - 3.84 (3H, m), 3.87 (1H, d, $J = 10.8$ Hz), 4.02 (1H, d, $J = 10.7$ Hz), 4.06 (1H, dt, $J = 3.2, 10.3$ Hz), 4.10 - 4.16 (1H, m), 4.18 - 4.25 (1H, m), 4.31 (1H, dd, $J = 3.6, 9.3$ Hz), 5.16 (1H, d, $J = 3.6$ Hz), 5.83 (1H, d, $J = 3.7$ Hz).

[0461] Example 35

5-Methoxymethylarbakacin

[Chemical formula 152]




Production step 35-(a)

The compound (60 mg) produced in production step 34-(c) was dissolved in 4 mL of methanol, 1.0 mL of a solution of diazomethane

(0.6 mmol/mL) in diethyl ether was added to the solution under ice cooling, and the mixture was stirred under ice cooling for 2 hr. The reaction solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, chloroform : methanol = 30 : 1) to give 50.6 mg of the following compound.

[Chemical formula 153]



[0462] Production step 35-(b)

44 mg of the compound produced in production step 35-(a) was used in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-methoxymethylarbekacin (5.8 mg).


FABMS: m/z 597 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.69 - 1.75 (1H, m), 1.90 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.99 - 2.06 (2H, m), 2.08 - 2.16 (2H, m), 2.24 (1H, ddt, $J = 3.9, 7.3, 14.4$ Hz), 2.39 (1H, ddd, $J = 4.6, 4.6, 12.9$ Hz), 3.20 - 3.24 (1H, m), 3.24 (2H, dd, $J = 7.4, 7.4$ Hz), 3.35 (1H, dd, $J = 3.4, 13.6$ Hz), 3.44 (1H, dd, $J = 10.5, 10.5$ Hz), 3.50 (3H, s), 3.63 - 3.68 (1H, m), 3.77 (1H, dd, $J = 10.0, 10.0$ Hz), 3.82 (1H, d, $J = 10.7$ Hz), 3.86 (1H, dd, $J = 3.7, 10.0$ Hz), 3.87 (2H, d, $J = 2.9$ Hz), 3.87 - 3.92 (1H, m), 3.94 (1H, d, $J = 10.8$ Hz), 4.02 (1H, d, $J = 10.7$ Hz), 4.06 (1H, dt, $J = 2.9, 10.0$ Hz), 4.12 (1H, d, $J = 11.0$ Hz), 4.26 (1H, dddd, $J = 3.4, 6.9, 6.9, 6.9$ Hz), 4.33 (1H, dd, $J = 3.6, 6.9$ Hz), 4.35 - 4.40 (1H, m), 5.19 (1H, d, $J = 3.6$ Hz), 5.76 (1H, d, $J = 3.2$ Hz).

[0463] Example 36

5-Vinylarbekacin

[Chemical formula 154]



Production step 36-(a)

The compound produced in production step 34-(c) was reacted with vinylmagnesium bromide in the same manner as in production step 34-(d), and the reaction product was then subjected to deprotection and purification in the same manner as in production steps 1-(i) and 1-(j) to give the title compound: 5-vinylarbekacin.


TSPMS: m/z 579 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.38 - 1.45 (2H, m), 1.54 - 1.63 (1H, m), 1.71 - 1.79 (3H, m), 1.89 - 1.94 (1H, m), 2.10 (1H, ddd, $J = 4.4, 4.4, 13.2$ Hz), 2.64 - 2.68 (2H, m), 2.75 - 2.79 (2H, m), 2.85 (1H, ddd, $J = 4.4, 4.4, 11.7$ Hz), 2.88 (1H, dd, $J = 10.0, 10.0$ Hz), 3.01 - 3.08 (1H, m), 3.30 (1H, dd, $J = 10.0, 10.0$ Hz), 3.37 (1H, dd, $J = 3.6, 10.2$ Hz), 3.43 (1H, d, $J = 10.3$ Hz), 3.70 - 3.85 (4H, m), 3.99 (1H, dt, $J = 2.9, 10.2$ Hz'), 4.07 (1H, ddd, $J = 4.4, 10.8, 10.8$ Hz), 4.18 (1H, dd, $J = 3.9, 9.2$ Hz), 4.98 (1H, d, $J = 4.0$ Hz), 5.12 (1H, d, $J = 3.4$ Hz), 5.53 (1H, dd, $J = 1.4, 10.9$ Hz), 5.58 (1H, dd, $J = 1.4, 17.1$ Hz), 6.09 (1H, dd, $J = 10.7, 16.8$ Hz).

[0464] Example 37

5-Aminomethylarbekacin

[Chemical formula 155]




Production step 37-(a)

The compound (50 mg) produced in production step 35-(a) was dissolved in 0.5 mL of dimethylformamide, 5.4 mg of sodium azide was added to the solution, and the mixture was stirred at 80°C for 2 hr. A saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate,

washed with saturated brine, and then dried over anhydrous sodium sulfate. The solution thus obtained was concentrated under the reduced pressure, and the residue was purified by preparative TLC (development system, chloroform : methanol = 30 : 1) to give 24.3 mg of the following compound.


[Chemical formula 156]



[0465] Production step 37-(b)

The following compound (5.3 mg) was produced from 24.3 mg of the compound produced in production step 37-(a) in the same manner as in production steps 1-(i) and 1-(j).

[Chemical formula 157]



TSPMS: m/z 608 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.66 - 1.77 (1H, m), 1.92 (1H, ddd, $J = 12.4, 12.4, 12.4$ Hz), 1.99 - 2.07 (2H, m), 2.08 - 2.16 (2H, m), 2.22 (1H, ddt, $J = 3.9, 7.3, 14.4$ Hz), 2.38 (1H, ddd, $J = 4.9, 4.9, 12.9$ Hz), 3.22 (2H, dd, $J = 7.1, 7.1$ Hz), 3.23 (1H, dd, $J = 6.8, 13.9$ Hz), 3.34 (1H, dd, $J = 3.4, 13.4$ Hz), 3.44 (1H, dd, $J = 10.5, 10.5$ Hz'), 3.65 - 3.70 (1H, m), 3.77 (1H, dd, $J = 10.0, 10.0$ Hz), 3.80 - 3.85 (2H, m), 3.87 (2H, d, $J = 3.4$ Hz), 3.91 (1H, d, $J = 13.7$ Hz), 3.96 (1H, d, $J = 13.7$ Hz), 4.05 (1H, d, $J = 10.7$ Hz), 4.08 (1H, dt, $J = 3.4, 9.8$ Hz), 4.14 (1H, d, $J = 10.7$ Hz), 4.21 - 4.33 (2H, m), 4.33 (1H, dd, $J = 3.7, 9.3$ Hz), 5.18 (1H, d, $J = 3.6$ Hz), 5.81 (1H, d, $J = 3.5$ Hz).

[0466] Production step 37-(c)

The compound (5.3 mg) produced in production step 37-(b) was dissolved in 1 mL of water, 4.6 mg of 10% palladium-carbon was added to the solution, and the mixture was subjected to catalytic

hydrogen reduction at room temperature under the atmospheric pressure for 3 hr. This reaction solution was filtered and was concentrated under the reduced pressure, and the residue was purified by CM-Sephadex (NH₄⁺) (development system; water : concentrated aqueous ammonia =

5 10 : 1) to give the title compound: 4.0 mg of 5-aminomethylarbekacin.


TSPMS: m/z 582 [M+H]⁺

¹H-NMR (D₂O+ND₃) δ: 1.70 - 1.81 (1H, m), 1.95 - 2.10 (3H, m), 2.10 - 2.20 (2H, m), 2.25 (1H, ddt, J = 3.7, 7.1, 14.4 Hz), 2.42 (1H, ddd, J = 4.8, 4.8, 12.9 Hz), 3.25 (2H, dd, J = 7.3, 7.3 Hz), 3.35 - 3.40 (3H, m), 3.55
10 (1H, d, J = 13.9 Hz), 3.56 - 3.65 (1H, m), 3.61 (1H, d, J = 13.9 Hz), 3.74 - 3.77 (1H, m), 3.78 (1H, dd, J = 10.0, 10.0 Hz), 3.88 (1H, dd, J = 4.1, 11.8 Hz), 3.92 (1H, dd, J = 3.9, 11.2 Hz), 3.97 (1H, dd, J = 2.2, 12.2 Hz), 4.05 (1H, ddd, J = 2.2, 4.1, 10.0 Hz), 4.27 (1H, d, J = 11.0 Hz), 4.30 - 4.45 (4H, m), 5.29 (1H, d, J = 4 Hz), 5.81 (1H, d, J = 3.2 Hz).

15 [0467] Example 38

5-Methylaminomethylarbekacin


[Chemical formula 158]



Production step 38-(a)

20 The compound (150 mg) produced in production step 35-(a) was dissolved in 5 mL of a solution of methanol : methylene chloride = 1 : 1, 0.5 mL of a 1 mol/L aqueous sodium hydroxide solution was added to the solution, and the mixture was stirred at room temperature for 4 hr. The reaction solution was neutralized with 1 mol/L
25 hydrochloric acid and then concentrated under the reduced pressure. The residue was extracted with methylene chloride, dried over anhydrous magnesium sulfate, and then concentrated under the reduced pressure to give 110 mg of the following compound.

[Chemical formula 159]



FABMS: m/z 1423 $[M+K]^+$.

[0468] Production step 38-(b)


5 Ethanol (1 mL) and 1.1 mg of a 40% aqueous methylamine solution were added to 10 mg of the compound produced in production step 38-(a), and the mixture was stirred at 80°C for 3 hr. The reaction solution was concentrated under the reduced pressure, and the residue was deprotected and purified in the same manner as in production step 1-(j) to give the title compound: 5-methylaminomethylarbekacin (3.7 mg).

10 TSPMS: m/z 596 $[M+H]^+$;
 $^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$), 1.38 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.41 - 1.44 (1H, m), 1.62 - 1.79 (4H, m), 1.91 - 1.93 (1H, m), 2.22 (1H, ddd, $J = 4.7, 4.7, 13.2$ Hz), 2.46 (3H, s), 2.65 - 2.70 (2H, m), 2.76 - 2.81 (2H, m), 2.90 (1H, dd, $J = 10.3, 10.3$ Hz), 2.93 - 3.01 (2H, m), 3.05 (1H, d, $J = 13.2$ Hz), 3.10 (1H, d, $J = 13.4$ Hz), 3.31 (1H, dd, $J = 9.8, 9.8$ Hz), 3.39 (1H, dd, $J = 3.8, 10.4$ Hz), 3.41 (1H, d, $J = 10.3$ Hz), 3.74 - 3.81 (3H, m), 3.82 - 3.92 (1H, m), 4.04 (1H, ddd, $J = 2.6, 3.9, 10.3$ Hz), 4.11 (1H, ddd, $J = 4.4, 12.2, 12.2$ Hz), 4.18 (1H, dd, $J = 3.7, 9.3$ Hz), 5.03 (1H, d, $J = 3.7$ Hz), 5.07 (1H, d, $J = 3.4$ Hz).

20 [0469] Example 39

5-(2-Hydroxyethyl)aminomethylarbekacin

[Chemical formula 160]



Production step 39-(a)

25 The compound (12.3 mg) produced in production step 38-(a) was reacted with hydroxyethylamine in the same manner as in production step 38-(b) to give the title compound: 5-(2-hydroxyethyl)aminomethylarbekacin (4.4 mg).


TSPMS: m/z 626 $[M+H]^+$;

1H -NMR (D_2O+ND_3) δ : 1.35 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.37 - 1.50 (1H, m), 1.60 - 1.85 (4H, m), 1.88 - 1.98 (1H, m), 2.04 (1H, ddd, $J = 4.6, 4.6, 13.2$ Hz), 2.62 - 2.70 (2H, m), 2.72 - 2.83 (4H, m), 2.85 - 3.00 (3H, m), 3.00 (1H, d, $J = 13.0$ Hz), 3.05 (1H, d, $J = 13.0$ Hz), 3.31 (1H, dd, $J = 9.8, 9.8$ Hz), 3.38 (1H, dd, $J = 3.7, 10.5$ Hz), 3.39 (1H, d, $J = 10.0$ Hz), 3.65 - 3.73 (2H, m), 3.75 - 3.83 (3H, m), 3.85 - 3.95 (1H, m), 4.02 - 4.08 (1H, m), 4.13 (1H, ddd, $J = 3.9, 11.4, 11.4$ Hz), 4.18 (1H, dd, $J = 3.6, 9.3$ Hz), 5.03 (1H, d, $J = 4.4$ Hz), 5.04 (1H, d, $J = 4.2$ Hz).

[0470] Example 40

5-(2-Aminoethyl)aminomethylarbakacin

[Chemical formula 161]



Production step 40-(a)

The compound (15 mg) produced in production step 38-(a) was reacted with diaminoethane in the same manner as in production step 38-(b) to give the title compound: 5-(2-aminoethyl)aminomethylarbakacin (4.4 mg).


TSPMS: m/z 625 $[M+H]^+$;

1H -NMR (D_2O+ND_3) δ : 1.35 (1H, ddd, $J = 12.9, 12.9, 12.9$ Hz), 1.42 (1H, dddd, $J = 4.9, 12.4, 12.4, 12.4$ Hz), 1.64 (1H, dddd, $J = 3.7, 12.4, 12.4, 12.4$ Hz), 1.71 - 1.79 (3H, m), 1.91 - 1.93 (1H, m), 2.03 (1H, ddd, $J = 4.7, 4.7, 13.2$ Hz), 2.62 - 2.82 (6H, m), 2.88 - 2.99 (3H, m), 2.99 (1H, d, $J = 13.2$ Hz), 3.05 (1H, d, $J = 12.9$ Hz), 3.31 (1H, dd, $J = 9.7, 9.7$ Hz), 3.38 (1H, dd, $J = 3.7, 10.5$ Hz), 3.40 (1H, d, $J = 10.2$ Hz), 3.73 - 3.79 (3H, m), 3.84 - 3.92 (1H, m), 4.02 (1H, dt, $J = 2.9, 9.5$ Hz), 4.13 (1H, ddd, $J = 3.8, 11.4, 11.4$ Hz), 4.18 (1H, dd, $J = 3.6, 9.2$ Hz), 5.04 (1H, d, $J = 3.9$ Hz), 5.07 (1H, d, $J = 3.2$ Hz).

[0471] Example 41

5-(3-Aminopropyl)aminomethylarbakacin

[Chemical formula 162]



Production step 41-(a)

The compound (30 mg) produced in production step 38-(a) was reacted with 1,3-diaminopropane in the same manner as in production step 38-(b) to give the title compound: 5-(3-aminopropyl)aminomethylarbekacin (4.0 mg).


FABMS: m/z 639 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.36 (1H, m), 1.43 (1H, m), 1.72 (5H, m), 1.94 (1H, m), 2.04 (1H, ddd, $J = 4.4, 13.2$ Hz), 2.68 (2H, m), 2.73 (4H, m), 2.78 (2H, m), 2.92 (2H, m), 2.99 (1H, m), 3.04 (2H, m), 3.32 (1H, dd, $J = 10.0$ Hz), 3.39 (2H, m), 3.79 (3H, m), 3.89 (1H, m), 4.02 (1H, m), 4.12 (1H, ddd, $J = 4.3, 11.4$ Hz), 4.19 (1H, dd, $J = 3.6, 9.3$ Hz), 5.03 (1H, d, $J = 3.9$ Hz), 5.05 (1H, d, $J = 3.4$ Hz).

[0472] Example 42

5-(3-Amino-2-hydroxypropyl)aminomethylarbekacin

[Chemical formula 163]



Production step 42-(a)

The compound (30 mg) produced in production step 38-(a) was reacted with 1,3-diamino-2-hydroxypropane in the same manner as in production step 38-(b) to give the title compound: 5-(3-amino-2-hydroxypropyl)aminomethylarbekacin (10.2 mg).

TSPMS: m/z 655 $[M+H]^+$;


$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.47 (2H, m), 1.75 (1H, m), 1.83 (3H, m), 2.04

(1H, m), 2.12 (1H, m), 2.76 (6H, m), 2.90 (2H, m), 3.04 (4H, m), 3.16 (1H, dd, $J = 10.0, 13.0$ Hz), 3.40 (1H, m), 3.47 (2H, m), 3.86 (3H, m), 3.98 (1H, m), 4.12 (1H, m), 4.23 (1H, dd), 4.31 (1H, m), 4.54 (1H, dd), 4.98 (1H, d, $J = 3.6$ Hz), 5.07 (1H, d, $J = 3.9$ Hz).

5 [0473] Example 43

5-(2-Pyridylmethyl)aminomethylarbekacin

[Chemical formula 164]



Production step 43-(a)


10 The compound (20 mg) produced in production step 38-(a) was reacted with 2-(aminomethyl)pyridine in the same manner as in production step 38-(b) to give the title compound: 5-(2-pyridylmethyl)aminomethylarbekacin (10.2 mg).

TSPMS: m/z 673 $[M+H]^+$.

15 [0474] Example 44

3',4'-didehydro-5-epiarbekacin

[Chemical formula 165]



Production step 44-(a)

20 3',4'-didehydroarbekacin was used in the same manner as in Example 13 to give the title compound: 3',4'-didehydro-5-epiarbekacin.

FABMS: m/z 551 $[M+H]^+$;


$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.77 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.92 - 2.01 (1H, m), 2.19 (1H, ddt, $J = 3.90, 7.32, 14.16$ Hz), 2.30 (1H, ddd, $J = 4.89, 4.89, 12.69$ Hz), 3.18 (2H, dd, $J = 7.32, 7.32$ Hz), 3.30 (1H, dd, $J = 6.34, 13.67$ Hz), 3.36 (1H, dd, $J = 3.90, 13.67$ Hz), 3.46 (1H, dd, $J = 10.25, 10.25$ Hz), 3.62 (1H, dd, $J = 9.77, 9.77$ Hz), 3.74 (1H, dd, $J = 6.83,$

11.72 Hz), 3.75 - 3.79 (1H, m), 3.81 (1H, dd, $J = 3.42, 10.75$ Hz), 3.89 (1H, ddd, $J = 1.96, 6.84, 9.28$ Hz), 3.94 (1H, dd, $J = 1.95, 11.72$ Hz), 4.06 (1H, dd, $J = 2.44, 10.74$ Hz), 4.19 - 4.25 (2H, m), 4.29 (1H, dd, $J = 3.91, 9.28$ Hz), 4.36 (1H, ddd, $J = 4.88, 10.75, 10.75$ Hz), 4.72 - 4.90 (2H, m), 5.18 (1H, d, $J = 3.91$ Hz), 5.59 (1H, d, $J = 3.91$ Hz), 6.04 (1H, ddd, $J = 2.93, 2.93, 10.75$ Hz), 6.18 (1H, ddd, $J = 2.44, 2.44, 10.25$ Hz).

[0475] Example 45

5-Deoxy-3',4'-didehydro-5-epifluoroarbakacin

[Chemical formula 166]



Production step 45-(a)


The title compound: 5-deoxy-3',4'-didehydro-5-epifluoroarbakacin was produced from 3',4'-didehydroarbakacin in the same manner as in Example 13 and Production step 2-(e).

FABMS: m/z 553 $[M+H]^+$.

[0476] Example 46

5-Deoxy-3',4'-didehydro-5-epichloroarbakacin

[Chemical formula 167]



Production step 46-(a)


The title compound: 5-deoxy-3',4'-didehydro-5-epichloroarbakacin (86 mg) was produced from 161 mg of 3',4'-didehydroarbakacin in the same manner as in Example 16.

FABMS: m/z 569 $[M+H]^+$.

[0477] Example 47

5-Deoxy-3',4'-didehydro-5-epiazidoarbakacin

[Chemical formula 168]



Production step 47-(a)


The title compound: 5-deoxy-3',4'-didehydro-5-epiazidoarbekacin was produced from 3',4'-didehydroarbekacin in the same manner as in Example 17.

FABMS: m/z 576 $[M+H]^+$.

[0478] Example 48

5-Deoxy-3',4'-didehydro-5-epiaminoarbekacin


10 [Chemical formula 169]



Production step 48-(a)

The following compound (86 mg) was produced from 161 mg of 3',4'-didehydroarbekacin in the same manner as in Example 17.

15 [Chemical formula 170]




[0479] Production step 48-(b)

The compound (85 mg) produced in production step 48-(a) was dissolved in 2 mL of dimethylformamide and 6 μ L of water. Tributylphosphine (0.03 mL) was added to the solution, and the mixture was stirred at room temperature for 15 hr. The reaction solution was

20

concentrated to dryness. The residue was dissolved in ethyl acetate (10 mL), and the solution was washed with water and 10% brine in that order, dehydrated over anhydrous magnesium sulfate, and concentrated to dryness. The compound (5-epiamino form) was dissolved in 2.4 mL of methylene chloride and 1.2 mL of methanol. 0.1 mL of 0.5 M sodium methoxide was added to the solution under ice cooling, and the mixture was stirred at room temperature for 15 hr. Dry ice was added to the reaction solution, and the mixture was concentrated under the reduced pressure. The residue was washed with hexane, isopropyl ether, and water and was then dried under the reduced pressure to give 54 mg of the following compound.

[Chemical formula 171]



[0480] Production step 48-(c)


The title compound: 5-deoxy-3',4'-didehydro-5-epiaminoarbakacin (17 mg) was produced as a solid from 54 mg of the compound produced in production step 48-(b) in the same manner as in production step 1-(j).

FABMS: m/z 550 $[M+H]^+$.

[0481] Example 49

1-N-[(S)-(3-Amino-2-hydroxypropanoyl)]-3',4'-didehydro-5-epidibekacin

[Chemical formula 172]



Production step 49-(a)

2.70 g of 2',3,6'-tri-N-(t-butoxycarbonyl)-3"-N-trifluoroacetyl-3',4'-didehydrodibekacin was used in the same reaction as in production step 9-(a). The compound (3.03 g) thus obtained was used in the same


manner as in production step 1-(c) to give a benzoylated compound (2.55 g). This compound was used in the same reaction as in production steps 1-(d) and (e). Further, the compound thus obtained was used in the same reaction as in production step 1-(i) to give a compound (1.77 g), which had been deprotected for benzoyl and acetyl groups. This compound (350 mg) was dissolved in 4 mL of anhydrous tetrahydrofuran. Further, under cooling, 20 mL of liquid ammonia was trapped in the reaction system, and 200 mg of metallic sodium was added thereto. After deep blue of the reaction solution was continued for 10 min, 515 mg of ammonium chloride was added to stop the reaction. Liquid ammonia was removed from the reaction system by evaporation at room temperature under a nitrogen gas stream. The reaction solution was then concentrated to dryness. The residue was extracted with chloroform : methanol = 5 : 1, followed by adjustment of pH to 6 by the addition of acetic acid. This solution was concentrated to dryness. The compound thus obtained was allowed to react in the same manner as in production step 9-(m), and deprotection was further carried out in the same manner as in production step 1-(j) to give the title compound: 1-N-[(S)-(3-amino-2-hydroxypropanoyl)]-3',4'-didehydro-5-epidibekacin (28 mg).

FABMS: m/z 537 $[M+H]^+$.

[0482] Example 50

1-N-[(R)-(3-Amino-2-hydroxypropanoyl)]-3',4'-didehydro-5-epidibekacin

[Chemical formula 173]



Production step 50-(a)


The title compound: 1-N-[(R)-(3-amino-2-hydroxypropanoyl)]-3',4'-didehydro-5-epidibekacin was produced by a reaction in the same manner as in Example 49.

FABMS: m/z 537 $[M+H]^+$.

[0483] Example 51

3',4'-Didehydro-5,4''-diepiarbekacin

[Chemical formula 174]



Production step 51-(a)

The title compound: 3',4'-didehydro-5,4''-diepiarbakacin was produced from 3',4'-didehydroarbakacin in the same manner as in Example 1.


FABMS: m/z 551 $[M+H]^+$;

$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{ND}_3$) δ : 1.35 (1H, m), 1.82 (1H, m), 2.02 (2H, m), 2.80 (2H, m), 2.89 (2H, m), 3.00 (1H, dd, $J = 2.9, 10.7$ Hz), 3.18 (1H, m), 3.53 (2H, m), 3.59 (1H, dd, $J = 3.9, 10.7$ Hz), 3.76 (2H, m), 3.82 (1H, dd, $J = 2.7, 10.7$ Hz), 3.89 (1H, brd), 4.09 (1H, m), 4.22 (1H, dd, $J = 3.6, 9.3$ Hz), 4.26 (1H, m), 4.37 (1H, m), 4.59 (1H, m), 5.09 (1H, d, $J = 4.0$ Hz), 5.16 (1H, d, $J = 4.2$ Hz), 5.80 (1H, s), 5.80 (1H, s).

[0484] Example 52

5-Deoxy-3',4'-didehydro-4''-epi-5-epifluoroarbakacin

[Chemical formula 175]



Production step 52-(a)

The title compound: 5-deoxy-3',4'-didehydro-4''-epi-5-epifluoroarbakacin was produced from 3',4'-didehydroarbakacin in the same manner as in Example 2.

FABMS: m/z 553 $[M+H]^+$;


$^1\text{H-NMR}$ ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.70 (1H, ddd, $J = 12.7, 12.7, 12.7$ Hz), 1.76 - 1.86 (1H, m), 2.03 (1H, ddt, $J = 3.90, 7.32, 14.65$ Hz), 2.20 (1H, ddd, $J = 4.39, 4.39, 13.19$ Hz), 3.03 (2H, dd, $J = 7.33, 7.33$ Hz), 3.12 (1H, dd, $J = 6.35, 13.67$ Hz), 3.22 (1H, dd, $J = 3.42, 13.67$ Hz), 3.49 (1H, dd, $J = 2.93,$

11.23 Hz), 3.59 - 3.66 (1H, m), 3.63 (2H, d, J = 5.86 Hz), 3.84 (1H, dd, J = 3.91, 10.74 Hz), 3.95 - 4.04 (3H, m), 4.07 - 4.10 (1H, m), 4.14 (1H, dd, J = 3.91, 9.28 Hz), 4.15 - 4.23 (2H, m), 4.54 - 4.56 (1H, m), 5.05 (1H, d, J = 3.91 Hz), 5.48 (1H, d, J = 3.91 Hz), 5.50 (1H, d, J = 51.27 Hz), 5.86 (1H, ddd, J = 1.95, 1.95, 11.23 Hz), 6.00 (1H, ddd, J = 1.95, 1.95, 10.74 Hz).

[0485] Example 53

5-Deoxy-3',4'-didehydro-4"-epi-5-epiaminoarbakacin

[Chemical formula 176]




10

Production step 53-(a)

The following compound was produced from 3',4'-didehydroarbakacin in the same manner as in Example 4.

[Chemical formula 177]



15

[0486] Production step 53-(b)

The title compound: 5-deoxy-3',4'-didehydro-4"-epi-5-epiaminoarbakacin (10 mg) was produced as a solid from 150 mg of the compound produced in production step 53-(a) in the same manner as in production steps 48-(b) and 48-(c).


ESIMS: m/z 572 [M+Na]⁺

[0487] Example 54

4"-Deoxy-3',4'-didehydro-5-epiarbakacin

[Chemical formula 178]


20



Production step 54-(a)

1.50 g of 3,2',6',3''-tetra-N-t-butoxycarbonyl-3',4'-didehydro-4''-p-methoxybenzyloxycarbonyl-arbekacin was used in the same reaction as in production steps 1-(b) to 1-(g) to give the following compound (0.74 g).


[Chemical formula 179]



[0488] Production step 54-(b)

300 mg of the compound produced in production step 54-(a) was used in the same reaction as in production steps 8-(a) and 8-(b) to give the following compound (100 mg).

[Chemical formula 180]



[0489] Production step 54-(c)

97 mg of the compound produced in production step 54-(b) was used for the deprotection in the same manner as in production step 1-(i) and 1-(j) to give the title compound: 4''-deoxy-3',4'-didehydro-5-epiarbekacin (20 mg).

ESIMS: m/z 557 $[M+Na]^+$


1H -NMR (D_2O+DCI) δ : 1.68 (1H, m), 1.79 (1H, m), 2.01 (1H, m), 2.15 (1H, m), 2.21 (1H, m), 2.32 (1H, m), 2.32 (1H, m), 3.21 (2H, m), 3.35 (2H, m), 3.73 (5H, m), 4.05 (1H, dd, $J = 2.4, 10.7$ Hz), 4.21 (2H, m), 4.25 (1H,

brs), 4.32 (1H, dd, $J = 3.7, 9.3$ Hz), 4.38 (1H, m), 4.75 (1H, brs), 5.22 (1H, $J = 3.6$ Hz), 5.61 (1H, d, $J = 3.9$ Hz), 6.07 (1H, m), 6.21 (1H, m).

[0490] Example 55


5,6''-Dideoxy-3',4'-didehydro-6''-fluoro-5-epifluoroarbekacin

5 [Chemical formula 181]




Production step 55-(a)

2',3,6'-Tri-N-(t-butoxycarbonyl)-3''-N-trifluoroacetyl-3',4'-
 10 didehydrodibekacin (2.537 g) was reacted with (S)-4-(p-methoxybenzyloxycarbonylamino)-2-hydroxybutanoic acid in the same manner as in Example 9 to give 3.325 g of the following compound.
 [Chemical formula 182]



[0491] Production step 55-(b)

15 The following compound (1.71 g) was produced from 2.80 g of the compound produced in production step 55-(a) in the same manner as in production step 1-(g).
 [Chemical formula 183]




20 [0492] Production step 55-(c)

The following compound (1.64 g) was produced from 1.54 g

of the compound produced in production step 55-(b) in the same manner as in production step 2-(a).


[Chemical formula 184]



5 [0493] Production step 55-(d)

1.08 g of the compound produced in production step 55-(c) was used for the removal of a triphenylmethyl group in the same manner as in production step 33-(c) to give the following compound (700 mg).

[Chemical formula 185]




10

[0494] Production step 55-(e)

The following compound (180 mg) was produced from 340 mg of the compound produced in production step 55-(d) in the same manner as in production step 2-(e).

15 [Chemical formula 186]



[0495] Production step 55-(f)

The title compound: 5,6"-dideoxy-3',4'-didehydro-6"-fluoro-5-epifluoroarbekacin (17 mg) was produced from 180 mg of the compound produced in production step 55-(e) in the same manner as in production steps 9-(b) and production step 1-(j).

FABMS: m/z 555 [M+H]⁺;


20

¹H-NMR (D₂O+DCI) δ: 1.71 (1H, ddd, J = 12.7, 12.7, 12.7 Hz), 1.77 - 1.89 (1H, m), 2.03 (1H, ddt, J = 3.90, 7.32, 14.65 Hz), 2.19 (1H, ddd, J = 4.40, 4.40, 12.70 Hz), 3.02 (2H, dd, J = 7.32, 7.32 Hz), 3.14 (1H, dd, J = 6.35, 13.67 Hz), 3.22 (1H, dd, J = 3.42, 13.67 Hz), 3.29 (1H, dd, J = 10.25, 10.25 Hz), 3.59 (1H, dd, J = 10.26, 10.26 Hz), 3.62 - 3.65 (1H, m), 3.69 (1H, dd, J = 3.42, 10.75 Hz), 3.90 - 3.99 (1H, m), 4.02 (1H, ddd, J = 1.96, 10.74, 28.30 Hz), 4.08 - 4.10 (1H, m), 4.14 (1H, dd, J = 3.42, 9.28 Hz), 4.17 - 4.25 (2H, m), 4.54 - 4.74 (3H, m'), 5.07 (1H, d, J = 3.91 Hz), 5.31 (1H, d, J = 51.76 Hz), 5.50 (1H, d, J = 3.91 Hz), 5.87 (1H, ddd, J = 2.44, 2.44, 10.74 Hz), 6.01 (1H, ddd, J = 1.95, 1.95, 10.74 Hz).

[0496] Example 56

3"-N-Methylarbekacin

[Chemical formula 187]



15 Production step 56-(a)

4.10 g of the compound produced in production step 28-(b) was used for the Deprotection in the same manner as in production step 1-(j). A reaction was then allowed to proceed in the same manner as in production step 28-(f) to give the title compound: 3''-N-methylarbekacin (1.54 g).


FABMS: m/z 567 [M+H]⁺;

¹H-NMR (D₂O+ND₃) δ: 1.55 (2H, m), 1.76 (1H, m), 1.87 (3H, m), 2.04 (2H, m), 2.55 (3H, s), 2.78 (2H, m), 2.87 (3H, m), 2.98 (1H, m), 3.04 (1H, m), 3.46 (1H, dd, J = 9.3 Hz), 3.57 (1H, dd, J = 9.7, 10.0 Hz), 3.64 (1H, dd, J = 3.6, 10.5 Hz), 3.86 (4H, m), 3.98 (1H, m), 4.10 (2H, m), 4.30 (1H, dd, J = 3.6, 9.3 Hz), 5.20 (1H, d, J = 3.6 Hz), 5.27 (1H, d, J = 3.5 Hz).

[0497] Example 57

3"-N-Ethylarbekacin

[Chemical formula 188]



Production step 57-(a)

The reaction was allowed to proceed in the same manner as in production step 28-(b) except acetaldehyde was used instead of formaldehyde. Further, the compound thus obtained was used in the same manner as in production step 56-(a) to give the title compound: 3''-N-ethylarbakacin.


FABMS: m/z 581 $[M+H]^+$;

1H NMR (D_2O+DCI) δ : 1.19 (3H, t, $J = 7.3$ Hz), 1.42 - 1.58 (1H, m), 1.62 - 2.13 (7H, m), 2.93 - 3.46 (9H, m), 3.61 - 3.92 (8H, m), 3.94 - 4.09 (2H, m), 4.13 (1H, dd, $J = 3.7, 9.3$ Hz), 5.03 (1H, d, $J = 3.7$ Hz), 5.64 (1H, d, $J = 3.6$ Hz).

[0498] Example 58

3''-N-(2-Hydroxyethyl)arbakacin

[Chemical formula 189]



Production step 58-(a)


3,2',6'-Tri-N-t-butoxycarbonyl-4''-N-p-methoxybenzyloxy-carbonyl-arbakacin (61 mg) was dissolved in 0.6 mL of DMF and 0.02 mL of water. Potassium carbonate (14 mg) and 42 mg of 2-(2-bromoethoxy)tetrahydro-2H-pyran were added to the solution, and the mixture was stirred at 60°C overnight. The reaction solution was concentrated under the reduced pressure. Water was added to the residue. The mixture was filtered, and the residue was then purified by preparative TLC. The compound thus obtained was treated in the same manner as in production step 1-(j) to give the title compound: 3''-N-(2-hydroxyethyl)arbakacin.

FABMS: m/z 597 $[M+H]^+$.

[0499] Example 59

3''-N-Benzylarbekacin

[Chemical formula 190]



5

Production step 59-(a)

85 mg of the compound produced in production step 28-(a) was used in the same manner as in production step 1-(j) to give the title compound: 3''-N-benzylarbekacin (56 mg).

10 TSPMS: m/z 643 $[M+H]^+$;


^1H NMR ($\text{D}_2\text{O}+\text{DCI}$) δ : 1.58 - 1.72 (1H, m), 1.86 - 2.15 (5H, m), 2.16 - 2.33 (2H, m), 3.15 (1H, dd, $J = 7.3, 13.4$ Hz), 3.21 (2H, t, $J = 7.3$ Hz), 3.30 (1H, d, $J = 7.3, 13.4$ Hz), 3.51 - 3.64 (3H, m), 3.82 (1H, dd, $J = 4.2, 12.5$ Hz), 3.82 - 3.88 (1H, m), 3.87 (1H, dd, $J = 2.2, 11.7$ Hz), 3.93 (1H, t, $J = 10.0$ Hz), 3.94 (1H, t, $J = 10.3$ Hz), 3.97 - 4.08 (3H, m), 4.15 (1H, ddd, $J = 4.6, 10.7, 12.2$ Hz), 4.19 - 4.26 (1H, m), 4.32 (1H, dd, $J = 3.8, 9.4$ Hz), 4.47 (2H, q_{Ab}, $J = 12.9, 16.9$ Hz), 5.22 (1H, d, $J = 3.6$ Hz), 5.81 (1H, d, $J = 3.7$ Hz), 7.54 (5H, s).

15

[0500] Example 60

20 3''-N-(3-Hydroxybenzyl)arbekacin

[Chemical formula 191]



Production step 60-(a)

25 A reaction was allowed to proceed in the same manner as in production step 28-(a), except that m-hydroxybenzaldehyde was used

instead of benzaldehyde. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3"-N-(3-hydroxybenzyl)arbakacin.


FABMS: m/z 659 [M+H]⁺;

- 5 ¹H NMR (D₂O:DCI) δ: 1.36 - 1.51 (1H, m), 1.63 - 2.12 (7H, m), 2.89 - 3.12 (4H, m), 3.29 - 3.43 (3H, m), 3.57 - 4.23 (11H, m), 4.65 (2H, s), 5.00 (1H, d, J = 3.6 Hz), 5.59 (1H, d, J = 3.4 Hz), 6.77 - 6.89 (3H, m), 7.15 - 7.21 (1H, m).

[0501] Example 61

- 10 3"-N-(4-Hydroxybenzyl)arbakacin

[Chemical formula 192]



Production step 61-(a)

- 15 A reaction was allowed to proceed in the same manner as in production step 28-(a), except that p-hydroxybenzaldehyde was used instead of benzaldehyde. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3"-N-(4-hydroxybenzyl)arbakacin.


FABMS: m/z 659 [M+H]⁺;

- 20 ¹H NMR (D₂O+DCI) δ: 1.35 - 1.48 (1H, m), 1.60 - 2.10 (7H, m), 2.87 - 3.09 (4H, m), 3.25 - 3.42 (3H, m), 3.54 - 4.04 (10H, m), 4.08 (1H, dd, J = 3.6, 9.5 Hz), 4.14 (2H, q_{AB}, J = 13.2, 16.3 Hz), 4.97 (1H, d, J = 3.6 Hz), 5.57 (1H, d, J = 3.4 Hz), 6.74 (2H, d, J = 8.5 Hz), 7.17 (2H, d, J = 8.5 Hz).

[0502] Example 62

- 25 3"-N-(3-Aminobenzyl)arbakacin

[Chemical formula 193]



Production step 62-(a)

A reaction was allowed to proceed in the same manner as in production step 28-(a), except that m-(t-butoxycarbonyl)aminobenzaldehyde was used instead of benzaldehyde. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3''-N-(3-aminobenzyl)arbakacin.


FABMS: m/z 658 $[M+H]^+$;

1H NMR (D_2O+DCI) δ : 1.37 - 1.50 (1H, m), 1.63 - 2.11 (7H, m), 2.90 - 3.12 (4H, m), 3.30 - 3.43 (3H, m), 3.58 - 4.05 (10H, m), 4.09 - 4.14 (1H, m), 4.32 (2H, q_{Ab} , $J = 13.4, 15.6$ Hz), 5.01 (1H, d, $J = 3.7$ Hz), 5.60 (1H, d, $J = 3.5$ Hz), 7.31 - 7.48 (4H, m).

[0503] Example 63

15 3''-N-(2-Phenylethyl)arbakacin

[Chemical formula 194]



Production step 63-(a)

A reaction was allowed to proceed in the same manner as in production step 28-(a), except that 3-phenylpropionaldehyde was used instead of benzaldehyde. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3''-N-(2-phenylethyl)arbakacin.

FABMS: m/z 657 $[M+H]^+$;


1H NMR (D_2O+DCI) δ : 1.28 - 1.41 (1H, m), 1.55 - 2.02 (7H, m), 2.80 - 3.03 (6H, m), 3.21 - 3.34 (5H, m), 3.47 - 3.97 (10H, m), 4.00 (1H, dd, $J = 3.7, 9.5$ Hz), 4.90 (1H, d, $J = 3.7$ Hz), 5.52 (1H, d, $J = 3.4$ Hz), 7.05 -

7.18 (5H, m).

[0504] Example 64

3''-N-Amidinoarbekacin

[Chemical formula 195]



5

Production step 64-(a)

3,2',6'-Tri-N-t-butoxycarbonyl-4'''-N-p-methoxybenzyloxy-carbonyl-arbekacin (104 mg) was dissolved in 1 mL of N,N-dimethylformamide. A solution (0.2 mL) of 40 mg of N,N'-bis(tert-butoxycarbonyl)-S-methylisothiurea in N,N-dimethylformamide, 0.034 mL of triethylamine, and a solution of 38 mg of mercury chloride in 0.2 mL of N,N-dimethylformamide were added to the solution in that order, and the mixture was stirred at room temperature for 3 hr. The reaction solution was filtered and concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (chloroform : methanol = 10 : 1). The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3''-N-amidinoarbekacin (43 mg).

10

15


FABMS: m/z 595 $[M+H]^+$.

20

[0505] Example 65

3''-N-Formimidoylarbekacin

[Chemical formula 196]



Production step 65-(a)

25

3,2',6'-Tri-N-t-butoxycarbonyl-4'''-N-p-methoxybenzyloxy-carbonylarbekacin (102 mg) was dissolved in 4 mL of methanol. Ethylformimidate hydrochloride (37 mg) was added to the solution, and

the mixture was stirred at room temperature for 2 days. The reaction solution was concentrated to dryness, and the residue was washed with diethyl ether. The solid thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 3"-N-


formimidoyl arbekacin.

FABMS: m/z 580 $[M+H]^+$.

[0506] Example 66

6'-N-(2-Hydroxybenzyl)arbekacin

[Chemical formula 197]



Production step 66-(a)


The compound (50 mg) produced in production step 12-(c) was dissolved in 1 mL of methanol. 2-Hydroxybenzaldehyde (9.6 mg) was added to the solution, and the mixture was stirred at room temperature for 2 hr. Further, 16 mg of sodium borohydride was added to this reaction solution, and the mixture was stirred for 1 hr. This reaction solution was filtered and was concentrated under the reduced pressure, and the residue was subjected to deprotection in the same manner as in production step 1-(j) to give the title compound: 6'-N-(2-hydroxybenzyl)arbekacin (27.4 mg).

FABMS: m/z 659 $[M+H]^+$.

[0507] Example 67

6'-N,N-Bis(2-aminoethyl)arbekacin


[Chemical formula 198]



Production step 67-(a)

A catalytic amount of p-TsOH·H₂O and 2,2-dimethoxypropane (210 mg) were added to a solution of the compound (620 mg) produced in production step 12-(b) dissolved in 10 mL of N,N-dimethylformamide, and the mixture was stirred at room temperature for 20 hr. Triethylamine was added to the reaction solution, and the mixture was concentrated under the reduced pressure. The residue was washed with isopropyl ether and dried under the reduced pressure to give 640 mg of the following compound.


[Chemical formula 199]



[0508] Production step 67-(b)

The compound (640 mg) produced in production step 67-(a) was dissolved in a solution of 10 mL of dioxane, 10 mL of methanol, and 8 mL of water. Palladium hydroxide (170 mg) was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction at a hydrogen pressure of 30 lbs for 16 hr. This reaction solution was filtered through Celite and washed with a solution of methanol : water = 1 : 1, and the filtrate was then concentrated to dryness to give 560 mg of the following compound.

[Chemical formula 200]




[0509] Production step 67-(c)

The compound (95 mg) produced in production step 67-(b) was dissolved in 5 mL of methanol. N-Benzyl-N-(t-butoxycarbonyl)aminoacetaldehyde (70 mg) and 14 mg of sodium

cyanide borohydride were added to the solution, and the mixture was stirred at room temperature for 1 hr. The reaction solution was concentrated under the reduced pressure, and the residue was subjected to deprotection in the same manner as in production step 1-(j) to give 27 mg of the following compound.

[Chemical formula 201]



[0510] Production step 67-(d)


The compound (21 mg) produced in production step 67-(c) was dissolved in 2 mL of water and 0.3 mL of acetic acid. Palladium hydroxide (17 mg) was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction under a hydrogen atmosphere for 16 hr. The reaction solution was filtered through Celite, and the filtrate was concentrated to dryness. The compound thus obtained was treated in the same manner as in production step 1-(j) to give the title compound: 6'-N,N-bis(2-aminoethyl)arbekacin (13 mg).

FABMS: m/z 639 $[M+H]^+$.

[0511] Example 68

6'-N-amidinoarbekacin

[Chemical formula 202]



Production step 68-(a)

The compound (109 mg) produced in production step 12-(c) was dissolved in 1 mL of N,N-dimethylformamide. To the solution, a solution (0.2 mL) of 41 mg of N,N'-bis(tert-butoxycarbonyl)-S-methylisothiurea in N,N-dimethylformamide, 0.032 mL of triethylamine,


and 0.1 mL of a solution of 37 mg of mercury chloride in N,N-dimethylformamide were added in that order, and the mixture was stirred at room temperature for 3 hr. This reaction solution was filtered, was concentrated under the reduced pressure, and the residue was then
 5 purified by column chromatography on silica gel (chloroform : methanol = 10 : 1). The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 6'-N-amidinoarbekacin (53 mg).

FABMS: m/z 595 $[M+H]^+$.

10 [0512] Example 69

6'-N-Formimidoylarbekacin

[Chemical formula 203]



Production step 69-(a)


15 The compound (196 mg) produced in production step 12-(c) was dissolved in 4 mL of methanol. Ethylformimidate hydrochloride (67 mg) was added to the solution, and the mixture was stirred at room temperature for 2 days. This reaction solution was concentrated to dryness, and the residue was washed with diethyl ether to give a solid.
 20 This solid was treated in the same manner as in production step 1-(j) to give the title compound: 6'-N-formimidoylarbekacin.

FABMS: m/z 580 $[M+H]^+$.

[0513] Example 70

6'-Aminomethyl-6'-deamino-6'-hydroxyarbekacin

25 [Chemical formula 204]



Production step 70-(a)


The compound (82 mg) produced in production step 30-(d) was dissolved in a solution of 7 mL of methanol, 3 mL of water, and 0.2 mL of acetic acid. Platinum oxide (50 mg) was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction at a hydrogen pressure of 40 lbs for 20 hr. This reaction solution was filtered through Celite and was washed with a solution of methanol : water = 1 : 1, and the filtrate was concentrated under the reduced pressure. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 6'-aminomethyl-6'-deamino-6'-hydroxyarbakacin (31 mg).

FABMS: m/z 583 $[M+H]^+$.

[0514] Example 71


6'-(2-Aminoethyl)-6'-deaminoarbakacin

[Chemical formula 205]

Production step 71-(a)

The compound (75 mg) produced in production step 30-(c) was dissolved in 3 mL of chloroform. $\text{Ph}_3\text{P}=\text{CHCN}$ (60 mg) was added to the solution, and the mixture was stirred at 40°C for 12 hr. The reaction solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, methylene chloride : methanol = 25 : 1) to give 54 mg of the following compound.

[Chemical formula 206]



[0515] Production step 71-(b)


The compound (54 mg) produced in production step 71-(a) was dissolved in a solution of 7 mL of methanol, 3 mL of water, and 0.2 mL of acetic acid. Platinum oxide (35 mg) was added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction at a hydrogen pressure of 40 lbs for 20 hr. The reaction solution was filtered through Celite and washed with a solution of methanol : water = 6 : 4, and the filtrate was concentrated under the reduced pressure. The product thus obtained was deprotected in the same manner as in production steps 1-(i) and (j) to give the title compound: 6'-(2-aminoethyl)-6'-deaminoarbakacin (19.8 mg).

FABMS: m/z 581 $[M+H]^+$.

[0516] Example 72

6''-Adizo-6''-deoxyarbakacin


[Chemical formula 207]



Production step 72-(a)

The compound (100 mg) produced in production step 32-(b) was dissolved in 4 mL of dimethylformamide, 65 mg of sodium azide was added to the solution, and the mixture was stirred at 90°C for 22 hr. Insolubles were removed from the reaction solution by filtration, and the filtrate was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water and dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, ethyl acetate : toluene = 1 : 1) to give 32 mg of the following compound.

[Chemical formula 208]



[0517] Production step 72-(b)


The compound (30 mg) produced in production step 72-(a) was dissolved in 3 mL of methanol, 0.2 mL of a 2 M aqueous sodium hydroxide solution was added to the solution, and the mixture was stirred at room temperature for 0.5 hr. This reaction solution was neutralized with 1 M hydrochloric acid and was then concentrated under the reduced pressure. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 6"-azido-6"-deoxyarbakacin (8 mg).

FABMS: m/z 578 $[M+H]^+$.

[0518] Example 73

6"-Amino-6"-deoxyarbakacin

[Chemical formula 209]



Production step 73-(a)


The compound produced in Example 72 (6"-azido-6"-deoxyarbakacin) (25 mg) was dissolved in 2 mL of water and 0.3 mL of methanol. Palladium black (10 mg) was added to this solution, and the mixture was subjected to a catalytic hydrogen reduction reaction under a hydrogen atmosphere for 3 hr. This reaction solution was filtered through Celite, and the filtrate was concentrated to dryness. The compound thus obtained was treated in the same manner as in production step 1-(j) to give the title compound: 6"-amino-6"-deoxyarbakacin (12.6 mg).

FABMS: m/z 552 $[M+H]^+$.

[0519] Example 74

6"-Deoxy-6"- (4-morpholinyl)arbekacin

[Chemical formula 210]




5

Production step 74-(a)

The compound (1.0 g) produced in production step 1-(a) was dissolved in 20 mL of pyridine. 4-Dimethylaminopyridine (900 mg) and 560 mg of trityl chloride were added to the solution, and the mixture was stirred at 70°C for 4 hr. Acetic anhydride (0.9 mL) was added to the reaction solution, and the mixture was stirred at room temperature for 16 hr. Methanol (1 mL) was added to the reaction solution, and the mixture was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with an aqueous potassium hydrogensulfate solution, an aqueous sodium hydrogencarbonate solution, and water in that order, and was then dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, methylene chloride : methanol = 25 : 1) to give 1.24 g of the following compound.

20

[Chemical formula 211]




[0520] Production step 74-(b)

The compound (480 mg) produced in production step 74-(a) was dissolved in 3 mL of diethyl ether. Formic acid (3 mL) was added to the solution, and the mixture was stirred at room temperature

25

for 20 hr. Ethyl acetate was added to the reaction solution, and the mixture was washed with an aqueous sodium hydrogencarbonate solution and water, and then dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure. The residue was purified by column chromatography on silica gel (development system, methylene chloride : methanol = 15 : 1) to give 200 mg of the following compound.


[Chemical formula 212]



10 [0521] Production step 74-(c)

The compound (200 mg) produced in production step 74-(b) was dissolved in 8 mL of benzene and 1 mL of dimethylsulfoxide. 180 mg of dicyclohexylcarbodiimide, 46 mg of pyridine, and 21 mg of trifluoroacetic acid were added to the solution, and the mixture was stirred at room temperature for 16 hr. This reaction solution was filtered, and the filtrate was concentrated under the reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with water and then dried over anhydrous magnesium sulfate. This solution was concentrated under the reduced pressure, and the residue was purified by column chromatography on silica gel (development system, methylene chloride : methanol = 60 : 1) to give 200 mg of the following compound.

[Chemical formula 213]



25 [0522] Production step 74-(d)

The compound (96 mg) produced in production step 74-(c) was dissolved in 5 mL of methanol. 230 mg of Morpholine and 18 mg of


sodium cyanide borohydride were added to the solution, and the mixture was stirred at room temperature for 3 hr. Further, 0.3 mL of a 2 M aqueous sodium hydroxide solution was added to the reaction solution, and the mixture was stirred for 0.5 hr. This reaction solution was neutralized with 1 M hydrochloric acid, and then concentrated under the reduced pressure. The compound thus obtained was deprotected in the same manner as in production step 1-(j) to give the title compound: 6"-deoxy-6"-(4-morpholinyl)arbekacin (31 mg).

FABMS: m/z 622 [M+H]⁺.

10 [0523] Example 75

6"-Deoxy-6"-(2-aminoethyl)aminoarbekacin

[Chemical formula 214]



Production step 75-(a)


15 The compound (70 mg) produced in production step 74-(c) was reacted with N-(tert-butoxycarbonyl)ethylenediamine in the same manner as in production step 74-(d) to give the title compound: 6" -deoxy-6"-(2-aminoethyl)aminoarbekacin (26 mg).

FABMS: m/z 595 [M+H]⁺.

20 [0524] Example 76

6"-Aminomethylarbekacin


[Chemical formula 215]



Production step 76-(a)

0.1 mL of 1 M sodium methoxide in methanol solution was added to a solution of the compound (108 mg) produced in production step 74-(c) dissolved in 5 mL of methanol, and the mixture was stirred at room temperature for 30 min. Further, 0.55 mL of nitromethane was added to the reaction solution, and the mixture was stirred at room temperature for 4 hr. This reaction solution was neutralized with 1 M hydrochloric acid under an ice bath and concentrated to dryness. The residue was purified by column chromatography on silica gel (methylene chloride : methanol = 15 : 1) to give 43 mg of the following compound.


10 [Chemical formula 216]



[0525] Production step 76-(b)

The compound (43 mg) produced in production step 76-(a) was dissolved in 2.5 mL of ethanol and 2.5 mL of water. Acetic acid (0.05 mL) and 20 mg of platinum oxide were added to the solution, and the mixture was subjected to a catalytic hydrogen reduction reaction under a hydrogen atmosphere. After 16 hr from the start of the reaction, 40 mg of platinum oxide was further added, and the mixture was subjected to a catalytic hydrogen reduction reaction for additional 12 hr under a hydrogen atmosphere. The reaction solution was filtered through Celite, and the filtrate was then concentrated to dryness. The residue was purified by column chromatography on silica gel (methylene chloride : methanol : aqueous ammonia = 60 : 10 : 1) to give 10 mg of the following compound.

25 [Chemical formula 217]



[0526] Production step 76-(c)

A 90% aqueous trifluoroacetic acid solution (1 mL) was added to the compound (10 mg) produced in production step 76-(b), and the mixture was stirred at room temperature overnight. Water (10 mL) was added to the reaction solution, and the aqueous layer was washed three times with 5 mL of diethyl ether. Further, the aqueous layer was adjusted to pH 7 by neutralization with aqueous ammonia and then purified by 20 mL of CM-Sephadex (NH_4^+) to give the title compound: 6'-aminomethylarbakacin (0.3 g).

FABMS: m/z 582 $[\text{M}+\text{H}]^+$.

[0527] Test Example 1

Antimicrobial activity

The minimal inhibitory concentration (MIC, $\mu\text{g/mL}$) against MRSAs (MRSA-HR and MRSA-LR) were measured for typical compounds of novel aminoglycoside antibiotic derivatives described in the Examples (Example 1, Example 2, Example 9, Example 13, Example 18, Example 24, Example 44, Example 45, Example 48, Example 49, Example 51, Example 52, Example 53, Example 54, and Example 76) by an agar plate dilution method based on the method based on the JAPANESE SOCIETY OF CHEMOTHERAPY. As a result, the MIC value of the compounds described in the Examples was not more than 8 against MRSA-HR and not more than 4 against MRSA-LR. The same test was carried out for arbekacin described in Japanese Patent Laid-Open No. 164696/1980. The MIC value was 64 for MRSA-HR and 16 for MRSA-LR. Further, the minimal inhibitory concentration (MIC) against *P. aeruginosa* PAO1 was measured using the above compounds of the Examples and was found to be not more than 4.